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ABSTRACT 
 
The currently used forms of cancer therapy are associated with drug resistance and toxicity 
to healthy tissues. Thus, more efficient methods are needed for cancer-specific induction of 
growth arrest and programmed cell death, also known as apoptosis. Therapeutic forms of 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) are investigated in 
clinical trials due to the capability of TRAIL to trigger apoptosis specifically in cancer 
cells by activation of cell surface death receptors. Many tumors, however, have acquired 
resistance to TRAIL-induced apoptosis and sensitizing drugs for combinatorial treatments 
are, therefore, in high demand. This study demonstrates that lignans, natural polyphenols 
enriched in seeds and cereal, have a remarkable sensitizing effect on TRAIL-induced cell 
death at non-toxic lignan concentrations. In TRAIL-resistant and androgen-dependent 
prostate cancer cells we observe that lignans repress receptor tyrosine kinase (RTK) 
activity and downregulate cell survival signaling via the Akt pathway, which leads to 
increased TRAIL sensitivity. A structure-activity relationship analysis reveals that the γ-
butyrolactone ring of the dibenzylbutyrolactone lignans is essential for the rapidly 
reversible TRAIL-sensitizing activity of these compounds. Furthermore, the lignan 
nortrachelogenin (NTG) is identified as the most efficient of the 27 tested lignans and 
norlignans in sensitization of androgen-deprived prostate cancer cells to TRAIL-induced 
apoptosis. While this combinatorial anticancer approach may leave normal cells unharmed, 
several efficient cancer drugs are too toxic, insoluble or unstable to be used in systemic 
therapy. To enable use of such drugs and to protect normal cells from cytotoxic effects, 
cancer-targeted drug delivery vehicles of nanometer scale have recently been generated. 
The newly developed nanoparticle system that we tested in vitro for cancer cell targeting 
combines the efficient drug-loading capacity of mesoporous silica to the versatile particle 
surface functionalization of hyperbranched poly(ethylene imine), PEI. The mesoporous 
hybrid silica nanoparticles (MSNs) were functionalized with folic acid to promote targeted 
internalization by folate receptor overexpressing cancer cells. The presented results 
demonstrate that the developed carrier system can be employed in vitro for cancer selective 
delivery of adsorbed or covalently conjugated molecules and furthermore, for selective 
induction of apoptotic cell death in folate receptor expressing cancer cells. The tested 
carrier system displays potential for simultaneous delivery of several anticancer agents 
specifically to cancer cells also in vivo. 
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INTRODUCTION 
 
Approximately one per mille of the 50–70 trillion cells of an adult body is replaced on a 
daily basis to serve the biological goals of our life, namely survival and reproduction. The 
balance between cell division and cell death enables us to maintain the relatively constant 
body size, and to succeed in this, each cell must obediently serve the benefit of the 
organism, even if it means sacrificing the life of the cell. A process called apoptosis is a 
mode of programmed cell death that enables cells to die in a well-coordinated manner and 
the remains to be cleared away by the neighboring cells. The signals that trigger this 
cellular suicide program can originate from within the cell in response to cellular injury, 
such as accumulating DNA damage, or from the exterior of the cell in the form of death 
ligands. In an adult, death ligands are utilized primarily by the cells of the immune system 
to activate apoptosis in cells the body no longer needs, or in cells that are considered 
dangerous to the organism. The activation proceeds by binding of the death ligands to cell 
surface proteins, termed death receptors, capable of transmitting the signal to the interior of 
the cell. Intracellular signaling leads to amplification of the received message and 
ultimately to enzymatic decomposition of the cellular structures. 
 
In cancer, individual cells continue to grow and divide despite the internal and external 
signals that demand the cell to commit suicide. This behavior stems from critical mutations 
in the cancer cell genome that promote cell survival and growth independent of external 
stimuli and disrupt mechanisms that normally limit cell division or induce apoptotic cell 
death. These internal differences in cell signaling can also be manifested at the cancer cell 
surface as altered expression of molecules, like receptors. Such patterns in cell surface 
composition can be identified and used for distinction of cancer cells from healthy cells. 
However, current cancer therapies rely heavily on the induction of apoptosis in dividing 
cells with the consequence of also damaging non-cancerous cells in tissues that are being 
rapidly replaced. The second major problem in dealing with cancer is that the cancer cells 
adapt to new circumstances and, therefore, evade applied treatments by becoming resistant. 
These critical issues are in the core of the challenges that cancer is currently posing to the 
aging populations and new more powerful and cost-efficient treatments as well as 
improved modes of cancer drug administration are desperately sought after. 
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REVIEW OF LITERATURE 
 
1. CANCER AS A THERAPEUTIC CHALLENGE 
1.1 Hallmarks of cancer  
 
In contrast to common perception, cancer is not one disease but a large group of variable 
diseases that should be treated in different ways in order to be cured. Cancers originate 
from distinct cell types and gradually harbor specific genome alterations during the course 
of cancer development and progression. Inherited mutations can predispose to cancer, but 
most of the diagnosed cancers occur through transformation of cells during our life span. 
These genetic and epigenetic changes that have capacity to transform cells include gain-of-
function mutations in proto-oncogenes, loss-of-function mutations in tumor suppressor 
genes and mutations that lead to inactivation of genes that control genomic stability 
(reviewed by Hahn & Weinberg 2002). Cellular proto-oncogenes function in regulation of 
normal cell growth and proliferation, but can be turned into growth promoting oncogenes, 
through processes such as gene amplification, chromosomal translocation, enhanced 
transcription, or impairment of negative regulation. Inactivation of genes that restrain cell 
proliferation and survival, designated as tumor suppressor genes, can occur through 
mutations that alter the gene expression, post-translational modifications or functionality of 
the gene product.  Reflecting the variety of genomic changes leading to cancer, all the 
disease entities take their own clinical course and respond to specific therapy forms, while 
being resistant towards others. 
 
In order to grow and invade, transforming cells must acquire several functional capabilities 
(Figure 1). These critical changes in cell physiology include impaired induction of 
programmed cell death (also called apoptosis), self-sufficiency for growth signals, 
insensitivity to antigrowth signals, sustained angiogenesis, limitless replicative potential, 
deregulating cellular energetics, avoiding immune destruction, tissue invasion and 
metastasis, as well as enabling characteristics, genomic instability and tumor-promoting 
inflammation (reviewed by Hanahan & Weinberg 2000, Hanahan 2010, oral 
communication). The one feature that makes cancer a lethal disease is tumor metastasis. In 
order to grow, tumors must acquire blood or lymphatic vessels to the tumor site for 
sufficient supply of oxygen and nutrients and removal of metabolites. Concomitantly, this 
process called angiogenesis enables tumor metastasis, but first the primary tumor cells 
need to obtain migratory and invasive properties. A developmental process called 
epithelial-mesenchymal transition (EMT) is thought to play a central role also in initiation 
of metastasis, as it transforms well-organized epithelial cells into cells of mesenchymal 
phenotype with loose cell-cell adhesion and lost cell polarity (reviewed by Thiery et al. 
2009). After local invasion and entry into the vasculature, imperative steps for metastasis 
include survival in the circulation, infiltration to distant organs, and finally colonization 
(reviewed by Chambers et al. 2002 and Nguyyen et al. 2009). All these processes are 
potential targets for cancer therapeutics. In addition, recent advances have highlighted the 
important role of tumor-associated tissues in promotion of cancer survival and metastasis, 
suggesting that also non-cancer tissues must be taken into consideration when developing 
new cancer therapeutics (reviewed by Joyce & Pollard 2009). 
Review of Literature 
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Figure 1. The hallmarks of cancer. Modified from (Hanahan & Weinberg 2000). 
1.1.1 Conventional chemotherapy  
Treatment of solid tumors has largely employed surgery, radiation, photodynamic 
treatment, hyperthermia and chemotherapy. Many of the traditional chemotherapeutics are 
aimed at the particular weakness of cancer cells, which is their proliferation. Most cells in 
an adult body have entered post-mitotic state and do not proliferate any longer. Therefore 
antimitotic drugs, like tubulin-targeting taxanes and vinca alkaloids, can be employed to 
eliminate dividing cancer cells. Many treatments also take advantage of the vulnerabilities 
that the cells have once they have discarded critical checkpoint controls. In such cells, 
induction of DNA and chromosome damage does not cause cell cycle arrest but entry to 
mitosis occurs, which is likely to lead to cell death by mitotic catastrophe (reviewed by 
Castedo et al. 2004). Cancer treatments with alkylating agents or platinum drugs are based 
on these effects. Antimetabolites, such as methotrexate and 5-fluorouracil (5-FU), interfere 
with DNA and RNA synthesis and thereby prevent cancer cell growth and survival. 
Antitumor antibiotics, like doxorubicin, actinomycin-D and mitoxantrone, inhibit enzymes 
that are involved in DNA replication, and topoisomerase inhibitors, such as topotecan and 
etoposide, inhibit enzymes that separate DNA strands. Treatment with these drug types 
results in inhibited cell proliferation and induction of cell death. In some cases also 
corticosteroids, prednisolone and dexamethasone, are used as anticancer treatments due to 
their anti-inflammatory activity. All the mentioned anticancer agents have been successful 
in clinic alone or in combination to other compounds, but many patients either do not 
respond or alternatively develop resistance towards the therapy.  
 
1.1.2 Challenges in development of cancer therapeutics 
The side effects caused by chemotherapy are multiple and vary from anemia and nausea to 
problems in the function of vital organs. Drugs that target cell proliferation particularly 
harm the tissues that are under constant renewal, such as skin, hair, intestine and bone 
marrow. Similarly, treatments that damage the genome in order to induce tumor cell death 
can instead result in unrepaired DNA damage and cell loss or even cell transformation in 
other tissues (reviewed by Allan & Travis 2005). The risk of bystander toxicity is naturally 
increased when multiple cancer treatments are used in combination to achieve good drug 
response.  
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Tumors that initially respond well to a particular therapy often develop drug resistance. 
Deregulation of apoptosis and other cell death programs contributes to malignant growth 
both during the initial tumor development and acquisition of resistance to chemotherapy 
(reviewed by de Bruin & Medema 2008). During cancer initiation, progression and 
treatment tumor cells acquire genomic instability that creates new genetic and epigenetic 
changes that further provide selection advantage in altered environment. This plasticity of 
cancer cell populations drives the relapse of tumors. The molecular mechanisms behind 
cancer drug resistance include inhibited import of the drug molecules, acquired ability to 
pump the drugs out or ability to metabolize and detoxify the administered drugs (reviewed 
by Gottesman et al. 2002). For example, expression of the ABC transporter P-glycoprotein 
enables cancer cells to pump out a variety of different drug molecules, thereby lowering 
their intracellular concentrations to sub-toxic levels (Chen et al. 1986). Resistance can also 
arise from improved mechanisms for DNA repair or incapacity of the cell to induce 
apoptosis due to loss of critical effectors in the signaling cascade (Gottesman et al. 2002). 
To overcome these mechanisms of resistance, application of two or three unrelated cancer 
drugs simultaneously is often required.  
 
Increasing evidence supports the existence of a particular population of tumor cells called 
cancer stem cells that maintain their ability for self-renewal, generate differentiated cells as 
their progeny by asymmetric cell division and most importantly, have the capacity of 
giving rise to new tumors in animal hosts (Clarke et al. 2006). It has also been reported that 
reprogramming of somewhat differentiated tumor cells back to cancer stem cells may 
occur, and that the signals within the tumor microenvironment have a critical role in this 
process (Gupta et al. 2009). As cancer stem cells are more resistant to conventional 
therapeutics than the rest of the tumor, optimal cancer therapy is likely to require 
treatments that successfully eliminate both cancer stem cells and differentiated cancer 
cells. In order to better identify the subgroups of patients that are most likely to profit from 
particular therapy forms, researchers are trying to find new molecular markers. For 
example, in the case of colon cancer individualized data from tumor gene expression arrays 
can be used for identifying gene signatures that help to predict the patient’s response to 
certain drugs as well as prognosis (reviewed by Gangadhar & Schilsky 2010). When 
combined to this type of molecular diagnostics, multiagent therapy might turn out to be the 
most effective weapon against cancer.  
 
1.1.3 Targeted cancer therapies 
Cancer treatment is slowly heading towards the assignment of tailor-made drug therapies 
to each individual patient and the targeted elimination of cancer without inducing 
undesirable side effects. Targeted cancer therapy is based on using drugs or other 
substances to identify and eliminate cancer cells while doing little damage to normal cells. 
In order to distinguish cancer cells from normal cells, cancer-specific features need to be 
identified, but finding such molecular targets is a big challenge to cancer research. Cancer 
cells often rely on hyperactive forms of growth and survival-promoting proteins for their 
proliferation and escape from apoptosis (Hahn & Weinberg 2002). Inhibition of these 
oncoproteins by small-molecule drugs, monoclonal antibodies and other means has been 
pursued vigorously in order to develop targeted cancer therapeutics (reviewed by 
Gschwind et al. 2004 and Engelman 2009). Several new therapeutic forms, such as drugs 
that target the vascular endothelial growth factor receptors (VEGFRs) in tumor 
angiogenesis or inhibit epidermal growth factor receptors (EGFRs) in breast cancer, have 
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already been discovered, while many future advances against cancer are likely to arise 
from this field. 
 
Cancer patients can also be treated with immunotherapies that stimulate the natural 
immune system to more efficiently identify and attack cancer cells. While the purpose of 
active immunotherapies, such as therapeutic vaccines, is to stimulate the host’s defenses 
against the disease, passive immunotherapies are based on administering components, such 
as antibodies, that are created outside the body (reviewed by Melief & Burg 2008, Higano 
et al. 2009). In addition, advances in targeted gene therapy might succeed in curing the 
disease by replacing the mutated sequences in cancer cell genome. For example, 
reintroduction of the wild-type tumor suppressor p53 gene, which is mutated in no less 
than half of all human tumors, has been shown to benefit cancer therapy of head and neck 
cancers (reviewed by Huang et al. 2009).  
 
1.1.4 Treatment of prostate cancer 
Prostate cancer is the most common malignancy and the second leading cause of cancer 
mortality in men of the western world (Jemal et al. 2008). The majority of prostate cancer 
patients are aged and diagnosed with clinically localized, low-risk prostate cancer that can 
be effectively treated with surgery and radiation. However, prognosis is poor for locally 
advanced or metastatic disease that has progressed to castration-resistant prostate cancer 
(CRPC) (reviewed by Shepard & Raghavan 2010). Improved diagnostics with serum 
prostate specific antigen (PSA) as a relatively good marker for prostate cancer risk have 
resulted in earlier diagnosis of prostatic carcinomas. For advanced prostate cancer, the 
typical sites of metastasis are lymph nodes and bone, and the disease-related symptoms are 
often connected to bone metastasis.  
 
Despite extensive research efforts, androgen-deprivation therapy (ADT) by surgical 
castration or nowadays more commonly by chemical castration with antiandrogens remains 
the most effective therapy for advanced metastatic prostate cancer. Recently, novel higher 
affinity androgen receptor inhibitors have been developed and proven effective in 
preclinical prostate tumor models (Tran et al. 2009). Successful clinical trials with an 
inhibitor of the enzyme that catalyzes androgen biosynthesis, cytochrome P17, have 
unexpectedly demonstrated that CRPC often remains hormone-dependent (reviewed by 
Attard et al. 2009). Upregulated expression of androgen receptor in seemingly hormone-
independent tumor xenografts might compensate for the low level of androgens upon ADT 
(Chen et al. 2004). Despite the good initial response, ADT is of limited benefit because of 
the difficult adverse effects of androgen deprivation, especially on the cardiovascular 
system, and the CRPC that occurs in most patients within some years (Shepard & 
Raghavan 2010). However, chemotherapy with docetaxel provides significant survival 
benefit in patients with CRPC (Tannock et al. 2004, Petrylak et al. 2004), and treatment 
regimens together with several other chemotherapeutics, such as cabazitaxel, prednisone 
and sartraplatin, are being investigated in clinical studies as second-line therapy for 
advanced prostate cancer (Shepard & Raghavan 2010). New therapeutic agents that are not 
directed against rapidly proliferating cells are urgently needed in treatment of prostate 
cancer, because the proliferative fraction of prostate cancer cells is usually less than 10% 
(Berges et al. 1995) and only a fraction of the patients with metastatic prostate cancer 
responds to current chemotherapeutics. Targeted therapy forms currently in clinical trials 
for advanced prostate cancer include antiangiogenic and bone-targeted agents, and 
immunotherapies, like the sipuleucel-T vaccine, as well as specific inhibitors for critical 
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survival signaling proteins, such as the Src kinases, mammalian target of rapamycin 
(mTOR) and insulin-like growth factor receptor I (reviewed by Fizazi et al. 2010).  
 
1.2 Growth factor-induced survival signaling in prostate cancer 
 
Proliferation of normal cells depends on the presence of mitogenic growth factors (GFs) in 
the surroundings of the cell. Stimulation of the cell surface growth factor receptors (GFRs) 
by these ligands leads to activation of intracellular signaling pathways and regulation of 
cell differentiation, growth, proliferation, survival, migration and metabolism. Cancer cells, 
in contrast, frequently harbor mechanisms that make them self-sufficient in terms of these 
signals through acquisition of mutations in key proteins of the pathways. Such 
oncoproteins include GFRs and their downstream signaling molecules, like the small 
GTPase Ras, which is found mutated in perhaps one quarter of all human tumors (Hahn & 
Weinberg 2002). 
 
GFs can function in autocrine, paracrine or endocrine manner with some GFs displaying 
more local regulatory roles [epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF)] and others regulating growth and metabolism at the whole organism level 
[insulin, insulin-like growth factor I (IGF-I)]  (reviewed by Pollak 2009). It has been 
estimated that upregulation of the GFR signaling and the downstream phosphatidylinositol-
3-OH kinase (PI3K) pathway occurs approximately in 30–50% of prostate cancers 
(reviewed by Morgan et al. 2009). Thus, the PI3K signaling pathway constitutes a key 
target for prostate cancer therapy (reviewed by Engelman 2009, Morgan et al. 2009, Wong 
et al. 2010). In addition, extensive crosstalk exists between the androgen receptor signaling 
and the PI3K signaling pathways. Activation of PI3K signaling through GFRs may play a 
critical role in allowing prostate tumors to maintain continued proliferation in low-
androgen environments, thereby promoting the development of CRPC (reviewed by 
Mulholland et al. 2006).  
 
1.2.1 Receptor tyrosine kinase activation by growth factors 
Growth factor receptors are receptor tyrosine kinases (RTKs) that convey signals through 
activation of a conserved tyrosine kinase domain. All the 58 currently known human RTKs 
divided into 20 subfamilies have a similar molecular architecture, with ligand-binding 
domains in the extracellular region, a single transmembrane helix, and a cytoplasmic 
region that contains the protein tyrosine kinase domain as well as additional regulatory 
regions (reviewed by Lemmon & Schlessinger 2010). Binding of the ligand stabilizes the 
interaction between the individual receptor molecules in a RTK dimer, which leads to 
sequential trans-autophosphorylation of the tyrosine kinase domains and subsequent 
release of the autoinhibitory interactions in each receptor (Lemmon & Schlessinger 2010). 
Autophosphorylation of the tyrosine kinase domain creates phosphotyrosine-based binding 
sites for a number of cytoplasmic signaling molecules containing Src homology-2 (SH2) or 
phosphotyrosine-binding (PTB) domains (Songyang et al. 1993, Kavanaugh & Williams 
1994). They may bind directly to RTKs or via docking proteins, such as Grb-2, IRS-1 
(Insulin receptor substrate-1) and Gab-1 (Grb-2 associated binder-1), which are recruited to 
and phosphorylated by RTKs (reviewed by Schlessinger 2000). The assembled complexes 
initiate signaling cascades leading to enhanced protein synthesis and transcriptional 
regulation of target genes involved in cell survival, growth, and differentiation.  
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The two major signaling cascades triggered upon RTK stimulation comprise the PI3K/Akt 
pathway and the mitogen-activated protein kinase (MAPK) pathway (Figure 2), although 
activation of other signaling proteins, such as phospholipase Cγ and signal transducer and 
activator of transcription (STAT) also occurs (Schlessinger 2000). The MAPK pathway 
involves binding of the adaptor Grb-2 directly or via Shc to the tyrosine phosphorylated 
RTK, and subsequent recruitment of the guanine nucleotide exchange factor son of 
sevenless (Sos) close to the plasma membrane (reviewed by Margolis & Skolnik 1994). 
Sos activates membrane-tethered small GTPase Ras proteins by converting them from 
inactive GDP-bound state to active GTP-bound state. Activated Ras proteins further 
stimulate c-Raf-1 that phosphorylates mitogen-activated protein kinase kinases 1 and 2 
(MEK1/2). MEK, in turn, phosphorylates extracellular signal-regulated protein kinase 1 
and 2 (ERK1/2) that again phosphorylates a variety of substrates in the cytoplasm and in 
the nucleus. 
 
 
 
 
Figure 2. Growth factor (GF) –
stimulated receptor tyrosine kinases 
(RTK) activate the PI3K and MAPK 
pathways. Auto-phosphorylated RTK 
recruits adaptor proteins as well as 
enzymes like PI3K and Sos. Activation 
of the small GTPase Ras by Sos induces 
the MAPK pathway via activation of 
Raf. Thereafter, sequential 
phosphorylations lead to activation of 
MEK and ERK. PI3K, in turn, activates 
the Akt kinase. Both pathways promote 
cell survival and proliferation. 
 
 
 
 
 
 
Aberrant RTK activation in human cancers is principally mediated by autocrine activation, 
chromosomal translocations, RTK overexpression or gain-of-function mutations (Lemmon 
& Schlessinger 2010). Growth of normal and malignant prostate cells is also regulated by 
RTKs, such as IGF-I receptor (IGF-IR), EGFR, fibroblast growth factor receptor (FGFR), 
PDGF receptor (PDGFR) and VEGFR (reviewed by Hellawell & Brewster 2002). In the 
prostate, stromal cells produce most of the GFs, which act on the GFRs on epithelial cells. 
In prostate cancer, the production of most GFs is upregulated and autocrine pathways 
emerge in epithelial cells for example for IGF-I and FGF (Hellawell & Brewster 2002). 
Most prostate cancers arise from the epithelial compartment, where EGF and IGF-I have 
important functions in promotion of cell growth, proliferation, differentiation and survival.  
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1.2.2 Phosphatidylinositol-3-OH kinase generates lipid second messengers 
Among RTK-induced signaling pathways, the PI3K pathway has been identified as a key 
mechanism in carcinogenesis and survival of many different types of cancer (reviewed by 
Engelman 2009). When PI3Ks are activated by G-protein coupled receptors (GPCRs), 
RTKs or other cell surface receptors that induce tyrosine kinase activity, they 
phosphorylate the 3′-hydroxyl group of plasma membrane inositol lipids. According to 
their substrate preference and sequence homology, PI3Ks can be divided into three classes 
(I-III), of which Class I PI3Ks primarily generate phosphatidylinositol-3,4,5-trisphosphate 
(PIP3, Figure 3) by phosphorylation of phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2). 
These PI3Ks are further grouped into two subfamilies with distinct receptors to which they 
are recruited. Class IA PI3Ks are activated by growth factor RTKs, whereas the class IB 
PI3Ks are activated upon recruitment to GPCRs. The class IA PI3Ks seem to be most 
involved in cancer (Engelman 2009).   
 
 
 
Figure 3. Phosphatidylinositol-3,4,5-trisphosphate (PIP3).  
 
Phosphate and tensin homolog located on human chromosome number 10 (PTEN) 
phosphatase counteracts the class I PI3K activity by removing phosphates from PIP3 
promoting formation of PIP2 (Maehama & Dixon 1998). The function of this tumor 
suppressor is commonly disturbed in prostate cancer, resulting in constitutive activation of 
the PI3K pathway (Li et al. 1997, Vlietstra et al. 1998). Overwhelmingly, loss of 
heterozygosity or mutation at the PTEN locus occurs in up to 35% and 12% of prostate 
cancer samples, respectively (Engelman et al. 2006). The activity of the PI3K pathway can 
also be enhanced by increased RTK activation or genetic mutation and amplification of key 
components of the pathway (Engelman 2009). 
 
The class IA PI3Ks are heterodimers consisting of a p85 regulatory subunit and a p110 
catalytic subunit, which both come in numerous isoforms. Three longer p85 regulatory 
subunits, p85α, p85β and p55γ, as well as two shorter isoforms, p55α and p50α, interact via 
their p110-binding domain with the three catalytic subunits, p110α, p110β and p110δ. In 
addition to the C-terminal catalytic domain and other regulatory structures, the p110 
subunits contain a Ras-binding domain (RBD) that mediates their activation by the small 
GTPase Ras. The class IA PI3Ks are recruited to the plasma membrane by the SH2 
domains of the p85 regulatory subunit that bind tyrosine-phosphorylated consensus 
sequences at either active RTKs or adaptor proteins that bind to them (Carpenter et al. 
1993). Inhibition of the catalytic subunit p110 by the regulatory p85 subunit is released 
upon binding, which leads to enzymatic activation of PI3K (Yu et al. 1998). The produced 
PIP3 functions as a lipid second messenger that recruits to plasma membrane a wide array 
of a pleckstrin homology (PH) domain -containing signaling molecules (reviewed by 
DiNitto et al. 2003). The protein serine/threonine kinase Akt (also known as PKB) is a 
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primary target of PIP3 (Franke et al. 1997, Klippel et al. 1997). The PI3K pathway 
activation has been associated with advanced pathological tumor stage, increased incidence 
of lymph node metastases and development of androgen-independent growth, which is 
why PI3K and its downstream signaling molecules offer critical drug targets for 
therapeutic intervention in prostate cancer (reviewed by Morgan et al. 2009). 
 
1.2.3 Akt activity promotes cell growth and survival 
c-Akt is the cellular homolog of the transforming oncogene of the AKT8 retrovirus (Staal 
1987). The mammalian Akt family of serine/threonine kinases comprises three isoforms 
(Akt1–3) that are highly conserved throughout evolution, but present different expression 
profiles and may have overlapping and distinct roles in cancer (reviewed by Altomare & 
Testa 2005). By phosphorylation of target proteins, Akt regulates a wide range of cellular 
functions, such as protein synthesis, cell metabolism, cell cycle progression and cell 
survival (reviewed by Datta et al. 1999) (Figure 4). PI3K activation leads to accumulation 
of PIP33, which recruits the normally cytoplasmic Akt as well as phosphoinositide-
dependent protein kinase 1 (PDK1) to the plasma membrane through PH domain 
interactions (Franke et al. 1997). This colocalization leads to Akt phosphorylation by 
PDK1 at the Tyr308 (Alessi et al. 1997) and by mTOR complex 2 at Ser473 (Sarbassov et 
al. 2005). These two phosphorylation events are required for full activation of the Akt 
kinase and subsequent phosphorylation of downstream targets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Examples of Akt-regulated signaling pathways for cell survival, growth and proliferation.  
See text for details. Adapted from (Engelman et al. 2009). 
 
 
Akt activates mTOR complex 1 that stimulates cellular translation machinery by 
phosphorylation of S6-kinase (S6K) and 4E binding protein 1 (4E-BP1) (reviewed by 
Raught et al. 2001), and inactivates glycogen synthesis by phosphorylation of glycogen 
synthase kinase 3β (GSK-3β) (Cross et al. 1995). Phosphorylation of GSK-3β also results 
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in stabilization the cell cycle proteins c-Myc and cyclin D1 that in the absence of RTK 
activation become degraded (reviewed by Liang & Slingerland 2003). In muscle and fat, 
Akt upregulates expression of GLUT4 glucose transporter, thereby promoting glucose 
uptake (Kohn et al. 1996). Activation of Akt favors G1/S cell cycle transition by blocking 
the transcription of cell cycle inhibitors, such as p27KIP1, through phosphorylation of 
Forkhead Box O (FoxO) transcription factors (Liang & Slingerland 2003). Other targets of 
FoxO that become suppressed upon Akt activation include the proapoptotic molecules 
BH3-interacting mediator of cell death (Bim) and CD95 ligand. Akt can promote cell 
survival also directly by phosphorylation of the proapoptotic proteins Bad (Bcl-2-
antagonist of cell death) and procaspase-9 leading to their inactivation (Datta et al. 1997, 
Cardone et al. 1998). Furthermore, Akt-mediated phosphorylation of mouse double minute 
2 (MDM2) leads to proteasomal degradation of p53, which supports cell cycle progression 
and inhibits p53-induced apoptosis upon cellular stress (Mayo & Donner 2001). Akt is also 
able to activate the IkB kinase (IKK), a positive regulator of the nuclear factor kappaB 
(NF-κB) transcription factors, which promote the transcription of antiapoptotic genes 
(Kane et al. 1999). 
 
In addition to ubiquitin-dependent Akt degradation and caspase-dependent Akt cleavage, 
Akt signaling can be attenuated by the protein phosphatases PP2A and pleckstrin 
homology domain leucine-rich repeat protein phosphatase (PHLPP) that dephosphorylate 
Akt (reviewed by Liao & Hung 2010). More than 50% of prostate carcinomas exhibit Akt 
hyperactivity and the therapeutic use of Akt inhibitors is currently being investigated 
(Altomare & Testa 2005). For example, simultaneous targeting of several Akt isoforms or 
inhibition of both mTOR complexes by pharmaceutical compounds may be beneficial in 
prostate cancer treatment (reviewed by Sarker et al. 2009). 
 
 
2. REGULATION OF APOPTOTIC CELL DEATH 
2.1 Activators and inhibitors of apoptosis 
 
Apoptosis is the predominant mechanism of programmed cell death that animals employ 
for coordinated elimination of excess or damaged cells during development and 
maintenance of tissue homeostasis (Kerr et al. 1972). However, as errors occur in 
biological systems, also regulation of apoptosis may fail. Excessive cell loss due to 
apoptotic cell death is known to occur in various human pathologies, including cerebral 
ischemia (reviewed by Broughton et al. 2009), AIDS (reviewed by Muthumani et al. 
2003), and neurodegenerative disorders, such as Alzheimer’s disease (reviewed by Rohn 
2010). Excessive cell accumulation because of impaired apoptosis is key component of 
cancer development (reviewed by Hanahan & Weinberg 2000), and contributes to the 
etiology of several autoimmune diseases (reviewed by Maniati et al. 2008).  
 
At the cellular level, apoptosis can be triggered by a variety of stimuli, including DNA 
damage, chromosomal abnormalities, growth factor withdrawal, viral infection, oncogene 
activation, substrate detachment, hypoxia and death receptor activation. Apoptosis is an 
energy-dependent process that occurs in sequential steps of morphological events (Wyllie 
et al. 1980). The dying cell undergoes nuclear and cytoplasmic condensation, blebbing of 
the plasma membrane, and fragmentation into membrane-enclosed particles. Professional 
Review of Literature 
 20 
phagocytes, including neutrophils, monocytes, macrophages and dendritic cells, or the 
neighboring cells rapidly identify and engulf these apoptotic bodies, thereby preventing 
induction of inflammatory response. The opposite happens when a cell dies a necrotic cell 
death. Swelling of the cell and rupture of the plasma membrane result in release of the cell 
contents into surrounding tissues, which is why necrosis can cause inflammation. Necrosis 
has traditionally been defined as an accidental and uncontrolled process, but accumulating 
evidence now suggests that also necrosis can occur in a more regulated manner through 
specific signaling events (reviewed by Golstein & Kroemer 2007). Whether a cell dies by 
apoptosis, necrosis or by other characterized modalities of programmed cell death between 
these two classical types, depends on the nature and severity of the stimulus, as well as the 
cell type. Crosstalk between these cell death pathways even enables switching from one 
mode to another in case the functional requirements for a particular cell death modality are 
not met. Of the various forms of programmed cell death, apoptosis is the major regulator of 
embryogenesis and organismal homeostasis. 
 
2.1.1 Caspases – The executers of apoptosis 
The biochemical markers of apoptosis include fragmentation of nuclear DNA, cell surface 
exposure of phosphatidylserine phospholipids, and activation of caspases, the specialized 
cysteine-dependent aspartate proteases that execute the apoptotic cell death (reviewed by 
Hengartner 2000). In contrast, the caspase-independent forms of programmed cell death, 
including autophagy and necroptosis, are executed typically by other cellular proteases, 
such as cathepsins and calpains (reviewed by Bröker et al. 2005). Caspases are expressed 
as inactive zymogens, procaspases, which can be activated by specific proteolysis. Upon 
apoptotic stimuli, the hierarchical activation of caspases is set off by the activation of the 
initiator caspases, including caspase-2, -8, -9, and -10, by induced proximity at 
multiprotein platforms (Muzio et al. in 1998, Chen et al. 2002, Boatright et al. 2003, 
Bouchier-Hayes et al. 2009). Upon dimerization at the activating complexes, initiator 
caspases undergo autocleavage that stabilizes the active enzyme (Pop et al. 2007). The 
stimulated initiator caspases proteolytically activate the downstream effector caspases, 
including caspase-3, -6 and -7. As the effector procaspases already form constitutive 
dimers, the only requirement for their activation is the cleavage that allows the caspase to 
adopt the active conformation (reviewed by Riedl & Shi 2004). The objective of these 
sequential activation events is the amplification of the original death signal. At the terminal 
phase of apoptosis, hundreds of structural and regulatory proteins are specifically cleaved 
by caspases, which leads to death of the cell (reviewed by Lüthi & Martin 2007). Caspase-
1, the prototype of inflammatory caspases, which also include caspase-4, -5, -11, -12 and -
13, contributes to the maturation of inflammatory cytokines instead of apoptosis-induction, 
and can be activated in the inflammasome complex (Martinon et al. 2002).  
 
Caspases are subject to multiple regulatory mechanisms. Indeed, the regulation of initiator 
caspase activation needs to be careful, as the activation of these apical proteases will 
trigger the cascade of downstream caspase activation and apoptosis. The prodomains of 
initiator caspases contain conserved interaction modules that serve in formation of 
homotypic protein interactions and in generation of the first proteolytic signal in the 
apoptosis pathway. The two death effector domains (DEDs) on caspase-8 and caspase-10 
mediate the recruitment and dimerization of these caspases at active cell surface death 
receptors (DRs) via the adaptor Fas-associated death domain protein (FADD) in activation 
of the extrinsic apoptosis pathway (Muzio et al. 1998). Caspase-9 and caspase-2 initiate 
apoptosis through the intrinsic pathway via their caspase-associated recruitment domains 
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(CARDs), which mediate homotypic interactions in formation of the activating platforms 
for these caspases (Hofmann et al. 1997). The extrinsic and the intrinsic apoptosis 
pathways serve to start the apoptotic process in response to signals of different origin. 
Extracellular cytokines called death receptor ligands engage the extrinsic pathway through 
the cell surface DRs, while mitochondria play a critical role in induction of apoptosis by 
cell intrinsic cues.  
 
2.1.2 Caspase-inhibitory proteins suppress apoptotic signaling 
The family of Fas-associated death domain-like interleukin-1β-converting enzyme 
(FLICE) -inhibitory proteins (FLIPs), comprising three mammalian isoforms, c-FLIP long 
(FLIPL), c-FLIP short (c-FLIPS) and c-FLIPR, and a viral FLIP, has a critical function in 
regulation of DR-mediated initiator caspase activation (Thome et al. 1997, Irmler et al. 
1997, Hu et al. 1997). As the c-FLIP proteins are homologous to caspase-8 and caspase-10, 
they contain also the two DEDs and can be recruited to activated DRs and dimerize with 
caspases (Irmler et al. 1997).  c-FLIP, however, lacks both the catalytic active site and the 
residues that form the substrate-binding pocket of an active caspase. This feature makes c-
FLIP enzymatically inactive, unable to promote caspase activation and thereby powerful 
dominant negative inhibitor of caspase-8 and caspase-10 activation. Not surprisingly, 
mouse embryonic fibroblasts from c-FLIP knockout animal are more sensitive to extrinsic 
apoptosis induction (Yeh et al. 2000). c-FLIPL has an inactive caspase-like catalytic 
domain at the C-terminus, while the shorter isoforms, c-FLIPS and c-FLIPR, completely 
lack the catalytic domain and instead have unique splicing tails. Differential regulation and 
function of c-FLIP isoforms are based on these structural differences. The short c-FLIP 
isoforms simply block recruitment and activation of caspase-8, but c-FLIPL:caspase-8 
dimerization leads to partial cleavage of both proteins and localized proteolytic activity of 
caspase-8 (Krueger et al. 2001). c-FLIPL may exert an antiapoptotic role in caspase 
activation when expressed in large amounts, but when present in lower amounts, c-FLIPL is 
likely to promote caspase-8 and caspase-10 activity (Chang et al. 2002). Interestingly, c-
FLIP is not only an inhibitor of caspase activation, but can also promote activation of NF-
κB and ERK survival signaling pathways (Kataoka et al. 2000). As accumulating evidence 
indicates that overexpression of c-FLIP in cancer correlates with inhibition of DR-
mediated apoptosis and resistance to chemotherapy, c-FLIP has become an attractive target 
for cancer therapy (reviewed by Safa et al. 2008). 
 
Another critical group of proteins controlling the activity of both initiator and effector 
caspases is the inhibitor of apoptosis (IAP) protein family (reviewed by Gyrd-Hansen & 
Meier 2010). IAPs are defined by the presence of 1–3 baculovirus IAP repeat (BIR) protein 
domains that can bind to caspases. Some of IAPs contain a RING domain with the 
capability to function as an E3 ubiquitin ligase and to target proteins to proteasomal 
degradation.  The X-linked IAP (XIAP) has been reported to directly inhibit the activity of 
the executioner caspases-3 and -7 and the initiator caspase-9 (Eckelman & Salvesen 2006). 
However, caspase-independent actions of IAPs by employment of the ubiquitin ligase 
activity promote the activation of NF-κB survival-signaling, which might be the most 
important contribution of XIAP and the cellular IAPs, cIAP1 and cIAP2, in regulation of 
cell fate as well as tumorigenesis (Gyrd-Hansen & Meier 2010). IAPs are recruited to NF-
κB activating signaling complexes, where ubiquitination not only regulates degradation of 
target proteins, but also creates docking sites for interacting proteins (Gyrd-Hansen & 
Meier 2010). 
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2.1.3 Mitochondrial permeabilization releases proapoptotic factors 
The mitochondria undergo two major alterations upon apoptosis-induction. These are the 
outer mitochondrial membrane permeabilization (MOMP), and the loss of the 
electrochemical gradient (mitochondrial polarity) that normally is present across the inner 
mitochondrial membrane. It is commonly accepted that MOMP precedes the mitochondrial 
membrane depolarization and dictates the point-of-no-return in cellular apoptosis. The 
mitochondrial apoptosis pathway, also known as intrinsic pathway, can be triggered by 
intracellular events through induction of MOMP. Permeabilization of the outer 
mitochondrial membrane (OMM) is currently thought to occur by formation of proteolipid 
pores, when the proapoptotic B-cell lymphoma gene 2 (Bcl-2) family proteins Bcl-2-
associated X protein (Bax) and Bcl-2 homologous antagonistic/killer (Bak) homo-
oligomerize within the OMM (Wei et al. 2001).  
 
When MOMP is induced, apoptogenic proteins are released from the mitochondrial 
intermembrane space to the cytosol. These proteins include cytochrome c, SMAC (second 
mitochondria-derived activator of caspases)/DIABLO (direct inhibitor of apoptosis (IAP)-
binding protein with low pI), AIF (apoptosis-inducing factor), EndoG (endonuclease G) 
and Omi/HTRA2 (high-temperature-requirement protein A2) (Susin et al. 1999, Du et al. 
2000, Verhagen et al 2000, Li et al. 2001, Suzuki et al. 2001). In intact mitochondria 
cytochrome c resides in the mitochondrial intermembrane /intercristae spaces and functions 
as an electron transporter in the respiratory chain. Once released from the mitochondria, 
cytochrome c binds to the apoptotic protease activity factor-1 (Apaf-1) in the cytosol, 
which triggers the oligomerization of Apaf-1 into a ring-like structure in the presence of 
ATP (reviewed by Riedl & Salvesen 2007). Following formation of this structure called 
the apoptosome, the CARD domains on Apaf-1 molecules become exposed, cytosolic 
procaspase-9 monomers are recruited to apoptosome via CARD domain interactions, and 
caspase-9 is activated (Zou et al. 1999). The activation does not require caspase-9 cleavage 
but occurs by dimerization of the procaspase-9 monomers (Renatus et al. 2001). As an 
initiator caspase, caspase-9 will propagate the apoptotic signal by cleaving and activating 
effector caspases, like caspase-3, eventually causing cell death. The mitochondrial protein, 
Smac/DIABLO, which also is released form the mitochondria after MOMP, inhibits IAPs 
by direct inhibition and induction of their proteasomal degradation, thereby ensuring that 
the mitochondrial caspase cascade will eventually result in apoptosis of the cell (Chai et al. 
2000). 
 
The therapeutic effect of many conventional cancer treatments is based on their ability to 
initiate the mitochondrial apoptosis pathway by inducing DNA damage or the production 
of reactive oxygen species (ROS)  (reviewed by Ozben 2007). Following oxidative, 
genotoxic or oncogenic stress, the tumor suppressor protein p53 is stabilized and 
transcriptionally regulates many genes involved in apoptosis, cell-cycle arrest, and other 
cellular functions (Zhao et al. 2000). In the cytosol, p53 promotes apoptosis independent of 
its transcriptional activity by localizing to the mitochondria (Marchenko et al. 2000) and 
interacting with the Bcl-2 family proteins that regulate mitochondrial integrity (reviewed 
by Yee & Vousden 2005). The stabilized p53 is also involved in activation of caspase-2 in 
response to genotoxic stress in a complex called the PIDDosome (Tinel & Tschopp 2004). 
Caspase-2 forms this complex together with RIP-associated ICH-1/CED-3 homologue with 
death domain (RAIDD) and p53-induced protein with death domain (PIDD). Unlike other 
initiator caspases, caspase-2 does not directly activate executioner caspases, but instead 
acts via MOMP to induce apoptosis (Guo et al. 2002). 
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2.1.4 Regulation of the mitochondrial integrity by the Bcl-2 protein family  
Permeabilization of the OMM is controlled through interactions of the proapoptotic and 
antiapoptotic proteins of the Bcl-2 family, which is characterized by Bcl-2 homology (BH) 
domains in the protein structure (Figure 5) (Reviewed by Chipuk et al 2010). The 
functional activity of the Bcl-2 family proteins is based on homo- and heterodimerization 
by interaction of the BH3 domain α helix with a groove formed by the BH1 and BH2 
domains (Sattler et al. 1997). The antiapoptotic Bcl-2 protein subfamily members, A1, Bcl-
2, Bcl-w, Bcl-xL and Myeloid cell leukemia 1 (Mcl-1), contain four BH domains and act 
by sequestering the proapoptotic Bcl-2 proteins, thereby preventing their participation in 
apoptotic complexes (Cheng et al. 2001). The proapoptotic Bcl-2 proteins include the 
multidomain effector proteins, Bax and Bak, as well as the BH3 domain–only subfamily. 
The release of the effectors Bax and Bak leads to their homo-oligomerization at the OMM, 
and formation of pore complexes to promote MOMP. The BH3-only proteins are upstream 
sensors of cellular damage that can be divided to the “direct activators” and  
“sensitizers/de-repressors” (reviewed by Chipuk et al. 2010). The direct activators, Bim, 
BH3-interacting domain death agonist (Bid) and potentially also p53-upregulated 
modulator of apoptosis (PUMA), interact with both the antiapoptotic Bcl-2 proteins and the 
effectors Bax/Bak. These BH3-only proteins can directly induce Bax and Bak 
oligomerization and MOMP (Kim et al. 2006). The “sensitizers/derepressors”, Bcl-2-
associated death protein (Bad), Bcl-2-interacting killer (Bik), Bcl-2-modifying factor 
(Bmf), Harakiri (Hrk) and Noxa, predominantly bind to the antiapoptotic Bcl-2 proteins 
with the capacity to competitively liberate Bax and Bak from these repressors. In addition 
to the direct activator BH3-only proteins, p53 can bind and activate oligomerization of Bax 
and Bak (Chipuk et al. 2004, Leu et al. 2004). 
 
 
Figure 5.  The Bcl-2 protein family. Schematic overview of the Bcl-2 homology (BH) domains and 
membrane-inserting domains (TM) in members of each Bcl-2 protein category. Adapted from (Tait 
& Green 2010). 
 
Bcl-2 is a known oncoprotein that is able to co-operatively drive malignant progression in 
mouse models in vivo by promoting cancer cell survival (Vaux et al. 1988, Strasser et al. 
1990, Schmitt et al. 2000). It is clear that also Bax and Bak are critical mediators of 
apoptosis, as their combined deletion causes severe developmental defects in mice due to 
abolishment of most apoptotic processes (Lindsten et al. 2000). However, the model that 
regards Bid and Bim as direct activators of Bax and Bak, has been challenged by another 
model according to which all the BH3-only proteins simply function as neutralizers of the 
prosurvival Bcl-2 family members and thereby promote the release of Bax and Bak (Willis 
et al. 2007). The induction of Bax and Bak oligomerization can reportedly occur also by 
non-protein factors, such as heat shock and detergents (Hsu & Youle 1997, Pagliari et al. 
Review of Literature 
 24 
2005), and Bax and Bak –dependent apoptosis was observed to take place in the absence of 
Bid and Bim (Willis et al. 2007). These studies suggest that mechanisms alternative to Bid 
and Bim –mediated induction of Bax and Bak activation exist. The in vivo results of 
Merino et al. (2009) highlight that the direct interaction with Bax and the ability to engage 
the antiapoptotic Bcl-2 proteins are both important features in Bim BH3-only protein 
function, showing that these mechanisms of are not exclusive during MOMP induction.  
 
The Bcl-2 family members are regulated at the level of transcription, as well as by post-
translational mechanisms (reviewed by Chipuk et al. 2010). Different BH3-only proteins 
share little homology, and also seem to function as sensors for distinct cellular stresses. 
Phosphorylation of BH3-only proteins can lead to their sequestration by other proteins, and 
prevention of relocalization to the mitochondrial membrane. For example, growth factor 
stimulation promotes Bad phosphorylation at multiple residues, primarily by Akt, which 
leads to cytosolic sequestration and inactivation of Bad by the 14-3-3 proteins until Bad 
becomes dephosphorylated upon apoptotic stimuli (Zha et al. 1996, Wang et al. 1999). 
Also Bim is negatively regulated by Akt-mediated phosphorylation in response to survival 
signals (Qi et al. 2006), and by ERK1/2-mediated phosphorylation that targets Bim to 
proteasomal degradation (Ley et al. 2003). In contrast, phosphorylation of Bim by c-Jun N-
terminal kinase (JNK) upon cellular stress leads to the release of Bim from the dynein 
motor proteins and relocalization to the mitochondria where Bim promotes cytochrome c 
release (Lei & Davis 2003).  
 
2.1.5 Bid as a mediator between extrinsic and intrinsic apoptosis pathways   
The BH3-only protein Bid is regulated by proteolytic cleavage and subsequent exposure of 
the BH3 domain (Figure 6). Activated caspase-8 can cleave Bid to its truncated form, the 
C-terminal tBid, which then accumulates into the mitochondria and promotes MOMP (Li 
et al. 1998, Luo et al. 1998). In order to activate the proapoptotic function of Bid, the 
cleavage and proteasome-dependent degradation of the autoinhibitory N-terminal portion 
of cleaved Bid need to occur (Chou et al. 1999, Tan et al. 1999, Tait et al. 2007). The 
chain of events leading to tBid-mediated activation of Bax starts with rapid tBid 
association with the mitochondrial membrane, followed by Bax or Bak recruitment, 
insertion, and oligomerization (Wei et al. 2001, Kuwana et al. 2002, Lovell et al. 2008). 
The translocation of the C-terminal tBid to the mitochondria has been reported to depend 
on the N-terminal myristoylation of tBid, which promotes its insertion to the mitochondrial 
membrane (Zha et al. 2000). Targeting of tBid for proteasomal degradation functions as a 
mechanism for limiting the mitochondrial apoptosis cascade (Breitschopf et al. 2000).  
 
 
Figure 6. Schematic presentation of the Bid protein structure. Casein kinase II (CKII) 
phosphorylation site and cleavage sites for caspase-3, caspase-8, calpain, cathepsin, and granzyme B 
as well as the JNK-activated cleavage site are indicated. Modified from (Billen et al. 2009). 
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In addition to cleavage by caspase-8, Bid can be cleaved by caspase-3 downstream of 
cytochrome c release (Li et al. 1998, Slee et al. 2000). Bid may also be a physiologically 
relevant substrate for caspase-2 in heat shock (Li et al. 1998, Bonzon et al. 2006), 
granzyme B in T cell-mediated cytotoxicity (Sutton et al. 2000, Heibein et al. 2000), 
lysosomal proteases upon lysosomal permeabilization (Stoka et al. 2001, Reiners et al. 
2002) and calpains in ischemia and cisplatin-induced apoptosis (Chen et al. 2001a, Mandic 
et al. 2002). Phosphorylation of Bid at multiple sites close to the cleavage region by 
enzymes of the casein kinase family, and potentially also by other kinases, inhibits the 
caspase-mediated cleavage of Bid and its proapoptotic activation (Desagher et al. 2001, 
Degli-Esposti et al. 2003). JNK is involved in generation of a large C-terminal fragment of 
Bid, jBid, which accumulates to mitochondria but induces selective release of apoptotic 
factors from the mitochondria due to the longer N-terminal part (Deng et al. 2003). 
Furthermore, ATM kinase-phosphorylated Bid seems to play a role in DNA damage-
induced apoptosis and cell cycle arrest (Zinkel et al. 2005, Kamer et al. 2005). Careful 
control of the proapoptotic activity of Bid reflects its importance at the cross roads between 
the caspase-8-activating extrinsic apoptosis pathway and apoptosis signaling through the 
mitochondria. This link is of major significance, as many cell types require Bid-mediated 
activation of MOMP and cytochrome c release in order to commit to death receptor-
mediated apoptosis. 
 
2.2 Death receptor-mediated apoptosis 
 
The signals from the extracellular ligands to the intracellular caspase machinery are 
transmitted via a group of cell surface proteins called the DRs. This route of signaling is 
known as the extrinsic cell death pathway. DRs belong to the tumor necrosis factor 
receptor (TNFR) superfamily that comprises 29 proteins characterized by one to six 
extracellular cystein-rich domains (CRDs) (reviewed by Aggarwal 2003). Although most 
TNFRs are type I transmembrane proteins, some of them are anchored to plasma 
membrane by glycophospholipid moieties or secreted as soluble molecules. Once 
activated, the members of the TNFR family mediate a multitude of cellular functions from 
differentiation to regulation of immunological responses (Aggarwal 2003). A specific 
feature of the TNFR members that are classified as DRs, is the relatively conserved 
cytoplasmic death domain (DD) of approximately 80 amino acid residues that is required 
for signal transduction (Itoh & Nagata 1993, Tartaglia et al. 1993). To date, six DRs have 
been identified: TNFR1 (p55), CD95 (Fas/APO-1), DR3 (TRAMP), DR4 (TRAIL-
R1/TNFRSF10A), DR5 (TRAIL-R2/TNFRSF10B) and DR6 (Figure 7). Although 
ectodysplasin A receptor (EDAR) and nerve growth factor receptor (NGFR/p75NTR) also 
contain intracellular DD, these receptors are not typically designated as DRs. Several 
decoy receptors that lack functional signaling properties can compete with the DRs in 
ligand binding and inhibit DR signalling (reviewed by Askenazi & Dixit 1999). 
 
2.2.1 Death receptor ligands are important regulators of the immune system 
DRs are activated by their cognate ligands that belong to the TNF family of cytokines 
(Aggarwall 2003) (Figure 7). Of the 19 identified TNF superfamily ligands, five are known 
to activate DRs. Tumor necrosis factor α (TNFα) and lymphotoxin α (LTα) bind to 
TNFR1 (Dembic et al. 1990), CD95 ligand (CD95L, Fas-ligand) binds to CD95 (Suda et 
al. 1993), and TL1A binds to DR3 (Migone et al. 2002). Both CD95L and TL1A can also 
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interact with the soluble decoy receptor 3 (DcR3) (Pitti et al. 1998, Migone et al. 2002). 
Tumor necrosis factor-related apoptosis inducing-ligand (TRAIL/Apo2L) has been shown 
to bind five receptors, including two DRs, DR4 (Pan et al. 1997a) and DR5 (Pan et al. 
1997b, Sheridan et al. 1997), and two decoy receptors, decoy receptor 1 
(DcR1/TRIDD/TRAIL-R3/TNFRSF10C; Pan et al. 1997b, Sheridan et al. 1997) and decoy 
receptor 2 (DcR2/TRUNDD/TRAIL-R4/TNFRSF10D; Marsters et al. 1997). In addition to 
these four membrane-bound receptors, TRAIL binds with lower affinity to a soluble 
receptor, osteoprotegerin (OPG), with the consequence of blocking the 
antiosteoclastogenic activity of OPG and the apoptotic activity of TRAIL (Emery et al. 
1998).  The extracellular fragment of β-amyloid precursor protein (N-APP), characteristic 
to Alzheimer’s disease pathology, was only recently discovered to bind to DR6 and trigger 
neuronal degeneration, thereby functioning as a long lost ligand for DR6 (Nikolaev et al. 
2009).  
 
 
Figure 7. The interactions of TNF ligands with death receptors (DRs) and decoy receptors (DcRs). 
Single DR ligands can interact with the cystein-rich extracellular domains of several death domain 
(DD) containing DRs (grey) or DcRs (yellow) that do not have a functional DD. See text for details. 
Adapted from (Gonzalvez & Ashkenazi 2010). 
 
All death receptor ligands, except for lymphotoxin α and N-APP, are expressed as type II 
transmembrane proteins predominantly on the cell surface of immune cells, such as T cells, 
B cells, monocytes, dendritic cells and natural killer (NK) cells (Aggarwal 2003). In 
addition to transmitting apoptosis-inducing signals, DR ligands can activate signaling 
pathways that promote growth and survival, but some ligands are more potent than others 
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with this respect. All TNF ligands can activate to varying degree the NF-κB transcription 
factor that regulates expression of a large number of target genes involved in cell 
proliferation and survival as well as apoptosis (reviewed by Hayden & Ghosh 2008). 
TNFα, for example, is better known as a proinflammatory cytokine that induces 
proliferation, differentiation and cellular activation, but also elicits activation of caspases 
and apoptosis in certain cell types. TNFα is involved in various physiological and 
pathological processes, with the main focus on immune responses and autoimmunity 
(Aggarwal 2003).  
 
CD95L and TRAIL, in turn, represent the prototypic death receptor ligands that potently 
trigger cellular apoptosis. Like TNFα, CD95L also plays a critical role in regulation 
homeostasis in the immune system. The loss-of-function mutations gld or lpr, in mouse 
CD95L or the CD95 receptor, respectively, induce a severe lymphoproliferative phenotype, 
similar to the human autoimmune lymphoproliferative syndrome (ALPS) associated with 
mutations in the CD95 signaling pathway (Watanabe-Fukunaga et al. 1992, Takahashi et 
al. 1994, Rieux-Laucat et al. 1995, Fisher et al. 1995). Expression of CD95L and its 
receptor on activated T cells is involved in a process called activation-induced cell death 
(AICD) (Brunner et al. 1996) that mediates peripheral deletion of autoreactive T cells 
(reviewed by Bouillet & O’Reilly 2009). Expression of CD95L on sites of immune 
privilege, such as brain, uterus, eye and testis, attenuates induction of immune responses 
against foreign antigens at these locations (Griffith et al. 1995). Inducible cell surface 
translocation of CD95L from intracellular storage is employed in cytotoxic T cell and NK 
cell -mediated killing of infected or transformed target cells (Bossi & Griffiths 1999). The 
ability of CD95L to induce non-apoptotic signals has been evidenced for example by 
studies demonstrating, how CD95-signaling is able to enhance liver regeneration (Desbarts 
& Newell 2000), provide co-stimulation for activated T cells (Maksimow et al. 2006) and 
most recently, how CD95-mediated prosurvival signals promote tumor growth (Chen et al. 
2010). 
 
2.2.2 Regulation of death receptor ligand activity 
The activity of death receptor ligands can be modulated through their recruitment to 
dynamic plasma membrane domains, called membrane rafts (reviewed by Simons & Gerl 
2010). This membrane compartment, rich in sphingolipids and cholesterol, has been shown 
to accommodate multiple signaling receptors and their intracellular effectors. CD95L 
recruitment to membrane rafts enhances its killing activity possibly due to increased 
aggregation of both the ligand and the bound CD95 receptor at the target cell (Eramo et al. 
1994, Muppidi & Siegel 1994, Nachbur et al. 2006). Regulation of TNFα and TRAIL 
activity by distribution to plasma membrane rafts has not yet been characterized, but 
translocation of their receptors to rafts influences the outcome of DR signaling. While raft-
localized TNFR1 is more likely to induce survival signaling than apoptosis (Treede et al. 
2009), DR4 and DR5 have enhanced ability to trigger apoptosis, once recruited to 
membrane rafts (Rossin et al. 2009).  
 
Proteolytic shedding of the membrane-associated ligands by metalloproteases produces 
soluble forms of TNFα (Black et al. 1997) and CD95L (Tanaka et al. 1995) further 
expanding the possibilities for stringent regulation of death receptor ligand activity. In a 
recent in vivo study, O’Reilly and coworkers (2009) elucidated whether the soluble death 
ligands possess attenuated killing activity. They generated transgenic mice that specifically 
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lacked either the secreted from (sCD95L) or the transmembrane form of CD95L 
(mCD95L), and thereby demonstrated that only mCD95L was essential for cytotoxic 
activity, as only the mice lacking mCD95L developed severe lymphadenopathy and 
autoimmunity similar to CD95L-deficient mice. Soluble TNFα (sTNFα), on the other 
hand, has a different action profile than its transmembrane counterpart. Only sTNFα is able 
to sensitize T-cells for AICD (Muller et al. 2009), while non-cleavable TNFα can still kill 
tumor cells or virally infected cells (Perez et al. 1990, Borsotti et al. 2007). In contrast to 
metalloprotease-mediated cleavage of TNFα and CD95L, in vitro studies have 
demonstrated that TRAIL shedding might involve cellular cysteine proteases (Mariani & 
Krammer 1998). Further studies are required to elucidate if production of soluble TRAIL 
by shedding also occurs in vivo. 
 
2.2.3 The initial phases of death receptor activation 
Unlike their ligands, the DRs seem to be present on the surface of most normal and 
transformed cells. Increasing evidence suggests that several of the DRs and other TNFR 
family members arrange into preformed receptor complexes by homotypic interactions 
between the extracellular protein domains. These interactions have been shown to require 
the proximal N terminus of the receptor called the pre-ligand assembly domain (PLAD). 
Identification of PLAD interactions for most DRs, including TNFR1 (Chan et al. 2000), 
DR4, DR5 and DcR2 (Clancy et al. 2005) and CD95 (Papoff et al. 1999, Siegel et al. 
2000), has changed the common view of ligand-induced trimerization. Inhibition of 
TRAIL-induced apoptosis by decoy receptor DcR2 was found to function through PLAD-
mediated formation of mixed complexes with DR5 in CD8+ T cells (Clancy et al. 2005). 
As for CD95, ligand-independent association of the receptors in lipid rafts dictates 
sensitivity to CD95L-induced apoptosis in CD4+ T cells (Muppidi & Siegel 2004). These 
results demonstrate that pre-ligand assembly is an important step in the regulation of DR-
mediated cellular responses, and may thereby provide an interesting target for 
pharmacological intervention (reviewed by Chan 2007). 
 
It has become evident that certain cell signaling pathways require receptor internalization 
for full activation or generation of a different biological response. Receptor internalization-
dependent and -independent signaling pathways also play a role in DR signaling. The 
seemingly contradicting biological activities of DRs, namely promotion of both survival 
and apoptosis, might be related to the dynamics of receptor localization at the plasma 
membrane and endocytosis into the intracellular compartments (reviewed by Schütze et al. 
2008). For example, transmission of proapoptotic signals in response to TNFα has been 
shown to depend on internalization of the activated TNFR1 complex, while activation of 
NF-κB occurs when the receptor is located at the plasma membrane (Schneider-Brachert et 
al. 2004). Similarly, effective caspase-8 activation in response to CD95 ligation seems to 
require the post-translational modification of CD95 by palmitoylation, localization at 
plasma membrane lipid rafts, and internalization into the endosomes (Eramo et al. 2004, 
Feig et al. 2007). Inhibition of CD95 internalization, in turn, results in the activation of the 
MAPK and NF-κB signaling pathways (Lee et al. 2006). 
 
DRs can be divided into two types according to the primary adaptor protein that they 
recruit upon ligand binding and formation of multiprotein signaling platforms. The adaptor 
molecules contain domains that bind to DRs and create docking sites for downstream 
signal transduction. CD95, DR4 and DR5 recruit FADD protein and primarily induce 
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proapoptotic signaling. Representing the other DR-type, TNFR1 and DR3 bind TNF 
receptor-associated death domain (TRADD) protein and show mainly proinflammatory and 
immune-stimulatory activity (Hsu et al. 1995). Cross talk between these two signaling 
modules enables, for example, TNFR1 to signal via FADD to induce apoptosis, and for 
CD95, DR4 and DR5 to stimulate prosurvival pathways through activation of NF-κB and 
MAP kinases in some circumstances (reviewed by Wilson et al. 2009). 
2.2.4 TNFR1- and CD95-induced signaling cascades 
The presence of TNFR1 on almost all nucleated cell types suggests a very versatile role for 
TNFR1 in regulation of biological functions (reviewed by Vandenabeele et al. 1995). The 
diversity of TNFR1 signaling is reflected by the capacity of TNFR1 to form two temporary 
and spatially distinct cytoplasmic signaling complexes that can signal either NF-κB 
activation form the cell surface or apoptosis from the internalized receptors (Micheau & 
Tschopp 2003). The TNFR1 signaling complex I is rapidly formed at the plasma 
membrane and composed of the adaptor proteins TRADD and TNF receptor-associated 
factor 2 (TRAF2), as well as DD-containing receptor-interacting protein 1 (RIP1) and other 
proteins.  Several of the TNFR1-associated proteins, such as cIAP1/2 and TRAF2, have the 
ability to regulate the signaling output of the complex through their E3 ubiquitin ligase 
activity (reviewed by Wertz & Dixit 2010). Once ubiquitinated, RIP1 interacts with 
transforming growth factor-β-activated kinase 1 (TAK1), which subsequently activates the 
IKK complex (reviewed by Hayden & Ghosh 2008). This leads to inhibitor kappaB (IκB) 
phosphorylation, polyubiquitination and proteasomal degradation, liberating NF-κB to 
move into the nucleus where it regulates target gene transcription.  Through TRAF2 
interactions, TNFR1 can also activate MAP kinases, such as JNK or p38 (Lee et al. 1997, 
Yuasa et al. 1998). Thus, TNFR1 complex 1 mediates the proliferative and 
proinflammatory effects of TNFα. Internalization of the activated TNFR1 receptor 
complex is a prerequisite for the formation of the secondary intracellular complexes. 
TNFR1 complex IIA (RIP1/FADD/procaspase-8/10) and IIB (TRADD/FADD/procaspase-
8/10) are formed with the participation of the adapter protein FADD and procaspases-8 and 
-10 in the cytosol (reviewed by Wilson et al. 2009). Activation of the initiator caspases in 
TNFR complex II leads to activation of caspase-3 and eventually apoptosis. The complex 
II –mediated TNFR1 pathway resembles the proapoptotic signaling cascades induced by 
CD95L and TRAIL.  
 
Unlike its ligand, the CD95 receptor is expressed in a wide range of tissues, including the 
thymus, heart, liver and kidney (reviewed by Nagata 1997). It was initially identified as an 
antigen for a monoclonal antibody that induced apoptosis in tumor cells (Trauth et al. 
1989, Itoh et al. 1991, Oehm et al. 1992), after which studies of CD95-induced apoptosis 
have greatly elucidated the mechanisms and regulation of DR signaling. CD95-induced 
apoptosis can be counteracted by expression of the soluble DcR3, which has been reported 
to occur in tumors through genomic DcR3 amplification (Pitti et al. 1998). Ligand binding 
to preformed CD95 complexes initiates rapid clustering of the receptors into micro-
molecular aggregates and further into larger surface clusters that can even be visualized by 
fluorescence microscopy (Algeciras-Schimnich et al. 2002, Siegel et al. 2004, Feig et al. 
2007) (Figure 8).  In these structures, CD95 directly recruits FADD and caspase-8 via 
homotypic interactions to form the death-inducing signaling complex (DISC) at the 
cytoplasmic death domain (Boldin et al. 1995, Chinnaiyan et al. 1995, Kischkel et al. 
1995, Muzio et al. 1996).  DISC serves as a platform for activation of caspase-8 and 
caspase-10 by induced proximity (Medema et al. 1997, Vincenz & Dixit 1997, Muzio et al. 
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1998).  Recruitment of c-FLIP to CD95–DISC regulates activation of caspase-8 and 
caspase-10 and participates in transmission of antiapoptotic CD95-signaling (reviewed by 
Thome & Tschopp 2001). 
 
 
 
Figure 8. The extrinsic and intrinsic apoptotic signaling pathways. Programmed cell death can be 
triggered by the extrinsic pathway that is mediated by death receptors (DRs) or the intrinsic pathway 
that is induced upon cell damaging stresses. Binding of a death ligand leads to formation of a death-
inducing signaling complex (DISC) at the intracellular death domain of the DR and activation of 
initiator caspases like caspase-8. In the DISC, c-FLIP is capable of inhibiting caspase activation. The 
proapoptotic (Bax, Bak) and antiapoptotic (Bcl-2, Bcl-xL, Mcl-1) Bcl-2 proteins regulate the 
integrity of the mitochondrial outer membrane Upon initiation of the intrinsic apoptosis pathway, 
apoptogenic factors, like cytochrome c, Smac/DIABLO and AIF, are released from mitochondria. 
Formation of apoptosome complex in the presence of cytosolic cytochrome c leads to activation of 
the initiator caspase-9. The initiator caspases cleave and activate effector caspases, like caspase-3, 
that execute the cellular apoptosis. Inhibitor of apoptosis proteins (IAPs) that inhibit caspases can, in 
turn, be inactivated by cytosolic Smac/DIABLO. The DR pathway can be coupled to the intrinsic 
apoptosis pathway by caspase-mediated cleavage of Bid protein to truncated Bid (tBid) that promotes 
mitochondrial permeabilization. 
 
Cells that are sensitive to CD95L-induced apoptosis can be categorized into type I and II 
cells based on their requirement of MOMP for apoptosis-induction (Scaffidi et al. 1998, 
reviewed by Barnhart et al. 2003). Type I cells release large amounts of activated caspase-
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8 upon CD95 stimulation through efficient DISC formation followed by direct cleavage 
and activation of caspase-3. Type II cells, by contrast, produce only little active caspase-8 
at the DISC, and therefore require further amplification of the apoptotic signal through the 
activation of MOMP. Bid cleavage by active caspase-8 is likely to serve as the link 
between DISC formation and MOMP (Li et al. 1998, Luo et al. 1998). Consequently,  
overexpression of antiapoptotic Bcl-2 proteins rescues only type II cells from CD95-
incuced apoptosis (Scaffidi et al. 1998). Hepatocytes from mice expressing the human Bcl-
2 transgene were protected from CD95-mediated apoptosis, suggesting that they are type II 
cells, while thymocytes from the same mice remained susceptible to CD95L, and later 
became categorized as type I cells (Strasser et al. 1995, Lacronique et al. 1996). Further 
evidence for the type II nature of hepatocytes was provided in a study with Bid-deficient 
mice, which were found resistant to CD95-mediated hepatocellular apoptosis (Yin et al. 
1999). 
 
Most of the studied CD95L-sensitive type I tumor cells have mesenchymal-like features, 
whereas type II tumor cells display a more epithelial phenotype, suggesting that type I and 
II signaling might correlate with different stages of carcinogenesis during the EMT 
(Algeciras-Schimnich et al. 2003). However, many tumors are resistant to CD95-mediated 
apoptosis, and instead of promoting cell death, CD95-signaling may promote tumor growth 
in vivo (Chen et al. 2010). CD95L can induce cell motility and invasion in apoptosis-
resistant tumor cell lines and clones that are selected under chemotherapy, suggesting that 
CD95 may even contribute to metastasis (Barnhart et al. 2004, Ametller et al. 2010). More 
research efforts are needed to understand the tumor-promoting role of CD95 and how it 
may influence the outcome of cancer therapy. 
 
2.2.5 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
TRAIL was originally identified through sequence homology with TNFα and CD95L, as a 
novel proapoptotic member of the TNF superfamily (Wiley et al. 1995, Pitti et al. 1996). 
Like other members of the TNF superfamily, TRAIL is a homotrimeric molecule, and the 
principles of TRAIL trimer binding to three DR5 receptors, revealed by crystallography of 
the complex, resemble the receptor-ligand interactions observed for other TNFR 
superfamily members (Hymowitz et al. 1999). A unique feature of TRAIL is a zinc ion 
buried at the TRAIL trimer interface (Hymowitz et al. 2000). Binding of this zinc ion to a 
single cysteine residue on each monomer maintains the native structure and stability and, 
hence, the biological activity of TRAIL (Hymowitz et al. 2000).  
 
2.2.5.1 The roles of TRAIL in the immune system  
The physiological roles of TRAIL are not yet fully understood, but there are clear 
indications that TRAIL participates in regulating immune responses and in killing of 
potentially harmful cells. In addition to being widely expressed in hematopoietic cells, 
TRAIL has also been detected in other tissues, like prostate, lung, colon, placenta, and 
small intestine (Wiley et al. 1995). Expression of TRAIL can be induced in dendritic cells, 
macrophages, T cells and NK cells in an activation-dependent manner by cytokines, such 
as interferons (Kayagaki et al. 1999 Halaas et al. 2000, Liu et al. 2001, Sato et al. 2001). 
For example, viral infections upregulate TRAIL expression in T cells and NK cells, 
thereby enhancing the clearance of infected cells (Sato et al. 2001, Ishikawa et al. 2005).  
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Experimental work with transgenic mouse models has given new insight into the biological 
functions of TRAIL, including an important role in maintenance of self-tolerance. In mice, 
mDR5 (mTRAIL-R2, mKILLER) acts as a single ortholog of both human DR4 and DR5 
(Wu et al. 1999), and two decoy receptors (mDcTRAILR1 and mDcTRAILR2), which 
lack the cytoplasmic domain, have been identified (Schneider et al. 2003). Mice lacking 
expression of either TRAIL or mDR5 develop normally, suggesting that TRAIL-induced 
signaling is not essential in embryonic development (Cretney et al. 2002, Sedger et al. 
2002, Diehl et al. 2004, Finnberg et al. 2005). Unlike the mice with CD95 mutations, 
TRAIL or mDR5 knockout mice also seem to have normal resting immune cell populations 
(Cretney et al. 2003, Diehl et al. 2004, Cretney et al. 2008). Instead, mDR5-deficiency 
increases innate immune responses against certain types of pathogens, suggesting that 
TRAIL receptor activation may also negatively regulate innate immunity (Diehl et al. 
2004).  
 
Mice deficient in TRAIL demonstrate increased susceptibility to experimental autoimmune 
disease (Lamhamedi-Cherradi et al. 2003, Cretney et al. 2005), and treatment with 
antibodies that block endogenous TRAIL have been shown to exacerbate the disease 
condition in mouse models for arthritis and multiple sclerosis (Song et al. 2000, Hilliard et 
al. 2001, Cretney et al. 2005). These results strongly suggest that one of the functions of 
TRAIL in vivo is to inhibit autoimmune inflammation. Indeed, elevated serum levels of 
soluble TRAIL have been detected in patients with autoimmune diseases, such as lupus 
erythematosus and multiple sclerosis (Wandinger et al. 2003, Lub-de Hooge et al. 2005). 
The cellular mechanisms employed by TRAIL to prevent autoimmunity might be different 
from those used in TRAIL-mediated target cell killing. Instead of increasing T cell 
apoptosis, TRAIL was shown to inhibit T cell proliferative response and to induce cell 
cycle arrest (Song et al. 2000, Hilliard et al. 2001, Lunemann et al. 2002), demonstrating 
that TRAIL can also function through inhibition of immune cell activation and 
proliferation. Taken together, these findings indicate that TRAIL has an important 
regulatory role in both innate and adaptive immunity. 
 
2.2.5.2 Molecular mechanisms of TRAIL-induced signaling 
Binding of trimeric TRAIL to DR4 or DR5 promotes receptor clustering into larger 
aggregates and induces the formation of the DISC (Wagner et al. 2007) (Figure 9). Similar 
to the CD95 activation discussed above, recruitment of FADD at the cytoplasmic death 
domain of DR4 and DR5 and subsequent binding of caspase-8 and caspase-10 to FADD 
are essential steps for TRAIL-induced caspase activation and apoptosis (Bodmer et al. 
2000, Kischkel et al. 2000, Kuang et al. 2000, Sprick et al. 2000). The ligand-induced 
receptor clustering and caspase-8 activation can be modulated by enzymatic O-
glycosylation of conserved residues at the extracellular domain of DR4 and DR5 (Wagner 
et al. 2007). Recruitment and activation of caspase-10 at the DISC may be able to 
substitute for lack of caspase-8 in some model systems in induction of TRAIL-induced 
apoptosis (Kischkel et al. 2001, Wang et al. 2001), although the opposite has also been 
reported (Sprick et al. 2002). Furthermore, binding of c-FLIP to TRAIL-induced DISC 
modulates the outcome of DR4 and DR5 signaling. For example, selective knockdown of 
c-FLIPS and especially c-FLIPL, in several cancer cell lines enhances the recruitment and 
activation of caspase-8 at the TRAIL–DISC as well as sensitizes the cells to TRAIL-
induced apoptosis (Sharp et al. 2005). Ubiquitylation of caspase-8 at TRAIL–DISC has 
been shown to promote its translocation to intracellular ubiquitin-rich foci, where 
activation of the caspase-8 is enhanced (Jin et al. 2009). Bid cleavage, Bax/Bak-dependent 
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release of cytochrome c and caspase-9 activation have been shown to occur downstream of 
caspase-8 activation, when cells are treated with TRAIL (LeBlanc et al. 2002, Ravi & Bedi 
2002, Kandasamy et al. 2003) (Figure 8). 
 
 
 
 
 
Figure 9. Current model for TRAIL-induced signaling. Activation of pre-ligand assembled DR4 and 
DR5 receptors by TRAIL induces formation of DISC with FADD and caspase-8/10, and 
translocation to lipid raft membrane compartment that is linked to actin cytoskeleton. Lipid raft 
localization enhances the activation of initiator caspases in the TRAIL-DISC, which promotes 
apoptotic signaling. An activation platform for non-apoptotic TRAIL-signaling has been reported to 
form downstream of DISC assembly. This complex II consists of the adaptors FADD or TRADD, 
caspase-8/10, RIP-1, TRAF2 and NEMO/IKKγ, and can promote survival signaling via Akt, MAPK 
and NF-κB pathways. c-FLIP proteins are able to inhibit caspase activation at the DISC, but also to 
mediate NF-κB activation. Although the TRAIL–DISC has been shown to undergo clathrin-mediated 
endocytosis, it is not yet known, how internalization influences TRAIL-induced signaling. Adapted 
from (Gonzalvez & Ashkenazi 2010). 
 
Besides caspase activation via FADD, DR4 and DR5 are able to recruit TRADD and RIP1 
to activate the transcription factor NF-κB (Chaudhary et al. 1997, Schneider et al. 1997, 
Sheridan et al. 1997, Lin et al. 2000) (Figure 9). NF-κB activation by TRAIL is less 
efficient than the activation of NF-κB by TNFα (Sheridan et al. 1997), but it involves a 
similar activation platform downstream of DISC formation, also called complex II, 
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consisting of RIP1, TRAF2 and NEMO/IKKγ (Varfolomeev et al. 2005). TRAIL-induced 
NF-κB activity is likely to protect cells from apoptosis by inducing transcription of 
antiapoptotic proteins, but it has also been suggested to upregulate chemokines that 
mediate phagocytosis of the dying cell (Varfolomeev et al. 2005). In addition, TRAIL-
induced NF-κB activity was reported to account for increased proliferation, survival and 
invasiveness in cancer cells that are resistant to TRAIL-induced apoptosis (Ehrhardt et al. 
2003, Ishimura et al. 2006). It is very important for the use of TRAIL in cancer therapy 
that the physiological role of TRAIL-induced activation of the NF-κB signaling pathway is 
clarified. 
 
DR4 and DR5 have also been shown to activate MAPK and Akt kinase pathways. 
Although the TRAIL-induced signaling cascades to activation of the MAP kinases JNK 
and p38 seem to have cell type specific features, they have been reported to involve 
TRAF2 and RIP1 as well as caspase activity (Mühlenbeck et al. 1998, Hu et al. 1999, Lin 
et al. 2000, MacFarlane et al. 2000, Varfolomeev et al. 2005). The mechanisms that 
mediate activation of Akt or ERK1/2 signaling in response to TRAIL stimulation are less 
clear (Tran et al. 2001, Secchiero et al. 2003, Zhang et al. 2003), but may require similar 
complexes as JNK, p38 and NF- κB activation (Figure 9). 
 
Kinase-mediated phosphorylation events can, in turn, modulate the components of the 
TRAIL signaling pathway (reviewed by Tran et al. 2004). Transcription-independent 
effects of ERK1/2 signaling have been shown to inhibit caspase-8 activation upon TRAIL 
stimulation, but the molecular targets of ERK1/2 within TRAIL–DISC have not yet been 
defined (Tran et al. 2001, Söderström et al. 2002). Protein kinase C (PKC) was shown to 
phosphorylate c-FLIP and increase the stability of the short c-FLIP isoforms, thereby 
inhibiting caspase-8 activation in the TRAIL–DISC (Kaunisto et al. 2009), whereas 
recruitment of FADD to TRAIL–DISC can also be reduced by PKC (Harper et al. 2003). 
Although the antiapoptotic activity of Akt in TRAIL-induced apoptosis has often been 
attributed to the promotion of c-FLIP expression (Panka et al. 2001), several studies 
suggest that Akt is able to inhibits TRAIL signaling downstream of caspase-8 activation at 
the level of Bid cleavage (Chen et al. 2001, Nesterov et al. 2001, Kandasamy & Srivastava 
2002, Goncharenko-Khaider et al. 2010). Furthermore, Akt has been shown to inhibit 
apoptosis by phosphorylating other effectors of TRAIL signaling, including Bad (Datta et 
al. 1997), caspase-9 (Cardone et al. 1998) and XIAP (Dan et al. 2004). 
 
DR4 and DR5 localization to plasma membrane lipid rafs upon TRAIL-stimulation was 
demonstrated to play an important role also in TRAIL-induced apoptosis (Song et al. 
2007). Similar to the mechanisms observed for CD95, palmitoylation of DR4 at the 
cytoplasmic juxtamembrane region promotes localization to lipid rafts and generation of 
more efficient TRAIL-signaling (Rossin et al. 2009). Interestingly, the non-raft localized 
receptors were able to induce NF-κB and ERK1/2 survival signals upon TRAIL 
stimulation, even when the cells were treated with cholesterol-depleting agent, methyl-β-
cyclodextrin, that disrupts lipid rafts (Song et al. 2007). Clathrin-dependent death receptor 
internalization follows after DR4 and DR5 activation (Austin et al. 2006, Kohlhaas et al. 
2007), but unlike the TNFα-TNF-R1 and CD95L-CD95 receptor complexes, the TRAIL 
receptor-ligand complexes need not be internalized for DISC formation and apoptosis to 
occur (Austin et al. 2006, Kohlhaas et al. 2007) (Figure 9). In contrast, inhibition of 
endocytosis by dominant negative dynamin or hyperosmotic sucrose increases TRAIL-
induced apoptosis (Austin et al. 2006, Kohlhaas et al. 2007). Although receptor 
endocytosis appears not to regulate non-apoptotic and apoptotic signaling through DR4 and 
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DR5, as it has been shown to do for TNFR-1 and CD95 signaling (Schneider-Brachert et 
al. 2004, Lee et al. 2006), lipid raft localization could be one of the determinants that 
dictate, whether apoptosis or survival signaling is induced by TRAIL.  
 
The decoy receptors are unable to recruit DISC upon ligand binding, as the intracellular 
death domain of DcR2 is truncated (Marsters et al. 1997), and DcR1 completely lacks the 
cytoplasmic domain (Pan et al. 1997b, Sheridan et al. 1997). The GPI-anchored DcR1 acts 
as a competitor for TRAIL binding, preventing DR5-associated DISC assembly in lipid 
rafts, while interaction of DcR2 with DR5 allows DISC formation, but prevents DR4 co-
recruitment and initiator caspase activation within the DR5 DISC (Mérino et al. 2006). 
Whether DcR2 spontaneously interacts with DR4 and DR5 via the extracellular PLAD 
(Clancy et al. 2005), or whether the interaction is TRAIL-dependent (Mérino et al. 2006), 
remains controversial.  
 
2.2.5.3 TRAIL induces apoptosis selectively in cancer cells 
Employment of CD95L in cancer therapy is limited by induction of fatal liver damage by 
in vivo engagement of CD95 (Ogasawara et al. 1993). Systemic toxicity limits also the use 
of TNFα as an anticancer agent, but the harmful effects of TNFα are rather caused by NF-
κB -induced inflammatory responses than activation of caspases through TNFR-1 
(reviewed by Vassalli 1992). However, substantial amount of preclinical data indicate that 
TRAIL can in vitro and in vivo specifically trigger apoptosis in cancer cells without 
harming non-transformed cells. First, TRAIL was shown to induce apoptosis in a range of 
tumor cell lines (Wiley et al. 1995, Pitti et al. 1996). Repeated injections with soluble 
recombinant TRAIL were found to be safe in experimental animal models, and the 
injections actively suppressed growth of established human tumor xenografts in 
immunocompromised mice (Ashkenazi et al. 1999, Walczak et al. 1999). Since then, a 
large number of studies have shown that TRAIL and agonistic antibodies against DR4 and 
DR5 are able to induce apoptosis in wide range of cancer cell lines and primary tumor 
cells, while being non-toxic to most of normal cells (reviewed by LeBlanc & Ashkenazi 
2003, Hylander et al. 2005). Interestingly, TRAIL can enhance apoptosis in cancer cells 
that have lost functional tumor suppressor p53 (Ravi et al. 2004).  
 
The initial discrepancy between several studies demonstrating tumor-specific activity of 
soluble TRAIL (Lawrence et al. 2001, Hao et al. 2004, Ganten et al. 2005) and studies, 
which reported that human primary hepatocytes are very sensitive to TRAIL-induced 
apoptosis (Jo et al. 2000, Ichikawa et al. 2001, Mori et al. 2004), was shown to stem from 
different in vitro culture procedures as well as different versions of recombinant TRAIL 
used in the experiments (Lawrence et al. 2001, Ganten et al. 2006). In vitro cytotoxicity to 
hepatocytes was observed only when the investigators used recombinant TRAIL that 
contained an exogenous tag, such as polyhistidine or Flag, as this was shown to cause over-
aggregation of TRAIL receptors and apoptosis of hepatocytes (Lawrence et al. 2001, 
Ganten et al. 2006). Therefore, an untagged version of trimerized TRAIL has been used in 
further studies without toxicity normal cells.  
 
The significance of TRAIL in immune surveillance against cancer has been demonstrated 
in studies with TRAIL-deficient mice or mice treated with TRAIL-neutralizing antibody. 
These animals displayed increased susceptibility to initiation, growth and metastasis of 
experimental tumors (Cretney et al. 2002, Sedger et al. 2002, Takeda et al. 2002). 
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However, some studies could not detect a critical role for TRAIL in tumorigenesis, as loss 
of mDR5 or TRAIL did not increase the in vivo formation of intestinal tumors in 
adenomatous polyposis coli (APC) mutant mice (Yue et al. 2005) or Her2/neu-initiated 
mammary tumors (Zerafa et al. 2005), respectively. An age-related increase in malignancy 
was, however, observed in the latter study, in which aged TRAIL-/- mice developed 
lymphoma with higher occurrence than the wild type mice (Zerafa et al. 2005). When 
Grosse-Wilde et al. (2008) aimed at resolving the conflicting data with respect to the 
physiological role of the TRAIL system during tumorigenesis, they observed that mDR5-
deficiency did not increase the growth rate or progression of tumors in multistage mouse 
model of squamous cell carcinoma, but instead significantly enhanced metastasis to lymph 
nodes (Grosse-Wilde et al. 2008). Increased metastasis was also seen in mDR5 -/- mice on 
lymphoma-prone genetic background, even though the development of lymphomas was not 
influenced by the loss of mDR5 (Finnberg et al. 2008). These results suggest that TRAIL-
induced signaling may play a role specifically in the suppression of metastasis. 
 
2.2.5.4 Overcoming TRAIL resistance in cancer cells 
Although some TRAIL-sensitive cancer cell lines have been reported to undergo TRAIL-
induced apoptosis independent of the mitochondrial pathway (type I signaling) (Özören et 
al. 2000, Walczak et al. 2000), most of the tested cancer cells appear to behave in type II 
manner requiring the mitochondrial pathway to be activated for efficient caspase activation 
upon TRAIL treatment (Özören & El-Deiry 2002). Consequently, overexpression of Bcl-2 
or Bcl-xL inhibits TRAIL-induced apoptosis in a variety of transformed cells (Hinz et al. 
2000, Sun et al. 2001, Fulda et al. 2002). The type II behaviour of cancer cells might be 
caused by higher expression of inhibitor of apoptosis proteins (IAPs) that oppose efficient 
caspase activation (Srinivasula et al. 2000). However, it has become obvious that the 
TRAIL-sensitive cancer cells are not as common as initially thought. Approximately half 
of the tumor cell lines tested so far and the large majority of primary tumors are resistant to 
TRAIL-mediated apoptosis (reviewed by Koschny et al. 2007 and Mellier et al. 2010, 
Todaro et al. 2008). The mechanisms of TRAIL resistance are diverse and range from 
activation of antiapoptotic signaling pathways (NF-κB, MAPKs and PI3K/Akt), 
overexpression of antiapoptotic proteins (FLIP, Bcl-xL, Bcl-2 and IAPs) and deficiency of 
proapoptotic Bcl-2 proteins (Bax) to increased expression of TRAIL decoy receptors and 
reduced DR4/DR5 expression (reviewed by Mellier et al. 2010). For example, mutated Bax 
is often the reason for TRAIL resistance in colon cancer (LeBlanc et al. 2002), whereas 
deregulated PI3K/Akt signaling can be an important source of TRAIL resistance in 
prostate cancer (Chen et al. 2001b).  
 
As the initiation of cancer cell apoptosis via the intrinsic pathway can cause DNA damage 
in the surviving cells, like many chemotherapeutic agents do, sublethal TRAIL treatment 
has also been reported to provoke mutations (Lovric & Hawkins 2010). Therefore, further 
studies are required to determine the effects of TRAIL-treatment in TRAIL-resistant cells, 
which could respond to the treatment with enhanced survival signaling and even DNA 
damage (Secchiero et al. 2003, Lovric & Hawkins 2010), and careful selection of patients 
that would benefit from TRAIL treatment is needed. The extracellular domains of DR5 and 
DR4 can be O-glycosylated at specific residues by O-glycosylation enzymes, such as 
GALNT14, with the consequence of facilitating ligand-induced clustering of DR4 and 
DR5, DISC formation and capsase-8 activation (Wagner et al. 2007). Gene expression 
profiles of specific O-glycosylation enzymes may serve as important biomarker to predict 
the sensitivity of cancer cells to TRAIL-based therapy, as comparison of 119 cancer cell 
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lines revealed a strong correlation between expression of these enzymes and TRAIL-
sensitivity (Wagner et al. 2007).  
 
Various strategies are employed in preclinical studies to restore cancer cell sensitivity to 
TRAIL (reviewed by Ashkenazi & Herbst 2008). Many chemotherapeutics upregulate 
surface expression of TRAIL receptors by increasing their transcription or protein half-life, 
downregulate expression of antiapoptotic proteins, including IAPs, c-FLIP, Bcl-2, Bcl-xL 
and Mcl-1, or enhance TRAIL-DISC redistribution into lipid rafts, thereby causing a 
synergistic apoptotic effect when combined with TRAIL (reviewed by Mellier et al. 2010). 
Downregulation of c-FLIP by compounds, such as proteasome inhibitors and cytotoxic 
drugs, or by RNA interference is an efficient way to enhance TRAIL-induced signaling at 
the level of caspase-8 activation (reviewed by Safa et al. 2008). Inhibition of IAPs by using 
small molecule IAP antagonists enhances antitumor activity of TRAIL (Li et al. 2004, 
Voggler et al. 2009). ABT-737 is a BH3-mimetic small-molecule inhibitor of the 
antiapoptotic proteins, Bcl-2, Bcl-xL and Bcl-w, that does not directly induce apoptosis, 
but enhances the effects of other death signals, such as TRAIL treatment (Oltersdorf et al. 
2005, Nieminen et al. 2007a). Inhibition of cancer cell survival signaling by compounds, 
like the tyrosine kinase inhibitor sorafenib, also sensitizes cancer cells to TRAIL-induced 
apoptosis (Rosato et al. 2007). The combinatorial treatments can only be of clinical benefit 
if they do not harm normal human cells. Ganten et al. (2006) tested a range of common 
chemotherapeutics together with TRAIL and found that most combinations were not toxic 
to primary human hepatocytes. However, the actual safety profile of each combination will 
not be defined until investigated in clinical phase I studies. 
2.2.5.5 TRAIL receptor agonists in clinical trials for cancer therapy 
Recombinant human TRAIL (dulanermin) and fully human or humanized monoclonal 
agonistic antibodies against DR4 (mapatumumab) or DR5 (conatumumab, CS-1008, 
lexatumumab and PRO95780) are currently investigated in phase Ib/II clinical trials for 
cancer therapy. Altogether, these agents have been well tolerated at the tested doses and 
most agents did not reach the maximum tolerated dose (reviewed by Wiezorek et al. 2010). 
Modest single-agent antitumor activity has been observed in phase I trials in two patients 
with refractory disease; one partial response in non-small cell lung carcinoma treated with 
conatumumab and one in chondrosarcoma treated with dulanermin (Herbs et al. 2006, 
LoRusso et al. 2007). In a single-agent phase II study with mapatumumab, two partial 
responses and one complete response were observed among 40 patients with pretreated 
follicular non-Hodgkin lymphoma (Younes et al. 2005). As TRAIL receptor agonist 
monotherapy appears not to be potent enough, several on-going trials combine TRAIL-
based treatments with chemotherapy (Wiezorek et al. 2010). Significant increase in TRAIL 
antitumor activity has been observed in preclinical studies when the intrinsic apoptosis 
pathway is activated simultaneously with cytotoxic drugs or by sensitizing pretreatments 
that target the key mediators of TRAIL resistance. As these advances are anticipated to 
translate into improved results in clinical trials, various cytotoxic drugs and targeted 
therapeutics are investigated in different combinations together with TRAIL receptor 
agonists. These clinical studies did not reveal increased toxicity in phase Ib, and the 
ongoing randomized phase II studies will soon provide further information about the safety 
and antitumor efficacy of the TRAIL receptor agonists in wide range of combinations and 
tumor types (Wiezorek et al. 2010). 
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3. TARGETED APPROACHES FOR CANCER ELIMINATION 
3.1 Lignans - Natural polyphenols with anticancer effects 
 
Lignans are plant polyphenols traditionally classified into two types, classical lignans and 
neolignans. Classical lignans are formed from two phenylpropanes linked in a β-β’ (8–8’) 
fashion, while neolignans are those dimers whose coupling patterns differ from β-β’ 
linkage (reviewed by Ayres & Loike 1990). Lignans are formed as secondary metabolites 
throughout the plant kingdom, while coniferous trees present one of the richest sources of 
lignans (reviewed by Holmbom et al. 2003). There is great diversity in lignan structures 
with several hundred naturally occurring lignans found in different plant parts, and the 
number of identified lignans is still increasing (reviewed by Pan et al. 2009, Ayres & Loike 
1990). Some lignans and neolignans participate in the synthesis of lignin, an important 
component of the plant cell walls, while others act as antioxidants, biocides and perhaps 
even as plant hormones (Ayres & Loike 1990). The reported antimicrobial, antifungal, 
antiviral, antifeedant, nematocidal and insecticidal properties suggest an important role for 
lignans in the plant defense system against various pathogens and pests (reviewed by 
Lewis et al. 1995).  
 
In human diet, lignans are enriched in whole-grain products, vegetables, berries, tea and 
fruits (reviewed by Adlercreutz 2007). Some of the best dietary sources of lignans are 
flaxseed and other oilseeds, such as sesame seeds. Plant lignan precursors can be converted 
into enterolignans, enterodiol (END) and enterolactone (ENL), by the activity of the 
microflora in the proximal colon of mammals, and therefore END and ENL are termed 
mammalian lignans (Setchell et al. 1981, Axelson et al. 1982, Boriello et al. 1985). 
Currently, at least secoisolariciresinol (SECO), matairesinol (MAT), pinoresinol, sesamin, 
lariciresinol, syringaresinol, 7-hydroxymatairesinol (HMR) and arctigenin are known to 
function as plant lignan precursors for the mammalian lignans (Axelson et al. 1982, 
Boriello et al. 1985, Saarinen et al. 2000, Heinonen et al. 2001, Peñalvo et al. 2005). For 
example, trachelogenin, isolariciresinol and nortrachelogenin (NTG) seem not to be 
converted to enterolactone or enterodiol in the gut, but are instead absorbed from the 
intestine and secreted as such or as metabolites to urine (Heinonen et al. 2001, Kitamura et 
al. 2003, Saarinen et al. 2005). Figure 10 shows the molecular structures of most lignans 
discussed in this thesis. 
 
Various lignans also exist as glycosides that are transformed into the aglycones in the 
gastrointestinal track (Setchell et al. 1981). The major lignan component (1% of dry 
weight) in flax seed is secoisolariciresinol diglucoside (SDG), although smaller amounts of 
MAT, pinoresinol, lariciresinol, isolariciresinol and SECO can also be found in flax seed 
(reviewed by Adolphe et al. 2010). The bioactivity of dietary SDG and its metabolites, 
SECO, ENL and END, has been reported to protect against cardiovascular disease, 
diabetes and cancer (Adolphe et al. 2010). Like many other lignans, SECO, ENL and END 
possess antioxidative activity (Prasad 2000), which can reduce oxidative stress and thereby 
mediate the observed health effects.  
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Figure 10. Molecular structures of dibenzylbutryrolactone lignans and some other precursors for 
mammalian lignans.  
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The ability of lignans to inhibit inflammatory responses has also been investigated with 
interest of potential pharmacological benefit. For example arctigenin and MAT were 
shown to display antiasthmatic activity in guinea pigs in a dose-dependent manner (Lee et 
al. 2010) and inhibition of the inflammatory cytokine TNFα production by arctigenin or 
HMR was reported to occur in lipopolysaccharide (LPS)-stimulated macrophages or 
monocytes, respectively (Cho et al. 2001, Cosentino et al. 2010). Lignans share a structural 
resemblance with 17β-estradiol and can be considered as phytoestrogens with especially 
ENL and END displaying the ability to modulate estrogen bioactivity (reviewed by 
Adlercreutz 2002). ENL is able to inhibit the enzyme aromatase, which converts androgens 
to estrogens, (Adlercreutz et al. 1993) and to bind to estrogen receptors with relatively 
weak affinity (Mueller et al. 2003). The effects of lignans on estrogen receptor signaling 
are likely to depend on the endogenous estrogen levels, as lignans are capable of exerting 
both estrogenic and antiestrogenic activities (Adlercreutz 2007). 
 
3.1.1 Anticancer properties of lignans  
Various structurally different lignans have demonstrated the ability to decrease cancer cell 
viability, growth and metastasis (reviewed by Saleem et al. 2005). The studies reviewed in 
this chapter have been conducted with the mammalian lignan ENL, other 
dibenzylburtyrolactone type lignans or the plant lignan precursors of ENL. In vitro studies 
with cultured cancer cell lines have demonstrated lignans have cytotoxic and 
antiproliferative characteristics. MAT and arctigenin have been reported to suppress 
growth of leukemic HL-60 cells (Hirano et al. 1994), whereas ENL inhibits the growth of 
prostate cancer cells (Lin et al. 2001, McCann et al. 2008).  MAT, arctiin and 
trachelogenin, and most efficiently arctigenin, reduce viability in human gastric 
adenocarcinoma AGS cells (Kang et al. 2007), and wikstromol has demonstrated 
antileukemic properties (Lee et al. 1981). Additionally, ENL and END have been shown to 
reduce adhesion and the invasive potential of breast cancer cells (Chen & Thompson 
2003). 
 
Due to their phytoestrogenic nature, lignans have been extensively studied in vivo in 
hormone-responsive breast cancer models (reviewed by Saarinen et al. 2007). Recent 
studies have shown that lignans are indeed accessible to human breast cancer xenografts in 
athymic mice, but also display sex-related differences in tissue distribution (Saarinen et al. 
2008, Saarinen & Thompson 2010). Dietary flax seed or purified SDG inhibit formation 
and growth of carcinogen-induced mammary tumors in rat (Thompson et al. 1996), while 
HMR can decrease the number of growing tumors and increase the proportion of 
regressing and stabilized tumors in the same experimental model (Saarinen et al. 2000). 
The enterolignans and their precursors lariciresinol, arctiin and sesamin have also been 
found to reduce mammary tumor multiplicity or growth in vivo (Saarinen et al. 2007). In 
contrast, NTG and tracheloside, both of which are lignans that are not converted to ENL or 
END, were not able to inhibit carcinogen-induced mammary tumorigenesis (Saarinen et al. 
2002, Kitamura et al. 2003). Hence, breast cancer research on dietary lignans has become 
more focused on those compounds that can be metabolized to enterolignans with reported 
estrogen modulating activity (Saarinen et al. 2007). 
 
Lignans have been reported to exert antitumorigenic effects also on other forms of cancer. 
Dietary HMR extract can inhibit the appearance of intestinal adenomas in the adenomatous 
polyposis colimultiple ApcMin mouse model for intestinal neoplasia (Oikarinen et al. 
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2000), and is able to suppress the growth of hormone-dependent human prostate cancer 
xenografts in atymic mice (Bylund et al. 2005). Intraperitoneal administration of a plant 
extract containing wikstromol, MAT and dibenzylbutyrolactol inhibits the growth of 
intramuscular xenografts of Ehrlich ascites carcinoma and colon carcinoma cells in mice 
(Singh et al. 2007), whereas arctigenin and arctiin exhibited inhibitory effects on skin 
carcinogenesis as well as formation of pulmonary tumors (Takasaki et al. 2000).  
 
Tumor metastasis has also been observed to reduce upon lignan exposure. HMR and ENL 
inhibited the growth and metastasis of subcutaneous hepatomas in rats (Miura et al. 2007), 
while SDG reduced pulmonary metastasis of injected murine melanoma cells (Li et al. 
1999) and prevented lymph node and lung metastasis of ortotopical breast cancer 
xenografts in nude mice (Chen et al. 2006). Flax seed, lariciresinol, ENL and END were 
able to significantly decrease VEGF secretion and tumor microvessel density in human 
breast cancer xenografts or carcinogen-induced mammary tumors in vivo (Bergman 
Jungeström et al. 2007, Saarinen et al. 2008). This suggested inhibition of tumor 
angiogenesis might play a role in the antimetastatic activity of lignans. 
 
The incidence of breast, colorectal and prostate cancer is higher in the Western world 
compared to countries in Asia, and dietary factors are likely to play an important role in 
risk of these malignancies (reviewed by Adlercreutz & Mazur 1997). As high levels of 
circulating estrogens have been associated with increased breast cancer risk (Hankinson & 
Eliassen 2007), modulation of estrogen bioactivity by lignans can be beneficial. 
Epidemiological studies concerning the association between plasma levels of ENL and risk 
of breast cancer have been conflicting, and the association might be different depending on 
whether premenopausal or postmenopausal women are studied (Pietinen et al. 2001, 
Hultén et al. 2002, McCann et al. 2002, Kilkkinen et al. 2004). A case-control study nested 
within a cohort of more than 15 000 Finnish females by Kilkkinen et al. (2004) did not 
support the hypothesis that high serum ENL concentration would be associated with 
reduced risk of breast cancer. Nevertheless, a recent meta-analysis of 23 individual studies 
revealed that plant lignan intake might be associated with a 15% reduction in post-
menopausal breast cancer risk (Velentzis et al. 2009). Further studies are required to 
confirm the results of this analysis and to decipher whether ENL is protective against 
breast cancer, or simply a biomarker of a healthy fiber-rich diet. One aspect that is likely to 
have a significant impact on lignan intake is the use of oral antibiotics that decrease the 
intestinal microflora and thereby also serum ENL concentration (Kilkkinen et al. 2002). 
 
Most epidemiological studies do not support linear correlation between serum 
enterolactone concentration and prostate cancer risk (Kilkkinen et al. 2003, Stattin et al. 
2004, Hedelin et al. 2006, Park et al. 2009a). Only one case–control study found a 60% 
reduction in prostate cancer risk associated with a high concentration of serum ENL (Heald 
et al. 2007). The failure of other studies to detect similar correlations might be due to too 
low ENL plasma concentrations in the studied population (Park et al. 2009a). Interestingly, 
dietary flaxseed lignan extract can improve lower urinary tract symptoms in patients with 
benign prostate hyperplasia (Zhang et al. 2008). The possibility that dietary lignans 
influence prostate cancer formation or progression in men needs to be studied further 
before any definitive conclusions can be made. 
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3.1.2 Cellular effects of lignan activity 
The reported molecular mechanisms for lignan-induced cellular effects are diverse and 
vary between cell types and lignan compounds assayed. Many lignans function as 
antioxidants preventing DNA damage induced by reactive oxygen species (ROS), which 
might be one of the general mechanisms behind the anticarcinogenic activity of lignans 
(Saleem et al. 2005). For example, MAT, NTG, SDG, SECO, ENL and END are all 
antioxidants in vitro (Kitts et al. 1999, Prasad 2000, Willför et al. 2003). Arctigenin 
treatment has been neuroprotective and hepatoprotective in primary cultures of rat cells 
possibly due to its antioxidative activity (Jang et al. 2001, Kim et al. 2003). Also hinokinin 
has significant antioxidative effects and the ability to reduce doxorubicin-induced 
chromosome damage in in vivo mouse model (Medola et al. 2007). However, the in vivo 
antioxidative effects of lignans require further investigation, as enhanced ENL plasma 
concentration in humans was not associated with reduced genetic damage in peripheral 
blood lymphocytes (Pool-Zobel et al. 2000).   
 
Cancer cell proliferation relies on growth-stimulatory signaling pathways and lignans have 
been associated with suppression of several critical signaling pathways. HMR was shown 
to normalize deregulated signaling through the Wnt/β-catenin pathway in the intestinal 
adenoma tissue of the ApcMin mice (Oikarinen et al. 2000). Also arctigenin inhibited 
growth of human colon cancer cells via inhibition of Wnt/β-catenin signaling (Yoo et al. 
2010). Interestingly, a study by Sharma et al. (2008) suggests that treatment with a plant 
extract containing wikstromol, MAT and dibenzylbutyrolactol may also inhibit the 
Wnt/Wg pathway in the fruit fly. Arctigenin can inhibit LPS-induced activation of MAPKs 
including ERK1/2, p38 kinase and JNK, possibly through inhibition of the upstream 
MAPK kinase activity in murine macrophages (Cho et al. 2004). While arresting growth of 
hormone-responsive breast cancer xenografts, SDG inhibits MAPK activity and expression 
of growth factor receptors, IGF-IR and EGFR (Saggar et al. 2010). Lignans have also been 
shown to modulate the signaling via growth factor receptors and the PI3K/Akt pathway 
(Vasilcanu et al. 2004, Lee et al. 2009, Chen et al. 2009a). Furthermore, the NF-κB 
pathway for survival and inflammatory signaling can be suppressed by lignans, such as 
arctigenin and sesamin, as both compounds have been shown to inhibit IκB degradation 
and NF-κB-p65 nuclear translocation (Cho et al. 2002, Harikumar et al. 2010). 
 
Induction of apoptotic cell death or sensitization to apoptosis-inducing signals can lead to 
the cytotoxic effects that lignans have been reported to produce. This might be 
accomplished by p53 stabilization, which in turn can induce cell cycle arrest and initiation 
of the mitochondrial apoptosis pathway (Chen et al. 2007, Fini et al. 2008). The unfolded 
protein response (UPR) in glucose-deprived conditions supports survival of cancer cells in 
stressful environment, whereas arctigenin is able to inhibit this response and to induce 
apoptosis through the mitochondrial pathway in colon cancer cells (Kim et al. 2010, Sun et 
al. 2010).  Lignan compounds have been reported to downregulate the expression of the 
antiapoptotic Bcl-2 proteins that counteract signals that promote mitochondrial 
permeabilization (Giridharan et al. 2002, Hausott et al. 2003, Saggar et al. 2010) and to 
reduce expression of c-FLIP, a protein which protects cells from the extrinsic death 
pathway (Raja et al. 2008), but also other molecular mechanims for enhanced induction of 
apoptosis are likely to be employed by lignans. 
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3.2 Mesoporous silica nanoparticles as targeted drug delivery vectors for cancer 
therapy 
 
The efficacy of a drug compared to its toxicity to normal tissues, also termed the 
therapeutic index, is often a critical issue for cancer treatment, particularly when several 
different therapeutic agents are used in combination. To have a pharmacological response, 
clinicians generally have to administer far more drug molecules than would be needed if 
the drug was concentrated at the target site. Drug molecules may become degraded in the 
blood stream and tissues, and active detoxification can chemically modify the compound 
by conjugating reactions (reviewed by Meijerman et al. 2008). Another significant 
challenge in cancer therapy stems from the fact that many effective anticancer compounds 
are hydrophobic, and due to their poor solubility cannot be administrated properly in 
significant concentrations. More soluble derivatives from these compounds might be easier 
to administer, but can have problems to cross the plasma membrane to have the required 
effects in cells. Both increased therapeutic index and more efficient drug delivery can be 
accomplished by targeting the therapeutic agents specifically into cancer cells. 
 
Nanoparticle carriers could meet many of the critical challenges in drug delivery (reviwed 
by Farokhzad & Langer 2009). Firstly, due to their small size (up to few hundred 
nanometers), nanoparticles can bypass biological barriers, be internalized by cells, and 
thereby allow efficient drug accumulation at the target sites. Secondly, sustained drug 
release at the target site can be obtained for a prolonged period of time to achieve optimal 
therapeutic efficacy. Thirdly, the particle surface can be engineered so that desired 
biodistribution occurs or conjugated to biospecific ligands, which direct them to the target 
tissues. Currently over twenty therapeutic products employing nanotechnology have been 
approved for clinical use, the majority of which improve the pharmaceutical efficacy or 
dosing of clinically approved drugs (Wagner et al. 2006). Research efforts are being placed 
on generating delivery systems that target drugs to specific tissues and cells of the body, 
including tumors. 
 
Various different nanoparticles of both inorganic (ceramic) and organic (polymeric) 
materials have been developed for drug delivery purposes. Organic nanoparticles include 
poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) polyester-based particles, 
polymeric micelles, liposomes, dendrimers and protein cages. Inorganic nanocarriers are 
made of materials, such as metal or metal oxides. The developed nanoparticle systems are 
different in terms of parameters, including the size and hydrophobicity of the particle core, 
particle size distribution, biocompatibility, charge, mechanical strength and stability. 
Surface coating of nanoparticles with polymers like poly(ethylene glycol) (PEG) can create 
a ‘stealth’ layer that reduces protein adsorption as well as inhibits the particle from being 
recognized as foreign by the immune system (reviewed by Moghimi et al. 2001). 
Furthermore, the particle surface may be functionalized with specific targeting ligands or 
tracers, such as fluorophores for light microscopy and magnetic components for magnetic 
resonance imaging (MRI).  
 
3.2.1 Targeting strategies for specific delivery of nanoparticles to cancer cells  
Nanoparticles have been observed to concentrate at the tumor site through the fenestrated 
and leaky blood vessels that are typical for tumor vasculature (Matsumura & Maeda 1986). 
Although this enhanced permeability and retention (EPR) effect allows passive 
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accumulation of optimally sized nanoparticles to the tumor, further targeting mechanisms 
may be needed for efficient and cancer-specific delivery of cytotoxic drugs (Figure 11). 
Such active targeting systems can be obtained by conjugation of nanocarriers with cancer-
specific targeting ligands that enhance the internalization of the particles into the tumor 
cells, while accumulation to normal cells is minimized (Table 1.). Increased cellular uptake 
may further promote the passive targeting mechanisms, as the nanocarrier concentration at 
the tumor interstitial compartment becomes lower creating a stronger diffusion gradient 
across the vasculature (Paulos et al. 2004).  
 
 
 
Figure 11. Passive and active targeting of nanoparticles. The EPR effect plays a major role in the 
passive accumulation of nanoparticles from the blood stream to the tumor site. Targeting ligands 
conjugated on the surface of the nanoparticle are recognized by cancer cell-specific receptors, which 
mediates the enhanced cellular uptake of the particles by endocytosis (magnification).  
 
Indeed, tumor cells and tumor-associated endothelial cells have been shown to display cell 
surface receptors that are associated with the malignant phenotype, and which are rare or 
absent on the surfaces of healthy cells. Targeted delivery via these specific receptors may 
result in higher bioavailability of the therapeutic agent at the tumor site and simultaneously 
reduce the side effects (reviewed by Brannon-Peppas & Blanchette 2004). Cancer-targeting 
ligands that specifically bind to these surface receptors can be antibodies, antibody 
fragments (FAb), protein ligands, small molecular enzyme inhibitors, receptor 
agonists/antagonists, peptides, hormones, venoms, or DNA/RNA aptamers (Table 1.). The 
attached ligand must preserve the active conformation when conjugated to the 
nanoparticle, exhibit high affinity for the corresponding receptors and induce high rate of 
receptor-mediated endocytosis. In addition to the physicochemical properties of the 
nanoparticle system, the efficiency of cellular uptake depends on the surface expression 
level of the target receptor. High affinity peptides for designated tumor specific receptors 
can be identified for example by phage display screening (reviewed by Brown 2010). In 
addition to the ligands listed in Table 1, various peptides that bind to endothelial cells at 
angiogenic vasculature have been investigated as potential tumor-targeting moieties. These 
peptides have been reported to specifically bind the platelet-derived growth factor receptor 
β (Joyce et al. 2003), the angiopoietin receptor Tie2 (Mai et al. 2009) or adhesion 
molecules, such as E-selektin (Shamay et al. 2009) and integrins (Arap et al. 1998, Hood et 
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al. 2002). For many other peptides with tumor specific affinity the receptors remain to be 
identified (Brown et al. 2010). Some ligands have been investigated for targeted drug 
delivery to intracellular organs, such as the nucleus and the mitochondria. For example, the 
nuclear localization signal (NLS) has been coated onto gold nanoparticles (Tkachenko et 
al. 2003). 
 
Table 1. Examples of cancer cell targeting ligands. 
Targeting ligand Receptor Nanocarrier Reference 
Monoclonal antibodies 
HER2/Neu mAb ErbB2 Liposome Nielsen et al. 2002 
Proteins 
Epidermal growth factor 
(EGF)  
EGFR Peptide-lipid 
nanocarrier 
Zhang et al. 2010 
Transferrin Transferrin receptor Liposome  Ishida et al. 2001 
Peptides 
Fibronectin mimetic 
peptide 
α5β1 Integrin Liposome Garg et al. 2009 
Urokinase plasminogen 
activator (uPA) peptide 
uPA receptor Iron oxide Yang et al. 2009 
 
SDFα derived peptides CXCR4 - Egorova et al. 2009 
Chlorotoxin Matrix 
metalloproteinase-2 
Iron oxide Veiseh et al. 2009 
Glucose-regulated protein-
78 kDa (GRP-78) targeted 
peptide 
GRP-78 Hybrid 
polymer  
Wood et al. 2008 
Nucleic acids 
RNA aptamer A10 Prostate-specific 
membrane antigen  
PLGA-b-PEG 
copolymer 
Farokhzad et al. 2006 
DNA aptamer sgc8 - MSN Zhu et al. 2009 
Small molecules 
Folic acid (FA) FA receptor, FA 
carrier 
Liposome Goren et al. 2000 
Riboflavin (RF) RF binding protein, RF 
carrier, RF transporter 
Dendrimer Thomas et al. 2010 
Testosterone Androgen receptor Liposome Mishra et al. 2009 
Galactose asialoglycoprotein 
receptors 
Solid lipid 
nanoparticles 
Xu et al. 2009 
Anisamide Sigma receptor Liposome Banerjee et al. 2004 
 
3.2.2 Cellular uptake mechanisms and intracellular transport of nanoparticles 
Both non-specific and receptor-mediated cellular uptake mechanisms function in 
nanoparticle internalization (Figure 12). The physicochemical properties of the particle 
play an important role in the process, but for ligand-targeted particles also the receptor in 
question determines, which endocytic pathway is utilized. Internalization of engineered 
nanoparticles occurs via pathways that are employed by cells to take up extracellular 
material, but also viruses use these gateways to enter cells (reviewed by Mercer et al. 
2010).  In addition to being internalized by the cells of the target tissue, nanoparticles are 
often recognized as foreign objects in the blood stream and taken up by the professional 
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phagocytes of the reticuloendothelial system (RES) (reviewed by Dobrovolskaia & McNeil 
2007). These immune cells reside in the liver and spleen, where nanoparticles may 
accumulate in case particle opsonization by immunoglobulins, complement and other 
serum proteins occurs in the bloodstream. Whether or not opsonization and subsequent 
phagocytosis are induced, depends mostly on the size of the particle as well as the stealth 
properties of the particle surface (reviewed by Hillaireau & Couvreur 2009). Drug delivery 
to RES organs can also be preferential, for example in the case of hepatocarcinoma or liver 
metastasis (Hillaireau & Couvreur 2009). However, in most cases avoidance of 
phagocytosis is considered desirable. Targeting-ligands have been observed to inhibit RES 
phagocytosis (reviewed by Wang & Thanou 2010), but too high coverage of the particle 
with the ligand should be avoided, as this might reduce the stealth properties and increase 
clearance by RES (Gu et al. 2008, Shmeeda et al. 2009).  
 
 
 
Figure 12. Endocytosis and intracellular trafficking of nanoparticles. Nanoparticles can be 
internalized via various routes, including macropinocytosis (red), clathrin-mediated endocytosis 
(black) and caveolar/raft-dependent endocytosis (blue). Vesicles containing the particles fuse with 
the endosomes characterized by gradually decreasing pH as the particles travel towards lysosomal 
compartment. The endosomal pathway from caveolar/raft-dependent endocytosis is directed to 
endoplasmic reticulum (ER) instead of leading to the acidic environment of the endolysosomes. RE, 
recycling endosomes; EE, early endosomes; ME, maturing endosomes; LE, late endosome; TGN, 
trans-golgi network. Adapted from (Mercer et al. 2010).  
 
Clathrin-mediated endocytosis (CME) is a process that is taking place in all mammalian 
cells (reviewed by Conner & Schmid 2003). It is involved in nutrient uptake and 
intracellular communication, but also in uptake of nanocarriers (Hillaireau & Couvreur 
2009). The pathway comprises the assembly of clathrin-coated pits that develop into deep 
invaginations and the fission of the vesicles by dynamin GTPase activity (Conner & 
Schmid 2003) (Figure 12). The clathrin-coated vesicles will thereafter become uncoated 
and deliver the contents into the endosomal compartment. The mildly acidified (pH~6) 
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“early” and “maturing” endosomes will transform into “late” endosomes also known as 
multivesicular bodies (pH~5), that subsequently fuse with prelysosomal vesicles containing 
acid hydrolases. Thus, CME causes the endocytosed material to end up in the degradative 
conditions in the lysomes, which can be utilized as a drug release mechanism in the cell 
interior (Hillaireau & Couvreur 2009). An alternative pathway from early endosomes leads 
to recycling endosomes and back to the plasma membrane after dissociation of the ligands 
forms their receptors. 
 
The caveolar/raft-dependent endocytosis pathway occurs in membrane invaginations 
enriched in caveolin, cholesterol and/or sphingolipids (Conner & Schmid 2003) (Figure 
12). Dynamin is required also for the generation of cytosolic caveolar vesicles that join the 
endosomal pathway. However, instead of being acidified in endolysosomes, the cargo from 
this uptake pathway is typically directed to endoplasmic reticulum. The caveolar/raft-
dependent endocytosis occurs at slower rate than CME and involves more complex 
signaling and regulatory mechanisms. For delivery of pH-sensitive molecules, such as 
nucleic acids, proteins or peptides, which cannot tolerate the lysosomal environment, 
targeting via the caveolar/raft-dependent endocytosis pathway may turn out advantageous 
(Hillaireau & Couvreur 2009). Also macropinocytosis as well as clathrin- and caveolin-
independent endocytic pathways have been described as means of nanoparticle uptake 
(Hillaireau & Couvreur 2009). Nanoparticle size has been shown to influence the mode of 
endocytosis. Particles with diameter less than 200 nm were found to internalize via CME, 
whereas the larger particles (500 nm) might favor the caveolar/raft-dependent pathway 
(Rejman et al. 2003). Again, the surface properties play a major role in determining how 
effectively particle uptake occurs. Because of the negatively charged cell plasma 
membrane, nanocarriers with positive surface charge generally demonstrate increased 
adherence and internalization (Harush-Frenkel et al. 2007). It should be noted that multiple 
endocytic pathways might be simultaneously functional in nanoparticle internalization.  
 
Nanoparticle systems can be made multifunctional by combininig cell-specific targeting 
ligands with other features that allow for more efficient internalization into cancer cells, 
escape from the endosomal compartment and even organelle targeting. This can be 
accomplished for example through pH-sensitive systems that enable new features to 
emerge on the particle surface in acidic environment of the endo/lysosomes (Lee et al. 
2005). Furthermore, the shape of the particle may influence intracellular 
compartmentalization, which could be exploited in organelle targeting (Xu et al. 2008). It 
is important that the nanocarrier or at least its cargo makes a successful escape from the 
endosomal compartment into the cytoplasm or nucleus, where the drug targets typically 
reside. Molecules that respond to the pH lowering, such as poly(ethylene imine) (PEI), can 
be used for destabilization of endosomes (reviewed by Demeneix et al. 2004). PEI has 
been reported to function as a ‘proton-sponge’ because of its the high buffering capacity 
that upon decrease of the pH causes PEI to become highly protonated (Boussif et al. 1995). 
This leads to osmotic swelling due to water entry into the vesicle and finally disruption of 
the vesicle, allowing the release of endosomal content to the cytoplasm. Another suggested 
mechanism for PEI-induced endosomal escape involves swelling of the polymer network 
due to increasing repulsion of the protonated groups (Demeneix et al. 2004). 
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3.2.3 Mesoporous silica nanoparticles as cancer drug delivery vectors  
 
Inorganic nanoparticles based on silica have been receiving increasing attention as 
sufficiently stable vehicles for drug delivery (reviewed by Tan et al. 2004). As an inherent 
component of cells, silica is non-toxic, biocompatible, becomes degraded in biological 
systems and ultimately gets excreted in urine. Preparation of porous silica nanoparticles by 
the sol-gel method allows control of the particle and pore size on a nanometric scale. Co-
condensation approach enables covalent incorporation of functional groups to the pore 
walls during particle synthesis and subsequently facilitates further funtionalization with 
molecules, like fluorophores and bioactive ligands (reviewed by Rosenholm et al. 2010). 
Mesoporous silica nanoparticles (MSNs) have pore sizes in the molecular size range 
(typically 2-10nm), high pore volume and surface area, 0.6–1cm3/g and 700–1000 m2/g 
respectively, which permits efficient accommodation of small molecules (Rosenholm et al. 
2010). Drug-loading capacities of up to 30 w% has been reported for mesoporous silica 
(Vallet-Regi et al. 2001). MSN loading with drug molecules can reduce the access of water 
into the pores, and thereby increase the hydrolytic stability of initially well-soluble 
particles (Andersson et al. 2004).  
 
Introducing organic functions, such as the amino groups of PEI, on the MSN surface can 
significantly reduce particle aggregation that might pose a threat in biological applications 
(Rosenholm et al. 2006). Also avoiding serum protein adsorption to the particle surface is 
important, as this could lead to decreased targeting of the particles and increase the 
clearance of the particles from circulation by RES. Covering the particles with optimized 
PEG layer can create a ‘shield’ around the particle inhibiting adsorption of serum proteins 
(He et al. 2010). Furthermore, MSNs have been conjugated to cancer specific targeting-
ligands, such as folic acid (Slowing et al. 2006, Gu et al. 2007, Liong et al. 2008), DNA 
aptamers (Zhu et al. 2009), sugar moieties (Gu et al. 2007, Park et al. 2008, Brevet et al. 
2009) and HER2/Neu antibodies (Tsai et al. 2009).  
 
The rate of MSN degradation in a biological setting needs to be carefully engineered to 
meet the needs of effective drug delivery. The hydrolytic stability of MSNs determines the 
ability of the particle to endure until it reaches the target site from the blood circulation and 
the rate of degradation in the intracellular compartment. Optimization of such particle 
behavior is complicated by the fact that intracellular and extracellular decomposition 
kinetics are likely to be different. For in vivo targeting of MSNs also the particle size, 
charge and polarity of the particle coating (stealth layer) are important parameters 
(Rosenholm et al. 2010). For example, the size of the nanoparticle is critical for 
permeability through biological membranes, but also influences internalization by target 
cells and the phagocytes of the RES (Hillaireau & Couvreur 2009). In the case of MSNs, 
particle diameter between 50-200 nm is considered suitable for cellular targeting in vivo, as 
particles larger than 200 nm cannot easily cross biological membranes, whereas smaller 
mesoporous particles are difficult to synthesize (Rosenholm et al. 2010). 
 
Loading of the cargo drug into MSNs can be done by adsorption from organic solvent or 
pH-matched aqueous solvent (Rosenholm & Lindén 2008). Drug molecules can also be 
covalently linked to the functional groups of the pore walls of the MSNs (Tournée-Péeteilh 
et al. 2003). In this case, the drug molecule must be able to reacquire the active 
conformation upon release from the MSN. MSNs have been employed for intracellular 
delivery of hydrophobic anticancer agents, such as camptothecin (Lu et al. 2007a, Liong et 
al. 2008) and paclitaxel (Lu et al. 2007b, Xia et al. 2009, Vivero-Escoto et al. 2009), as 
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well as the hydrophilic cancer drug doxorubicin (Chen et al. 2009b, Zhu et al. 2009). Other 
membrane-impermeable agents, including propidium iodide (Lu et al. 2008), calcein (Liu 
et al. 2009), cytochrome c (Slowing et al. 2007) and nucleic acids (Radu et al. 2004, Park 
et al. 2008, Xia et al. 2009, Torney et al. 2007, Zhu et al. 2009) have been loaded in MSNs 
and delivered into cultured cancer cells. The high drug-loading capacity of MSNs could 
also allow multidrug delivery (Chen et al. 2009b), which is the likely scenario for 
successful cancer treatment. 
 
An optimal drug delivery system releases the cargo in the right concentration at the target 
site within a predetermined amount of time. Although drug release rates can be easily 
measured in test tube conditions, the actual biological effect is the most important readout 
of successful drug delivery and release. Depending on the delivered substance, the 
outcome can vary from inhibited kinase activity or cell proliferation to induced gene 
expression, gene silencing or programmed cell death. MSNs allow versatile design of gate-
keeping functions for minimal premature drug release and controlled release at the target 
site. The release of the drug from its carrier may be designed to occur in response to 
specific exogenous cues, such as heat or magnetic field (reviewed by Cotí et al. 2009). 
Alternatively, the nanoparticle can be engineered to disassemble in the intracellular milieu, 
where differences in pH, redox state and enzymatic activity may activate the releasing 
mechanism (Cotí et al. 2009).  The gate-keeping properties at the particle surface are in a 
key role regulating the release dynamics. 
 
 
 
 
 
 
 
Aims of the Study 
AIMS OF THE STUDY 
 
The aim of this thesis work was to discover and validate new methods for cancer cell-
specific apoptosis induction. Previous studies in the laboratory had addressed the 
mechanisms of death receptor-mediated apoptosis and the role of kinases as regulators of 
death receptor signaling. I aimed at finding novel combinatorial approaches to sensitize 
resistant cancer cells to death ligand stimulation and apoptosis. Prior to the work described 
in this thesis, relatively little was known about cellular activities mediating the anticancer 
effects that had been attributed to lignan polyphenols. The goal of my study was to 
examine if lignans could be employed to sensitize androgen-dependent prostate cancer 
cells to TRAIL, a death ligand that has been reported to initiate tumor-specific apoptosis. 
During this work it became evident that lignans are powerful sensitizers to death receptor-
mediated apoptosis, and my further studies focused on elucidating the cellular mechanisms 
and molecular determinants of lignan structure that bring about the observed effects, the 
latter being conducted in collaboration with the Department of Organic Chemistry in Åbo 
Akademi University. 
 
Furthermore, I aimed at testing a novel nanoparticle drug carrier system under in vitro 
conditions for cancer cell targeting. A laboratory at the Department of Physical Chemistry 
in Åbo Akademi University had previously developed this drug delivery system with 
several advantages over conventional nanoparticle systems. The goal of this thesis work 
was to demonstrate cancer cell-specific nanoparticle internalization, drug delivery and 
apoptosis induction by the functionalized mesoporous hybrid silica nanoparticles.  
 
 
Briefly, the aims of this thesis were 
 
 
1) To investigate lignans as sensitizers for TRAIL-induced apoptosis in androgen-
dependent prostate cancer cells 
 
2) To test if mesoporous hybrid silica nanoparticles could be employed in development of 
targeted cancer therapies. 
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EXPERIMENTAL PROCEDURES 
 
1. Cell culture (I-V) 
HeLa cervical carcinoma cells and human embryonic kidney (HEK) 293 cells were 
purchased from ATCC and cultured on 12-well plates in Dulbecco’s modified Eagle’s 
medium (Sigma) supplemented with 10% fetal calf serum (BioClear), 2 mM L-glutamin, 
100 U/ml penicillin, 100 µg/mL streptomycin in 37°C, 5% CO2. The LNCaP prostate 
cancer cells (clone FGC; EACC) were cultured in RPMI-1640 medium (Sigma) 
supplemented with 10% fetal calf serum (BioClear), 2 mM L-glutamin, 100 U/ml 
penicillin, 100  µg/ml streptomycin and 1mM sodium pyruvate (Sigma). As the androgen-
dependence of LNCaP cells can be maintained when the passage number is restricted, we 
cultivated the cells only up to 20 passages. Before growth factor stimulation, the cells were 
serum-starved (1 % serum) overnight. When the role of androgen-stimulation was 
investigated, the medium was changed to phenol red free RPMI-1640 (Gibco) with or 
without 1 nM synthetic androgen (Mibolerone) one day before the experiment. This 
medium was supplemented with 10% charcoal/dextran treated fetal bovine serum 
(Hyclone), L-glutamine, penicillin and streptomycin. SV40 transformed prostate epithelial 
RWPE-1 cell line was kindly provided by Professor Olli Kallioniemi. RWPE-1 cells were 
cultivated in Keratinocyte medium (Gibco) with 100 U/ml penicillin, 100 µg/ml 
streptomycin, 1% fetal calf serum (BioClear), 5 ng/ml human recombinant epidermal 
growth factor (EGF; Gibco) and 50 µg/ml Bovine Pituitary Extract (Gibco). 
2. Reagents and treatments (I-II, IV) 
Lignan synthesis was performed at the Department of Organic chemistry, Åbo Akademi 
University. A 100 mM stock solution of each lignan compound was prepared in EtOH or 
DMSO and stored at +4°C or room temperature. The cells were treated with 0–100 µM 
lignans or solvent control for indicated times. Human recombinant isoleucin-zipper TRAIL 
(izTRAIL; kindly provided by Professor Henning Walczak) was used at 0–1 µg/ml with 
incubation time of 20 hours. Alternatively, doxorubicin (Sigma) was used at 0.2–1 µM for 
20 h. Insulin receptor (IR) and IGF-IR were stimulated with 10 nM IGF-1 (Millipore) or 10 
nM insulin (Sigma) for 10 minutes. EGFR activation was performed with 20 ng/ml EGF 
for 5 minutes (a kind gift from Professor Klaus Elenius laboratory). Treatment with 1 µM 
staurosporine for 24 h was used as a positive control in an apoptosis assay. Inhibition of 
actin polymerization was done by pretreating the cells with 10 µM cytochalasin D (CytD) 
for 30 min and incubating in 5 µM CytD during nanoparticle uptake. Dose-response to 
methotrexate (MTX) was measured after treatment with 0.2 ng–2 µg/ml MTX for 72 h.  
3. Particle synthesis (III-IV) 
Fluorescent MSNs with diameter of approximately 400 nm were synthesized according to 
the procedure described by Nakamura et al. (2007), but with the thiol-silane replaced by 3-
aminopropyltrimethoxysilane together with fluorescein isothiocyanate (FITC) in order to 
create inherently fluorescent particles. Functionalization of the particles was performed as 
explained by Rosenholm et al. (2006) and Rosenholm & Lindén (2007). Folic acid (FA) 
conjugation was performed according to standard bioconjugation protocols leading to 0.2 
or 2 weight percent (wt %) of FA or methotrexate (MTX) on the particle. The 2 wt% MTX 
conjugation in 1 µg/ml particle concentration and the 0.2 wt% MTX conjgation in 10 
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µg/ml particle concentration corresponded approximately to 20 ng/ml free MTX. DiI (1,1′-
dioctadecyl-3,3,3′,3′-tetramethindocarbocyanine perchlorate) or DiO (3,3-dioctadecyl-
oxacarbocyanine perchlorate) dissolved in cyclohexane were loaded to 1 wt % in the 
MSNs. After vacuum drying overnight to remove any excess solvent, the particles were 
washed in a HEPES buffer solution (25 mM, pH 7.2). All particles were resuspended in 
dimethyl sulfoxide (DMSO) or HEPES buffer at a concentration of 1 mg/ml. 
4. Particle preparation, application to cells and detection of intracellular particles by 
flow cytometry  (III-V) 
FITC-, FITC/PEI-, FITC/PEI/FA- or FITC/PEI/MTX-functionalized MSNs with or 
without DiI/DiO loading were suspended in growth medium at a concentration of 1–10 
µg/mL. After 20–30 min of sonication in a water bath, the medium with particles or control 
medium was added to the 50–70% confluent cells and incubated for 3–72 h at 37°C 
depending on the experimental setup. The cells were cultured in folate-free RPMI medium 
(Gibco) with supplements for 24 h before incubation with MTX-functionalized 
nanoparticles or the FA-functionalized reference particles. For FA competition 
experiments, the cells were cultured overnight with 0–3 mM FA (Sigma) prior to addition 
of the particles. After incubation with MSNs, the cells were trypsinized and the 
extracellular fluorescence was quenched by resuspension in trypan blue (200 mg/ml; 
Fluka) for 5–10 min at room temperature. The cells were washed once and resuspended in 
phosphate-buffered saline (PBS). Intracellular FITC fluorescence was used as a measure of 
the number of endocytosed particles inside the cells, and it was analyzed by using a 
FacsCalibur or an LSRII flow cytometer (BD Pharmingen). The MFI of the cells at the 
FITC channel (FL-1 or FITC-A) was measured, and the data were analyzed with BD 
FacsDiva, Cyflogic and Flowing softwares. The fraction of cells with fluorescent particles 
was gated above the background fluorescence. 
5. Assessment of apoptotic cell death (I-III,V) 
5.1 Mitochondrial depolarization (I-II) 
Tetramethyl Rhodamine Methyl Ester (TMRM; Invitrogen) was stored as 20 mM DMSO 
stock and diluted in medium prior to use. Floating and trypsinized cells were incubated in 
20 nM TMRM for 10 min in 37°C waterbath. The cells were placed on ice and analysed 
immediately by FACSCalibur flow cytometer (FSC; FL-2 channel). When the labeling was 
done in a 96-well format, the plate was centrifuged with a culture plate rotor (1000 rpm, 3 
minutes), the cells were trypsinized and prewarmed medium containing 20 nM TMRM was 
incubated with the cells for 10 minutes. The plate was analyzed with LSRII flow cytometer 
equipped with HTS platform (FSC, PE-A channel). The cells dsiplaying decreased labeling 
with TMRM that accumulates into active mitochondria, were considered to have 
undergone mitochondrial membrane depolarization. 
5.2 Caspase-3 activation (I-II) 
Activated caspase-3 in cells was labeled with phycerythrin (PE)-conjugated antibody 
according to manufacturer’s protocol (BD Pharmingen). Briefly, the floating and attached 
cells were collected by trypsinization, and placed on ice. After washing once with cold 
PBS the cells were fixed in Fix/Perm buffer for 20 minutes on ice. The cells were 
subsequently washed twice with Perm/Wash buffer and resuspended to the same buffer 
containing 10 µl antibody. After 30 minutes incubation at room temperature, the cells were 
washed and resuspended to Perm/Wash buffer. The samples were analyzed by FacsCalibur 
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flow cytometry (FL-2, FSC channel). Cells with high PE labeling were considered 
apoptotic cells with activated caspase-3. For flow cytometric analysis of transfected 
LNCaP cells, GFP-positive cells were gated (FL-1) and measured for caspase-3 activation 
(FL-2). 
5.3 Nuclear fragmentation (I-III,V) 
The cells were collected by trypsinization and resuspended in propidium iodide (PI) buffer 
(40mM Na citrate, 0.3% Triton X-100, 50 mg/ml PI; Sigma). After 10 min of incubation at 
room temperature the samples were analyzed for nuclear fragmentation with a FacsCalibur 
flow cytometer (FL-2, BD Pharmingen). When the cells were grown on 96-well plates, the 
culture plate was centrifuged with a culture plate rotor (1000rpm, 3 minutes), and PI buffer 
was added to the wells. After 10 minutes incubation at room temperature, the plate was 
analyzed with LSRII flow cytometer equipped with HTS platform (PE-A channel). The 
fraction of sub-G0/G1 events (nuclear fragmentation) was gated as a measure of apoptotic 
cell death.  
5.3 Nuclear morphology (I,III-V) 
For examination of nuclear fragmentation, the cells were collected, washed once in PBS 
and fixed for 15 minutes in 3% paraformaldehyde at room temperature. Cytospin (Thermo 
Shandon) preparations were made and mounted in 40,6-diamidino-2-phenylindole (DAPI) 
Vectashield (Vector Laboratories). The nuclei were viewed with Leica DMRE 
fluorescence microscope (40x objective) and the images collected with Wasabi (1.4) 
software (I, Figure 2C). Alternatively, when nanoparticles were applied to cells, the 
samples were fixed on glass-bottom culture plates (MatTek Corp), labeled with DAPI 
Vectashield and viewed by using Zeiss LSM 510 META laser-scanning confocal 
microscope (40x or 63x oil objective, 405/488 nm excitation) (III-V).  
6. Plasmid construction and transfection (I) 
The coding sequence for a constitutively active gag-Akt (kindly provided by Julian 
Downward) was amplified from the pSG5-PKBGAG vector by PCR and cloned in-frame 
into pEGFP-N1 vector (Clontech) in EcoRI and KpnI sites. LNCaP cells were seeded on 
24-well plates and grown to 30–50% confluency. The JetPEITM transfection complexes 
(PolyPlus-transfection) were prepared and transfected according to the manufacturer’s 
protocol. Empty pEGFP-N1 vector was transfected to control cells. The culture medium 
was replaced by medium with or without androgen 24 h post-transfection, and the cells 
were cultured for further 24 hours.  
7. Insulin receptor and IGF-I receptor immunoprecipitation (II) 
The LNCaP cells cultured on 10ml plates were placed on ice, rinsed with cold PBS and 
lysed in 1 ml of cold lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1.25% 
CHAPS, 1 mM Na3OV4, 2 mM NaF, 10 mM sodium pyrophosphate and complete 
protease inhibitor cocktail [Roche Applied Science]) for 10 minutes. After centrifugation at 
15 000 x g for 10 minutes, the supernatant was collected and subjected to preclearing with 
Protein A sepharose beads (Sigma) and Protein G sepharose beads (Amersham 
Biosciences) for 1 hour at +4°C. After preclearing, the lysate sample was collected and rest 
of the sample was divided in two for immunoprecipitation with 5 µg anti-Insulin receptor ß 
or 5 µg anti-IGF-I receptor ß antibody (Santa Cruz Biotechnology). After overnight 
incubation at + 4°C, Protein A and Protein G sepharose beads were added to samples and 
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incubated for 4 hours. The beads were washed 4 times with lysis buffer, resuspended to 50 
µl of Laemmli sample buffer (LSB) and boiled for 10 minutes. 
8. DISC-immunoprecipitation (I) 
To stimulate TRAIL receptors LNCaP cells were detached, pelleted by centrifugation and 
resuspended in 1 ml of the collected medium. Thereafter 1 µg izTRAIL was added to the 
cell suspension. The cells were incubated at 37 °C for 15–60 minutes after which the 
reaction was stopped by adding 10 ml of ice-cold PBS. Control cells were incubated 
without TRAIL at 37 °C for 60 min. After washing, the cells were lysed in 1 ml of lysis 
buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 0.2% Nonidet P40, and 
Complete protease inhibitor mixture [Roche Applied Science]) for 30 min on ice. The cell 
debris was removed by centrifugation at 15 000 x g for 15 min at 4 °C. Equal amount of 
protein from each sample was precleared with Sepharose CL-4B for 1,5 h at 4 °C. 
Monoclonal anti-DR4 (Clone HS101; Alexis) and anti-DR5 (Clone HS201, Alexis) were 
added 2.5 µg each to the samples and immunoprecipitated with 15 µl of protein G beads 
(Amersham Biosciences) for 2.5 h at 4 °C. The beads were washed 6 times with lysis 
buffer, resuspended in LSB, and finally boiled for 5 minutes.  
9. Western blotting (I-II) 
Whole cell lysates were prepared by lysing floating and attached cells in LSB and boiling 
the samples for 10 minutes after which proteins were separated with sodium dodecyl 
sulphate (SDS)-PAGE. The DISC-immunoprecipitated samples and corresponding cell 
lysates (input) were analyzed by 10% Criterion SDS-PAGE (BioRad). The proteins were 
transferred onto nitrocellulose (Schleicher & Schuell) or PVDF membrane (Millipore), 
which was then blocked with 5% non-fat milk or 5% bovine serum albumin. Western 
blotting was performed using antibodies against Akt, phospho(Ser473)-Akt, Bid, Bax, 
Bim, GSK-3ß, phospho(Ser9)-GSK-3ß and phospho-Tyr(1068) EGF receptor (Cell 
Signalling Technology), Bcl-xL, DR5, EGF receptor, Insulin receptor ß and IGF-I receptor 
ß (Santa Cruz Biotechnology), FADD (Transduction Laboratories), poly (ADP-ribose) 
polymerase (PARP, clone C-2-10; Sigma-Aldrich), Actin (clone AC-40; Sigma-Aldrich), 
caspase-8 (clone C15; Alexis) and c-FLIP (clone NF6; Alexis), PI3K p85α (clone 4/PI3-
Kinase; BD Pharmingen) and phospho-tyrosine (clone 4G10; Millipore). HRP-conjugated 
secondary antibodies were from Southern Biotechnology Associates, Promega, and 
Amersham Biosciences. The results were visualized using the enhanced 
chemiluminescence (ECL) method (Amersham Biosciences) on x-ray film. For 
densitometric analysis of Western blots, the x-ray films were scanned and the analysis was 
done with the MCID M5+ software. The values were normalized to the untreated control 
sample, which was given the value 1. The histograms present a relative change in ratio of 
phosphorylated vs. non-phosphorylated protein in treated samples as compared to control 
samples. 
10. Receptor surface expression (I,III) 
Surface expression of TRAIL receptors was evaluated by indirect immunostaining using 
the anti-DR4 (clone HS101), anti-DR5 (clone HS201), anti-DcR1 (clone HS301) and anti-
DcR2 (clone HS402) primary antibodies (5 µg/ml). Surface expression of the folate 
receptor was detected by labeling with anti-folate receptor α primary antibody (2 µg/ml, 
clone Mov18/ZEL, Alexis). Alexa 488 -conjugated anti-mouse secondary antibody (Alexis 
Biochemicals) was used for labeling of all primary antibodies. Nonspecific fluorescence 
was assessed using the secondary antibody only. Flow cytometric analyses of the mean 
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fluorescence intensity (MFI) were performed using a FACSCalibur (FL-1) or an LSRII 
flow cytometer (FITC-A). 
11. Immunofluorescence (II) 
After treatments, the cells cultured on coverslips were washed with PBS and fixed with 3% 
paraformaldehyde for 15 minutes at room temperature. The samples were permeabilized 
and blocked for one hour in 3% BSA 0.1% Tween in PBS. Akt was labeled with rabbit 
anti-Akt antibody (Cell signaling) and Alexa 546 -conjugated anti-rabbit secondary 
antibody (Molecular Probes). After washing with PBS, the samples were mounted with 
DAPI Vectashield (Vector Laboratories) and viewed by Zeiss LSM 510 META laser-
scanning confocal microscope (63x oil objective, 543 nm excitation). 
12. Live cell microscopy (II-V) 
For microscopic assessment of nanoparticle endocytosis, cells were plated on glass-
bottomed culture dishes (MatTek Corp). In some studies, the cells were labeled with 20 
µM CMAC CellTracker (Invitrogen) or 5 µM CellTracker Red (Invitrogen) in medium 
without additives for 30 min, after which the medium was replaced with normal culture 
medium. For assessment of lysosomal compartmentalization of particles, the cells were 
labeled with Lysotracker Red (Molecular Probes) according to the manufacturer’s 
instructions. Cells were incubated with nanoparticles (10 µg/ml) for up to 72 h and viewed 
with Leica DM Ibre inverted fluorescence microscope (16x, 20x objective) or Zeiss LSM 
510 META laser-scanning confocal microscope (63x oil objective, 543 nm excitation) at 
indicated time points.  
13. Statistical analysis (I-II) 
The statistical significance of differences in the data were calculated with a two-way 
Student’s t-test by using the GraphPad Prism software. The p-value < 0.05 was considered 
to indicate significant differences. The graphs in the figures represent mean 
values±standard error of mean (SEM) and numbers of independent experiments is 
indicated in the figure legends. 
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RESULTS AND DISCUSSION 
 
1. SENSITIZATION OF PROSTATE CANCER CELLS TO TRAIL-INDUCED 
APOPTOSIS BY LIGNANS 
1.1 Dibenzylbutyrolactone lignans enhance the death receptor-mediated apoptosis 
pathway in androgen-dependent prostate cancer cells (I) 
 
Activation of death receptor-mediated apoptosis by TRAIL has been shown to play an 
important role in immune surveillance against tumors in vivo (reviewed by Gonzalvez & 
Ashkenazi 2010). Because TRAIL is able to induce apoptosis selectively in cancer cells, 
different forms of TRAIL receptor agonists are investigated in clinical trials. However, 
TRAIL resistance has been reported in many primary tumors and combinatorial treatment 
approaches will be needed for successful TRAIL-based anticancer treatment. The initial 
aim of the study was to discover new combinatorial treatments that would be non-toxic per 
se, but able to selectively promote TRAIL-induced apoptosis in prostate cancer. Lignans 
had previously been reported to inhibit growth of prostate cancer cells (Lin et al. 2001), 
induce anticancer effects in prostate cancer (Bylund et al. 2005), and potentially reduce the 
risk of prostate cancer in humans (Heald et al. 2007). As these compounds have been 
extensively studied at the Department of Organic chemistry at Åbo Akademi University, 
we began to examine the possibilities to employ lignans as sensitizers to TRAIL. 
 
The group of polyphenols, termed lignans, comprises compounds that are structurally very 
different from each other, and the existing information about the effects of lignans at the 
cellular level also reflects this variability. When this thesis project was initiated, the lignans 
arctigenin, SDG, SECO, ENL and END had been demonstrated to induce antioxidative 
effects in cultured cells (Prasad 2000, Jang et al. 2001, Kim et al. 2003), and some lignans, 
such as arctigenin, HMR and picropodophyllin had been investigated for their role in 
cellular signaling (Oikarinen et al. 2000, Cho et al. 2002, Cho et al. 2004, Vasilcanu et al. 
2004). These studies showed that lignans are able to inhibit various important survival 
signaling pathways, including the Wnt/β-catenin, NF-κB, MAPK and PI3K pathways. 
Later ENL was shown to inhibit Akt signaling and to induce p53 stabilization, cell cycle 
arrest and apoptosis in prostate cancer cells (Chen et al. 2007). As the mechanisms of 
lignan activity in cells had been investigated mainly with single compounds or with 
extracts of several lignan components, the understanding the structure-activity relationship 
of lignan effects in cells was poor. Thus, more systematic approach was taken in order to 
elucidate the effects of lignans in prostate cancer cells, and the focus of the study was 
placed on dibenzylbutyrolactone (DBL) lignans, like the mammalian lignan ENL, and their 
derivatives (Figure 13). 
 
The androgen-dependent LNCaP cell line that was used as a prostate cancer model in this 
thesis originates from a lymph node metastasis of human prostatic adenocarcinoma 
(Horoszewicz et al. 1983). A single point mutation in the ligand-binding domain of the 
androgen receptor (AR) broadens the steroid binding specificity of the AR expressed in 
LNCaP cells (Veldscholte et al. 1992). The model systems for human prostate cancer 
contain around 20 established cell lines and derivate sublines, only minority of which 
display androgen-sensitivity (reviewed by Russell & Kingsley 2003). The androgen-
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dependent cell lines can be employed for developing new therapeutic strategies to eradicate 
locally advanced prostate cancer that is currently treated by ADT. In our studies, the 
LNCaP cells were grown the presence or absence of androgen in order to study the effects 
of androgen-deprivation in combination with the new treatment protocol. Unlike the 
commonly studied androgen-independent prostate cancer cell lines, PC3 and DU-145, 
LNCaP cells are resistant to TRAIL-induced apoptosis (Nesterov et al. 2001, Bucur et al. 
2006), even though they express the TRAIL receptors DR4 and DR5 as well as only low 
levels of the decoy receptor DcR2 on the cell surface (I, Figure 3A). Like various other 
prostate cancer cells, the LNCaP cells have lost the tumor suppressing function of PTEN 
that negatively regulates PI3K activity (Li et al. 1997, Vlietstra et al. 1998). This feature of 
LNCaP cells is linked to the mechanisms of TRAIL-resistance, which have been been 
shown depend on the constitutive Akt activity downstream of PI3K and to result from 
impaired Bid cleavage upon TRAIL-stimulation leading to less efficient mitochondrial 
amplification of the signal (Chen et al. 2001b, Nesterov et al. 2001). 
 
 
Figure 13. Molecular structures of 7-hydroxymatairesinol, enterolactone and matairesinol. 
 
To examine if lignans can sensitize LNCaP cells to TRAIL-induced apoptosis, we first 
tested three lignans, the mammalian lignan ENL and two plant lignans, MAT and HMR, 
which can be converted to mammalian lignans by the gut microflora. All three compounds 
were non-toxic at the tested concentrations, whereas only MAT was found to be efficient in 
sensitization of the cells to TRAIL (I, Figure 1B and 2A). When the LNCaP cells were 
pretreated with 0–100 µM MAT for 1 hour prior to addition of trimeric human 
recombinant izTRAIL for 20 hours, both the androgen-deprived and -stimulated LNCaP 
cells became significantly sensitized to izTRAIL-induced apoptosis in a dose-dependent 
manner (I, Figure 2AB). When 40 µM MAT was combined to izTRAIL treatment, much 
lower izTRAIL concentrations were able to induce caspase-3 activation and the maximum 
percentage of apoptotic cells was clearly higher. The observed sensitization was more 
pronounced in the androgen-deprived LNCaP cells suggesting that androgen is able to 
promote the mechanisms of TRAIL resistance, and combination of ADT to lignan and 
TRAIL treatment could be considered as an attractive therapeutic approach (I, Figure 2B). 
MAT pretreatment did not increase apoptotic cell death of LNCaP cells in response to 
doxorubicin, a commonly used chemotherapeutic agent that activates mitochondrial 
apoptosis pathway primarily by inhibition of topoisomerase II enzyme (I, Figure 2D). 
These results imply that lignans can have synergistic effects with the TRAIL-induced 
extrinsic apoptosis pathway, whereas the cytotoxic action of agents that promote the 
intrinsic mitochondrial pathway is probably not equally enhanced.  
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The rate of apoptosis in TRAIL-sensitive PC3 prostate cancer cells was not significantly 
enhanced by identical MAT pretreatment (I, Supplementary Figure 3), and longer MAT 
pretreatment (24 h) augmented TRAIL-induced apoptosis only to some extent in TRAIL-
sensitive leukemic Jurkat T cells and HeLa cervical carcinoma cells (I, Supplementary 
Figure 1). No further increase in the TRAIL treatment efficacy could therefore be seen in 
already TRAIL-sensitive cells. However, both ENL and MAT were capable of sensitizing 
HeLa cells to CD95-induced apoptosis (I, Supplementary Figure 2), which implies that 
common mechanisms of resistance in death receptor-mediated apoptosis can be overcome 
by lignan treatment. These mechanisms might be linked to the inhibitory effects that DBL 
lignans have previously been shown to exert on survival signaling pathways (Oikarinen et 
al. 2000, Cho et al. 2002). Further studies on lignan influence should be performed in cell 
types that are involved primarily in CD95-signaling, including various immune cells, in 
order to elucidate this matter. In addition, the potential effects of lignans on CD95-
mediated processes need to be taken into account when in vivo effects of TRAIL and 
lignan treatment are evaluated.  
 
1.2 Structure-activity relationship analysis identifies (-)-nortrachelogenin lignan as an 
effective compound for sensitization to TRAIL-induced apoptosis (II) 
 
The results obtained with MAT, ENL and HMR lignans prompted us to test 27 naturally 
occurring lignans and lignan derivatives in a structure-activity relationship (SAR) analysis 
(II, Table 1). A panel of 18 lignans (II, Figure 1) and 9 norlignans (II, Figure 2), including 
several ENL precursors and DBL lignans, was assayed for the ability of the compounds to 
sensitize androgen-deprived LNCaP prostate cancer cells to TRAIL-induced mitochondrial 
depolarization and nuclear fragmentation (II, Figure 3). Our results demonstrate that the 
DBL skeleton in its non-cyclic form (MAT, ENL, NTG, Me-MR, demetyl-MR) is the most 
active lignan structure in sensitizing to TRAIL-induced apoptosis. The substitution pattern 
of the aromatic rings only has a small effect on the activity, while addition of methyl, 
hydroxyl or oxo groups at position C-7 completely abolishes the active conformation. 
However, we discovered that an aliphatic OH-group in the lactone ring at position C-8 
significantly enhances the lignan activity (II, Figure 1). The (-)-nortrachelogenin (NTG) 
lignan containing this structure sensitizes androgen-deprived LNCaP cells to TRAIL-
induced apoptosis more efficiently than MAT (II, Figure 3).  
 
NTG, also called (-)-wikstromol or pinopalustrin, is not found in human nutrition, but it 
can be isolated in relatively large amounts from soft wood species such as Pinus sylvestris 
(Ekman et al. 2002). Early reports on the NTG enantiomer, (+)-wikstromol, suggest that 
wikstromol has antileukemic activity (Torrance et al. 1979, Lee et al. 1981), and both NTG 
and wikstromol have been shown to function as antioxidants (Tiwari et al. 2001, Willför et 
al. 2003). However, there is very limited experimental data on the in vitro and in vivo 
effects of NTG. In the only available in vivo study by Saarinen et al. (2005), NTG failed to 
inhibit the growth of carcinogen-induced mammary tumors, while HMR was able to 
increase the number of regressing and stabilized tumors in the same experimental setting 
(Saarinen et al. 2000). Unlike HMR, NTG is not converted into the mammalian lignans, 
ENL or END, in the colon, but is excreted in urine as such or as metabolites (Saarinen et 
al. 2005). Therefore, the effects of NTG are likely to differ from those obtained with HMR. 
Daily exposure to NTG beginning from the pregnancy showed weak endocrine-modulatory 
effects in adult rats, whereas the influence of HMR with same dosing was not statistically 
significant (Saarinen et al. 2005).  
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Arctigenin and wikstromol are examples of the interesting DBL lignans that could not be 
tested in our screening study due to availability problems, but have the structural 
determinants for activity in TRAIL-induced apoptosis. Also lignans that have 
methylenedioxy ring(s) (eg. savinin) or more than two substituent groups in the aromatic 
rings (eg. traxillagenin), would be attractive compounds for further SAR analysis of 
lignans as sensitizers to TRAIL-induced apoptosis. The enhanced TRAIL-induced 
apoptosis with NTG treatment suggests that the possible antitumorigenic effects of NTG 
might yet be revealed in other types of animal models for cancer. As TRAIL has 
demonstrated antimetastatic functions in vivo (Finnberg et al. 2008, Grosse-Wilde et al. 
2008), the influence of NTG on tumor metastasis alone or in combination to TRAIL 
treatment deserves to be studied in vivo.  
 
Interestingly, NTG did not sensitize non-malignant human epithelial prostate cells (RWPE-
1) to TRAIL, indicating that the combination of lignans and TRAIL may leave normal cells 
unharmed (II, Figure 4C). Due to the potential hepatotoxicity of the combinatorial 
treatments involving TRAIL (Ganten et al. 2006), the influence of TRAIL and NTG should 
also be assayed in primary human hepatocytes. We are still on our way to understand what 
kind of molecular mechanisms determine that tumor cells selectively become victims of 
TRAIL-induced apoptosis while normal cells remain unharmed. It has been suggested that 
the mechanisms for tumor-selective apoptosis-induction by TRAIL would lie downstream 
of receptor activation and DISC formation, as inhibited FADD and caspase-8 recruitment 
would abrogate also TRAIL-induced survival signaling in normal cells (reviewed by 
Nieminen et al. 2007a, Varfolomeev et al. 2005). Concequently, it has been proposed that 
activation of oncogenes, such as c-Myc, might predispose cancer cells to TRAIL-induced 
apoptosis by enhancing mitochondrial permeabilization via proapoptotic Bcl-2 proteins and 
inhibiting NF-κB survival signaling and c-FLIP transcription upon TRAIL-treatment 
(Nieminen et al. 2007b). 
 
1.3 The γ-butyrolactone ring is essential for the TRAIL-sensitizing activity of lignans 
(II) 
 
We had observed that MAT was an active lignan and SECO could not sensitize the LNCaP 
cells to TRAIL, while the only structural difference between these two molecules is that 
the γ-butyrolactone ring is not present in SECO (II, Figure 1). As only the DBL lignans, 
including MAT, ENL and NTG, were able to enhance TRAIL-induced apoptosis, the γ-
butyrolactone ring was considered likely to play an important role. To further study the 
importance of the γ-butyrolactone ring for sensitization to TRAIL-induced apoptosis, we 
synthesized two NTG derivatives lacking this functional group. To this end, NTG was 
reduced to corresponding lactol (CARS) and diol (CAR) derivatives (Figure 14). These 
compounds were tested and found inactive, while NTG could potently sensitize LNCaP 
cells to TRAIL stimulation (II, Figure 4D). The lactone ring has been mentioned as a 
critical structural determinant also in other SAR analyses of DBL lignans. Muta et al. 
(2004) observed in vitro that lignans with DBL structure could inhibit the enzymatic 
activity of matrix metalloproteinase-7, an extracellular protease that may play a critical role 
in tumor invasion and metastasis. They postulated that the lignan lactone ring may be 
involved in the binding to the active site of the enzyme, whereas the introduction of 
methylenedioxy ring(s) and hydroxyl group(s) to the aromatic rings was shown to 
contribute only to enhancement of the inhibitory activity (Muta et al. 2004). The lactone 
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ring and its polar position may also play an important role in inhibition of TNFα 
production in macrophages, but the underlying mechanisms remain to be determined in 
further studies (Cho et al. 2001). The carbonyl group of the DBL lignans can serve as a 
hydrogen bond acceptor in intermolecular interactions, while the additional hydroxyl group 
in NTG may enable enhanced hydrogen bonding between lignans and their target 
molecules (Figure 14). In this respect, the stereochemistry of NTG is likely to be important 
for the lignan activity, but this remains to be shown experimentally. The results of this 
study suggest that lignan derivatives with further increased activity in sensitization to 
TRAIL-induced apoptosis may possibly be synthesized and employed as anticancer agents. 
 
 
 
Figure 14. Molecular structures of nortracelogenin and the inactive derivatives, carissanol and 
carinol. 
1.4 Dibenzylbutyrolactone lignans increase TRAIL-induced Bid cleavage and signal 
amplification through the mitochondrial apoptosis pathway (I,II) 
 
To determine the molecular mechanisms by which DBL lignans permit the increased 
caspase activation and apoptosis upon TRAIL stimulation, we studied the effect of MAT 
on the main components of TRAIL receptor signaling: 1. Cell surface expression of the 
TRAIL receptors, 2. Formation of the TRAIL–DISC at the cytoplasmic death domain, 3. 
Depolarization of the mitochondrial membrane, and 4. Activation of the initiator and 
effector caspases. Lignans without DBL structure, namely nordihydroguaiaretic acid 
(NDGA), silibinin and honokiol, have recently been shown to facilitate TRAIL-induced 
apoptosis by induction of DR5 expression and downregulation of the apoptosis inhibitors 
c-FLIP and survivin (Son et al. 2007, Yoshida et al. 2007, Raja et al. 2008). Our results 
show that the membrane proximal events in TRAIL-induced signaling, including TRAIL 
receptor surface expression, TRAIL-DISC formation, and caspase-8 activation in the 
DISC, are not amplified by MAT treatment in androgen-stimulated or androgen-deprived 
LNCaP cells (I, Figure 3). These findings suggest that MAT and other DBL lignans may 
exert their sensitizing effect downstream of DISC formation. We noticed that androgen 
stimulation increases DR5 cell surface expression, enhances TRAIL-DISC formation and 
accelerates caspase-8 activation, although these proapoptotic events do not correlate with 
the apoptosis sensitivity of the cells. Our data, however, support the reported role of 
androgens as enhancers of TRAIL–DISC formation in LNCaP cells (Rokhlin et al. 2002).  
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Like most cancerous cells, the LNCaP prostate cancer cells have been shown to require 
mitochondrial amplification of the death receptor-initiated signals for efficient apoptosis 
induction. This has been demonstrated in experiments where the inhibition or 
downregulation of antiapoptotic Bcl-2 proteins has resulted in enhanced apoptosis in 
response to TRAIL receptor activation (Kim et al. 2005, Ray et al. 2005). This type II 
behavior in death receptor-mediated apoptosis often plays an important role in cancer cell 
TRAIL resistance, and involves high expression of antiapoptotic proteins, such as c-FLIP, 
XIAP, Bcl-2, Bcl-xL, survivin or Mcl-1, able to inhibit caspase activation at different steps 
of the cascade (reviewed by Mellier et al. 2010). Thus, overcoming these mechanisms of 
resistance upon TRAIL receptor engagement is likely to promote the execution of cancer 
cell death. Our results demonstrate that 40 µM DBL lignan pretreatment is able to increase 
TRAIL-induced mitochondrial depolarization and caspase-9 cleavage in LNCaP cells (I, 
Figure 4A; II, Supplementary Figure 2). The enhanced MOMP downstream of TRAIL-
DISC formation is a probable source for the boosted caspase activation and TRAIL-
induced apoptosis, when DBL lignans are combined with TRAIL.  
 
Although some lignans have been reported to downregulate the expression of the 
antiapoptotic Bcl-2 proteins (Giridharan et al. 2002, Hausott et al. 2003, Saggar et al. 
2010), we did not detect any MAT-induced changes in the expression of the Bcl-2 proteins 
known to regulate mitochondrial apoptosis pathway upstream of mitochondrial 
permeabilization (I, Figure 4C). In addition, the expression of the downstream caspase-
inhibitor XIAP remained uninfluenced by MAT treatment (unpublished results). ENL has 
been reported to induce p53 stabilization (Chen et al. 2007) and to inhibit the proliferation 
of the LNCaP cells (McCann et al. 2008). Chen et al. (2007) also showed that a 48–72h 
incubation with 50–100 µM ENL may induce apoptosis in LNCaP cells by initiation of the 
mitochondrial pathway of apoptosis. MAT has also been shown to reduce viability in 
human gastric adenocarcinoma AGS cells (Kang et al. 2007), but these effects were 
observed at concentrations corresponding to 150–500 µM MAT. We have also noticed that 
DBL lignans induce growth arrest in LNCaP cells (data not shown), and MAT has a minor 
effect on mitochondrial polarity (I, Figure 4A), but our data indicate that neither MAT 
(Figure 15) nor NTG (II, Supplementary Figure 1) is an effective inducer of apoptotic cell 
death at the concentration of 0–100 µM when incubated up to 72h. Therefore, we conclude 
that treatment with 40 µM MAT or NTG clearly requires TRAIL-induced signals to 
provoke apoptosis in LNCaP prostate cancer cells. In addition to the TRAIL-sensitizing 
influence, the growth suppressing effects of DBL lignans, which may result from inhibition 
of mitogenic signaling, are likely to contribute to the anticancer effects observed in vivo 
(Bylund et al. 2005). 
 
The caspase-cleaved form of the Bcl-2 BH3-only protein Bid, tBid, has been implicated as 
an important mediator between the death receptor-induced caspase activity and induction 
of the mitochondrial outer membrane permeabilization, or MOMP (Li et al. 1998, Luo et 
al. 1998). As the TRAIL resistance of LNCaP cells has previously been shown to arise 
from defective Bid cleavage (Chen et al. 2001b, Nesterov et al. 2001), we investigated if 
DBL lignans can amplify this link between the two cell death pathways. Our results show 
that MAT or NTG pretreatment increases the TRAIL-induced cleavage of the full-size Bid 
in androgen-deprived LNCaP cells (I, Figure 4B; II, Supplementary Figure 2). We were 
only able to detect the cleaved tBid after proteasomal inhibition by epoximicin (data not 
shown), suggesting that the active tBid protein fragment may be subject to fast turn over. 
Nevertheless, the efficient Bid processing upon TRAIL receptor activation was found 
caspase-dependent (data not shown), and is a likely reason for the enhanced mitochondrial 
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depolarization when the androgen-deprived cells are pretreated with DBL lignans. In the 
presence of androgen, TRAIL–DISC formation and caspase-8 activation are increased, and 
TRAIL treatment as a single-agent is enough for inducing Bid cleavage (I, Figure 4B; II, 
Supplementary Figure 2). The cellular processes that prevent the mitochondrial 
depolarization and apoptosis execution in response to TRAIL in the androgen-stimulated 
cells are likely to require androgen-induced transcription, but we have not investigated this 
matter further. How these mechanisms of resistance are influenced by DBL lignans to 
enable enhanced apoptosis induction in androgen-stimulated cells, remains also to be 
examined in future studies. 
 
 
Figure 15. Matairesinol (MAT) is not a potent initiator of apoptosis in LNCaP cells. The cells were 
cultured in the presence or absence of androgen and incubated with 0–100 µM MAT for 0–72 hours. 
The percent of apoptotic cells was determined by labeling of activated caspase-3 and analyzing by 
flow cytometry. 
 
In summary, our data demonstrate that DBL lignans are able to sensitize cancer cells to 
receptor-mediated apoptosis. In LNCaP cells, DBL lignans facilitate TRAIL-induced Bid 
cleavage, mitochondrial depolarization and caspase activation, especially when the cells 
are also deprived of androgen. Nortrachelogenin was identified as the most effective DBL 
lignan for TRAIL-sensitization in the systematic SAR screening study, which also 
recognized the γ-butyrolactone ring of DBL lignans as a critical structure in sensitization to 
TRAIL-induced apoptosis. Our results suggest that sensitization to TRAIL-induced 
apoptosis may be a key mechanism of DBL lignan anticancer activity in vivo, and this 
ability could be employed in cancer treatment to overcome resistance to therapeutic 
TRAIL receptor agonists. 
 
2. LIGNANS AS INHIBITORS OF AKT SURVIVAL SIGNALING  
2.1 Dibenzylbutyrolactone lignans sensitize to TRAIL-induced apoptosis by 
downregulating Akt activity (I,II) 
 
Recent studies indicate that inhibition of the PI3K pathway with chemotherapeutic agents 
is an attractive strategy to treat prostate cancers (reviewed by Sarker et al. 2009). The 
approach is based on the increasing evidence suggesting frequent deregulation of the PI3K 
survival pathway in prostatic carcinomas (reviewed by Engelman et al. 2009). In LNCaP 
cells, the loss of PTEN can be observed as constitutive activity of Akt, one of the most 
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important downstream targets of PI3K (Carson et al. 1999). Akt is a serine/threonine 
kinase that activates or inhibits a range of signaling molecules via phosphorylation, and 
thereby promotes cell growth, proliferation and survival. For example, GSK-3β, a protein 
that amongst other functions induces glycogen synthesis and suppresses cell cycle 
progression, is inhibited by Akt-mediated phosphorylation in order to promote growth and 
proliferation (Cross et al. 1995).  
 
As the tested DBL lignans were found to be non-toxic to LNCaP cells, lignans are likely to 
exert their anticancer activity by influencing factors that prevent effective TRAIL-induced 
apoptosis. As ENL was shown to inhibit Akt activity (Chen et al. 2007), we decided to 
investigate if DBL lignans could sensitize LNCaP cells to TRAIL-induced apoptosis by 
inhibition of Akt activity. Our results show that MAT and NTG are more efficient than 
ENL in reducing the level of phosphorylated, and therefore active, Akt kinase especially in 
androgen-deprived LNCaP cells (I, Figure 5A; II, Figure 5). In addition, we observed that 
NTG treatment downregulates phosphorylation of the Akt target protein GSK-3β (II, 
Figure 5D). The inhibitory effect on Akt activity reaches the maximal repression at 2h 
NTG incubation and starts to recover somewhat thereafter (II, Figure 5C). These results 
suggest that the three investigated DBL lignans, MAT, NTG and ENL, have a common 
mode of action. MAT has previously been shown to function as a direct inhibitor of kinase 
activity. Already in 1981, MAT was demonstrated to inhibit cyclic AMP 
phosphodiesterase (Nikaido et al. 1981), and more recently, to prevent casein kinase-I 
(CKI) activity in vitro (Yokoyama et al. 2003). It is interesting to speculate that these 
inhibitory activities might be connected to the observed downregulation of Akt activity. 
Furthermore, several of the previously described DBL lignan effects on cell survival 
signaling could be linked to the observed reduction of Akt activity, but further studies are 
needed to investigate these possibilities 
 
The constitutive Akt signaling has been reported to protect hormone-dependent prostate 
cancer cells from TRAIL-induced apoptosis by inhibition of efficient Bid cleavage (Chen 
et al. 2001b, Nesterov et al. 2001). The recent results of Goncharenko-Khaider et al. 
(2010) also highlight Akt as a critical mediator of cancer cell TRAIL resistance that 
inhibits cleavage of Bid, prevents accumulation of tBid and also donwregulates Bid 
expression level. The mechanisms behind Akt inhibited Bid function have only recently 
been clarified, when Akt was shown to inhibit Bid localization to the mitochondria upon 
TRAIL stimulation by phosphorylation of PACS-2, a multifunctional sorting protein 
(Aslan et al. 2009). These results suggest that inhibited Akt activity is a likely reason for 
the enhanced Bid cleavage and apoptosis rate in response to TRAIL when the cells are also 
treated with DBL lignans. Consistently, synthetic PI3K inhibitors have been demonstrated 
to sensitize LNCaP cells to TRAIL-induced apoptosis, while overexpression of 
antiapoptotic Bcl-2 proteins is able to protect the cells from this combinatorial treatment 
(Chen et al. 2001b, Nesterov et al. 2001). We also observed that LNCaP cells can be 
sensitized to TRAIL by the PI3K inhibitor LY294002, and simultaneous treatment with 
LY294002 and MAT only showed minor additive effects in TRAIL-induced apoptosis, 
suggesting that these compounds are inhibiting at least partially the same mechanism of 
TRAIL resistance, the PI3K/Akt pathway (data not shown). To verify the involvement of 
PI3K/Akt pathway inhibition in DBL lignan action, we introduced a constitutively active 
form of Akt (ca-Akt) into androgen-deprived LNCaP cells. We found that ca-Akt is able to 
rescue a large portion of the cell population from MAT-mediated sensitization to TRAIL-
induced apoptosis (I, Figure 5C). These results provide evidence for the importance of 
DBL lignan-mediated inhibition of the PI3K/Akt pathway signaling as a mechanism of 
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sensitization to TRAIL treatment. Deregulated activation of PI3K/Akt signaling may play a 
critical role also in allowing prostate tumors to survive and maintain proliferation in 
androgen-deprived environments (reviewed by Mulholland et al. 2006). Although the 
constitutive Akt phosphorylation did not markedly differ between androgen-deprived and 
androgen-stimulated LNCaP cells (I, Figure 5A; II, Figure 5), inhibition of Akt by DBL 
lignans was more pronounced in the androgen-deprived cells. These results suggest that 
androgen stimulation counteracts the effects of the lignans by promoting Akt activity. 
Therefore, ADT is likely to enhance the anticancer activity of DBL lignans in treatment 
prostate cancer.  
 
Various naturally occurring polyphenols, such as flavonoids, stilbenes and phenolic acids, 
have been shown to sensitize cancer cells to TRAIL, and some of them inhibit Akt 
(reviewed by Jacquemin et al. 2010). For example, quercetin and genistein that belong to 
plant flavonoids are able to inhibit Akt activity while sensitizing to TRAIL (Kim & Lee 
2007, Siegelin et al. 2009). Curcumin, the yellow pigment in turmeric, has been shown to 
inhibit Akt by activation of PP2A and/or some other calyculin A-sensitive protein 
phosphatase (Yu et al. 2008), but also to enhance the apoptosis-inducing potential of 
TRAIL in prostate cancer cells both in vitro (Deeb et al. 2007) and in vivo (Shankar et al. 
2008). In addition, the stilbene resveratrol, found enriched in red wine, possesses ability to 
downregulate Akt activity as well as to sensitize prostate cancer cells to TRAIL-induced 
apoptosis (Gill et al. 2007). However, these studies do not demonstrate a direct link 
between Akt inhibition and increase in TRAIL-induced apoptosis. Our data show that 
inhibition of the PI3K/Akt signaling pathway is one of the major mechanisms by which 
DBL lignans sensitize androgen-deprived prostate cancer cells TRAIL-induced apoptosis.  
 
2.2 The effects of the lignan nortrachelogenin on Akt activity and TRAIL-sensitivity 
are rapidly reversible (II) 
 
Intriguingly, the effect of NTG on Akt activity and TRAIL-induced apoptosis was found to 
be rapidly reversible (II, Figure 7). When the medium with lignan pretreatment was 
removed and replaced by fresh culture medium prior to addition of izTRAIL, the 
apoptosis-enhancing effect was abrogated completely. Similarly, the inhibited Akt activity 
rapidly recovered to the phosphorylated state after medium replacement. Even a longer 
pretreatment (24h) with MAT was ineffective if the culture medium was replaced before 
addition of izTRAIL (data not shown). These results suggest that NTG may act directly on 
the Akt signaling pathway or other molecular targets regulating the cellular susceptibility 
to TRAIL-induced apoptosis, and imply that the cellular effects of lignans are likely to be 
membrane proximal or even occur outside of the cell. Preliminary results from biochemical 
studies with artificial membranes suggest that MAT or NTG are unlikely to spontaneously 
traverse the plasma membrane due to their polar nature. Instead, recent results suggest that 
both lignans tend to adhere at the lipid interphase (Björkbom A, unpublished results). 
Therefore, the Akt inhibition we observed might result from lignans effecting plasma 
membrane-tethered molecules involved in PI3K/Akt signaling, such as the receptor 
tyrosine kinases.  
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2.3 Nortrachelogenin (NTG) is a broad-spectrum inhibitor of receptor tyrosine kinase 
activity (II) 
 
In the prostate, the PI3Ks are generally activated upon growth factor stimulation by RTKs, 
such as IGF-IR, EGFR, FGFR, PDGFR and VEGFR (reviewed by Hellawell & Brewster 
2002). Inhibition of the catalytic subunit p110 by the regulatory p85 subunit in the 
heterodimeric class IA PI3Ks is relieved upon binding of p85 to tyrosine phosphorylated 
RTKs or RTK-bound adaptor proteins, which leads to enzymatic activation of PI3K (Yu et 
al. 1998). Recently, ENL was shown to suppress IGF-IR signaling and Akt activity in 
PTEN-deficient prostate cancer cells along with inhibition of cell proliferation and 
migration (Chen et al. 2009a). Prompted by these data and the efficient Akt inhibition we 
had observed with NTG treatment, we investigated how NTG influences the growth factor 
signaling of LNCaP cells in serum-starved conditions resembling low androgen 
environment.  According to our results, NTG is not only able to inhibit activation of IGF-
IR, but also insulin receptor (IR) and EGFR, by suppressing tyrosine autophosphorylation 
of the receptors upon ligand binding (II, Figure 6). We also observed that the p85 PI3K 
subunit is constitutively bound to IR and IGF-IR, and this recruitment is enhanced upon 
RTK activation. Importantly, NTG treatment reduced the amount of RTK-bound p85 in a 
dose-dependent manner (II, Figure 6B).  
 
In the PTEN-deficient LNCaP prostate cancer cells, however, basal PI3K activity was 
recently found not to depend on RTK tyrosine phosphorylation (Jiang et al. 2010). The 
authors postulated that particular p110 subunits of PI3K may have a modest level of 
constitutive activity in the absence of RTK or GPCR stimulation that would be sufficient 
for the maintenance of PI3K pathway activation in PTEN-deficient cells. We also 
discovered that in LNCaP cells Akt activity remains surprisingly unaltered both in low-
serum conditions and upon growth factor treatment (II, Figure 6B), suggesting that such 
RTK-independent mechanisms of PI3K activation may be functional. Nevertheless, we 
noticed that NTG is able to downregulate Akt phosphorylation regardless of the growth 
factor supply. Therefore, it remains to be clarified, whether NTG induces the observed Akt 
inhibition by 1. Interfering with RTK signaling, 2. Suppressing the basal PI3K activity, 3. 
Inhibiting Akt activity, 4. Activating pathways that promote Akt inactivation, or 4. 
Employing a mechanism, which is yet to be identified (Figure 16).  
 
As RTK-induced signaling has a critical role in malignancy, various therapeutic 
approaches have already been developed against GFR families, such as the VEGFRs, 
EGFRs, PDGFRs and IGF-IR. It would be worth examining if NTG is able to inhibit RTK 
activity in other cancer cell types, and what the consequences of NTG treatment are in cells 
that have wild type PTEN. Furthermore, sensitization of LNCaP cells to TRAIL-induced 
apoptosis by NTG may involve the inhibition of RTK activity. Karasic et al. (2010) have 
previously observed such mode of action for a cyclolignan, picropodophyllin, which was 
shown to inhibit IGF-IR signaling and to sensitize melanoma cells to TRAIL. The 
neolignan magnolol has been reported to inhibit EGFR signaling without influencing 
insulin-induced pathways in prostate cancer cells (Lee et al. 2009). In the same study, it 
was proposed that the binding affinity of magnolol to EGFR may depend on the 
intracellular redox state, and differences between cancer cells and normal cells with this 
respect would allow cancer cell-specific effects. Whether or not such mechanisms operate 
and can be applied to functions of NTG warrants further investigation. As we now 
observed that the reversibility and dynamics of the TRAIL-sensitizing NTG effect is equal 
in the presence and in the absence of androgen, the molecular mechanisms of lignan 
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activity may involve same targets in both conditions despite the differences in apoptotic 
signaling responses. Although the RTK/PI3K/Akt pathway seems to be one of the major 
lignan targets that regulate TRAIL sensitivity, other cell surface receptors and their 
downstream signaling cascades could be influenced by lignans. The Frizzled receptor 
could be such a target, as lignans have been shown to inhibit activity of the Wnt signaling 
pathway (Oikarinen et al. 2000, Yoo et al. 2010), but this possibility has not yet been 
experimentally addressed. 
 
 
 
Figure 16. A schematic presentation of the potential DBL lignan targets in the RTK signaling 
pathway of LNCaP prostate cancer cells. Activated PI3K induces generation of PIP3 at the plasma 
membrane, which leads to Akt recruitment and activation by phosphorylation. The lack of the 
phosphatase PTEN causes constitutive Akt activity and survival signaling in LNCaP cells, which 
accounts for suppression of TRAIL-induced apoptosis in these cells. The resistance to TRAIL has 
been shown to occur at the level of impaired Bid cleavage and mitochondrial permeabilization. DBL 
lignans, such as NTG, were found to inhibit Akt activity and RTK activation by growth factors. Both 
of these effects can result from inhibition of RTK activity, but independent effects on RTK, PI3K and 
Akt activity cannot be ruled out in the light of current evidence. Furhermore, other regulatory 
mechanisms (‘X’) that influence RTK/PI3K/Akt signaling can be targeted by DBL lignans. 
 
Due to the antioxidative nature of DBL lignans (Jang et al. 2001, Kim et al. 2003, Willför 
et al. 2003, Cosentino et al. 2010), it is tempting to hypothesize that DBL lignans would 
mediate the inhibitory effects on RTK signaling by reducing intracellular levels of ROS. 
Several lines of evidence suggest that low concentrations of ROS, such as hydrogen 
peroxide, may function as essential second messengers in mitogenic signaling pathways 
(reviewed by Lander 1997). RTK stimulation by insulin or EGF has been demonstrated to 
induce hydrogen peroxide production that inhibits protein tyrosine phosphatases and 
thereby further promotes tyrosine phosphorylation of IRβ and EGFR, respectively (Bae et 
al. 1997, Mahadev et al. 2001). Subsequently, inhibition of growth factor-induced positive 
feedback loops by lignans could lead to the observed inhibition of RTK activity. The 
NADPH oxidase (Nox) localized at the plasma membrane generates extramitochondrial 
superoxide and hydrogen peroxide in mitogenic signaling, and the activity of this enzyme 
has been seen to increase in cancer, including prostate cancer (Kumar et al. 2009). 
Furthermore, physiological levels of androgen increase ROS production in LNCaP cells 
(Ripple et al. 1997), and the androgen-induced ROS levels in prostate epithelial cells play 
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a key role in prostate cancer occurrence, recurrence as well as progression (Basu et al. 
2009). Inhibition of Nox activity or use of general antioxidants reduces Akt signaling, 
proliferation and survival of prostate cancer cells, including the LNCaP cells (Kumar et al. 
2009). Interestingly, also TRAIL induces ROS production through activation of Nox in a 
caspase-dependent manner (Choi et al. 2010). The effect, however, is opposite to the 
mechanisms of RTK signaling, as ROS was found to counteract TRAIL-induced apoptosis 
by inhibiting caspase-3 activation. Sesamin and honokiol are lignans that have been 
reported to inhibit Nox activity in aortic cells and endothelial cells, respectively (Nakano et 
al. 2008, Sheu et al. 2008), and ROS is an important mediator of several signaling 
pathways that lignans have been shown to suppress, including the PI3K/Akt and MAPK 
pathways. Thus, it would be worth examining if DBL lignans are able to inhibit production 
of extramitochondrial ROS in LNCaP cells, and thereby reduce RTK activity and sensitize 
to TRAIL-induced apoptosis. The location of Nox enzymatic activity at the plasma 
membrane makes it also available for DBL lignan activity from the outside of the cell. 
 
The observed effects of DBL lignans on growth factor signaling may account for some of 
the health benefits that mammalian lignans have been attributed with, including reduced 
risk of diabetes, cardiovascular diseases and cancer (reviewed by Adolphe et al. 2010). 
Whether dietary DBL lignans are a sufficient source for these effects to be detected in 
human subjects, warrants further studies. In our in vitro studies, the cellular effects were 
observed with DBL lignan doses in micromolar range, and doses that high can be 
challenging for sufficient drug delivery into the tumor site. The results from these in vitro 
studies are likely to be relevant for intravenous administration protocols in the preclinical 
uses, but not for nutritional intake of lignans. Our preliminary in vivo results in an 
experimental mouse model demonstrate that NTG is non-toxic at 15 mg/kg daily dose 
when administered intravenously. The future studies will address, how NTG influences in 
vivo growth of TRAIL resistant tumor xenografts in combination with TRAIL treatment. 
The stability as well as solubility of plant lignans, like MAT and NTG within the blood 
may have to be increased by carries systems such as liposomes or other nanoparticulate 
systems, previously applied for delivery of other polyphenols (Fang et al. 2006, Yuan et al. 
2006). It must, however, be noted that these delivery systems should allow extracellular 
release of the lignan cargo as the effects observed in this study are likely to be mediated by 
lignans from outside of the cancer cell plasma membrane. Also the halflife of TRAIL in 
blood circulation can be increased via conjugation to albumin (Müller et al. 2010) or 
encapsulation to liposomes (Martinez-Lostao et al. 2010). Furthermore, TRAIL can be 
targeted to tumor site for increased local concentration by expression of biologically active 
soluble TRAIL in a bacterial strain that selectively grows inside tumors (Zhang et al. 
2010). 
 
3. TARGETING OF HYBRID SILICA NANOPARTICLES INTO CANCER CELLS 
3.1 Mesoporous silica nanoparticles can be targeted to folate receptor expressing 
cancer cells by poly(ethylene imine) and folic acid surface functionalization (III) 
 
Liposomes and polymer nanoparticles have been the leading materials for current 
nanomedical research, but novel approaches may help to meet the properties of the optimal 
nanocarrier, namely the carrier biocompatibility, size control, stability and versatile surface 
functionalization possibilities as well as high drug-loading capacity and controlled drug 
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release without premature leakage of drug molecules (reviewed by Vivero-Escoto et al. 
2010). The beneficial features of mesoporous silica include tunable pore dimensions in the 
nanometer range, high pore volume and surface area, morphology control, and possibility 
for versatile surface function and controlled release strategies. As a biocompatible material, 
mesoporous silica has recently been used in development of potential nanocarriers for drug 
delivery and bioimaging approaches (Vivero-Escoto et al. 2010). The preceding work had 
established the synthesis of poly(ethylene imine), PEI –functionalized porous hybrid silica 
nanoparticles (Rosenholm et al. 2006, Rosenholm & Lindén 2008). In this novel hybrid 
nanoparticle system, the covalently conjugated hyperbranched PEI layer creates a positive 
charge at the particle surface preventing particle aggregation, but may also provide stealth 
properties, molecular gate properties, RES evasion and endosomal escape ability as well as 
a high surface density of reactive groups for further functionalization (Figure 17). 
 
 
 
Figure 17. Mesoporous hybrid silica nanoparticles. 
 
 
We sought to further test the developed system for its applicability to cancer cell targeting 
under in vitro conditions. To this end, the particles were functionalized with FITC 
molecules for imaging with fluorescence microscopy and analysis by flow cytometry 
(Figure 17). The mean diameter of the synthesized MSNs in our study was approximately 
400 nm, as surface-functionalized particles with smaller size (100 nm) had previously been 
shown to readily enter cells in the absence of targeting ligands (Slowing et al. 2006). 
Although it has been demonstrated that active targeting provides only a relatively modest 
improvement in tumor tissue accumulation of drug delivery systems when compared to 
non-targeted systems, a clear difference is observed in cellular uptake of the nanoparticles 
and the cytotoxic drug action at the tumor site (reviewed by Pirollo & Chang 2008). Due to 
this advantage, we introduced a targeting ligand to the MSNs by covalent conjugation of 
FA to the PEI layer. FA has high affinity to folate receptors (FRs) that are normally 
expressed at the luminal surface of certain epithelial cells, inaccessible to the blood stream 
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(Weitman et al. 1992). However, approximately one third of human cancers, including 
ovarian, endometrial, colorectal, breast, lung, renal cell carcinoma, overexpress the FR 
(reviewed by Sudimack & Lee 2000, Paulos et al. 2004). Furthermore, FRs have been 
observed to undergo internalization and cell surface recycling at a regular rate in cancer 
cells as well as tumors in vivo  (Paulos et al. 2004), which provides effective means for 
receptor-mediated endocytosis of an FA-conjugated nanocarrier. Interestingly, FA-targeted 
liposomes can also enter FR expressing tumor-associated macrophages, a feature that may 
be utilized in targeted cancer therapy (Turk et al. 2004). These things make FA a 
promising ligand for tumor-targeted drug delivery, which is why both FA-targeted 
therapeutic drugs and a FA-linked imaging agent are currently under evaluation in human 
clinical trials for cancer therapy (reviewed by Low & Kularatne 2009). 
 
Our strategy to selectively transport the MSN carriers into cancer cells by FR-targeting 
would ideally allow delivery of therapeutic agents to the interior of the cancer cells and 
specific induction of apoptosis in targeted cell population. MSNs have previously been 
conjugated to FA with the aim of active cancer targeting in vitro (Slowing et al. 2006, 
Liong et al. 2008), but the particle design in these studies differs significantly from ours 
concerning the particle coating. The conventional particle functionalization with 
aminosilanes (Slowing et al. 2006) or phosphonate silanes (Liong et al. 2008) does not 
provide the advantageous properties of PEI described above. To evaluate the cellular 
internalization of the PEI-functionalized and FA-targeted MSNs, we employed the HeLa 
cervical carcinoma cells as a cancerous cell model that expresses high amount of FR on the 
cell surface and human embryonic kidney 293 cells as a FR negative non-cancerous cell 
type (III, Figure 7). Prior to analysis of the cell samples, extracellular fluorescence was 
quenched with the cell-impermeable label, Trypan blue, in order to detect solely the MSNs 
that have been internalized (Slowing et al. 2006). Our result show that after 4h incubation 
with the particles, approximately 20% of HeLa cells internalize the PEI-functionalized 
MSNs (FITC/PEI), while further conjugation of a FA targeting ligand (FITC/PEI/FA) 
increases the fraction of particle-containing cells to 40% (III, Figure 4). The cationic PEI 
layer is likely to enhance MSN interaction with the negatively charged plasma membrane, 
and thereby contribute to non-targeted particle endocytosis. Xia et al. (2009) have recently 
observed that non-covalent coating with PEI enhances cellular MSN uptake and cargo 
delivery, but compromises cell viability if the polymer size is increased. In the approach of 
Slowing et al. (2006) the FA-conjugation significantly increased positive charge of the 
aminosilane-coated MSNs and thereby attraction to plasma membrane, which complicates 
evaluation of the suggested targeting into HeLa cells.  
 
The uptake efficiency of the FITC/PEI/FA particles by HeLa cells was observed to 
decrease in a concentration-dependent manner, when free FA was added to the medium 
(III, Figure 5), suggesting that competition with free FA inhibits specific particle 
endocytosis. When the effect of free FA on non-targeted uptake of MSNs was recently 
examined in our laboratories, the higher FA concentrations (>2mM) where found to also 
influence the unspecific endocytosis of FITC/PEI –particles in HeLa cells (Mamaeva et al. 
submitted for publication). However, the non-targeted uptake remained unaffected at 1mM 
free FA, while FA-targeted endocytosis is reduced 40–50% (Mamaeva et al.). It is 
important to note that ideally the non-targeted uptake should be examined using particles 
that are conjugated to a mock/scrambled ligand, as the physicochemical properties of the 
particle may change when no ligand is present. New means of diminishing the non-targeted 
MSN uptake, for example by optimization of the FA and PEI density or by including 
additional targeting-ligands on the MSNs, will be investigated in the future.  
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Importantly, our data demonstrate that the uptake of FITC/PEI/FA particles is substantially 
lower in non-cancerous 293 cells that also have very low FR surface expression (III, Figure 
8 and Supplementary Figure 6). Taking into account both the fraction of cells that have 
internalized particles and the amount of particles internalized per cell, the observed total 
particle internalization in HeLa cells is ten times higher than in 293 cells. Moreover, a 
significant difference in targeted endocytosis of FA-conjugated MSNs is observed when 
HeLa cells and 293 cells are co-cultured. In these conditions the FITC/PEI/FA particles 
preferentially accumulate to HeLa cells (III, Figure 9). Ectopic expression of FR in 293 
cells or in other FR-low cell types would elucidate the mechanism other than FR 
expression that can mediate the selective uptake of the FR-targeted MSNs by cancer cells. 
The recent results of Mamaeva et al. show that there are, indeed, cell type-specific 
differences that dictate the total level of FITC/PEI/FA uptake independent of the level of 
FR surface expression. However, when the uptake of FA-conjugated MSNs is compared to 
internalization of non-targeted MSNs in each cell type, FA-mediated uptake correlates well 
with the FR surface expression level (Mamaeva et al.). For example, while the FA-
conjugation increases particle uptake in HeLa cells, 293 cells internalize even less particles 
when FA is added to the MSNs (Mamaeva et al.).  These results validate the cancer cell 
targeting capacity of the developed MSN system and serve as an important basis for the in 
vivo application of the drug carrier system. 
 
3.2 FA-functionalized MSNs can be employed for targeted delivery of hydrophobic 
cargo molecules into the cytoplasm of folate receptor expressing cancer cells (IV, V) 
 
The mechanisms of nanoparticle internalization are varied and depend greatly on the 
particle size, shape and surface properties (reviewed by Hillaireau & Couvreur 2009). 
According to our results, internalization of the FA-functionalized MSNs is sensitive to 
actin cytoskeleton inhibition as well as cold temperature (IV, Figure 1C), indicating that 
particle uptake requires active endocytosis mechanisms. The pathway by which FR is 
internalized may involve several modes of endocytosis with many sorting events in 
multiple organelles (Paulos et al. 2004). Our data do not clarify the existing confusion of 
the FR recycling mechanisms (Paulos et al. 2004), as actin has been suggested to play a 
role in most, if not all endocytic pathways from caveolin-mediated and clathrin-mediated 
endocytosis to phagocytosis and macropinocytosis (reviewed by Engqvist-Goldstein & 
Drubin 2003). However, others have recently proposed that FA-conjugated MSNs may be 
preferentially endocytosed via the clathrin-dependent pathway (Fisichella et al. 2010). 
After successful entry into target cells, the drug cargo needs to be released from the 
nanoparticle carrier as well as from the endosomal compartment within the desired 
timeframe. The ability of the FITC/PEI/FA particles to release their cargo through 
endosomal escape was evaluated by loading 1wt% non-toxic poorly water-soluble 
molecules into the MSNs. The fluorescent dyes, DiI  and DiO, were used as model cargo 
and their trafficking in cells was observed by live-cell confocal microscopy. We were able 
to image the release of DiI from the FITC-labeled MSNs and from the endocytic vesicles 
into the cytoplasm within 24h, as well as to demonstrate that equal cargo release occurs 
when DiI and DiO are simultaneously loaded into the particles (IV, Figure 2). Furthermore, 
quantitative analysis demonstrates that selective model drug delivery can be accomplished 
to FR-expressing HeLa cells, as the FR-negative 293 cells internalize only one third of the 
DiO amount delivered to HeLa cells (IV, Figure 3).  
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Our results indicate that the developed hybrid MSN system may be employed for FR-
targeted co-delivery of multiple drug molecules. Lately, Chen et al. (2009b) 
simultaneously delivered Bcl-2 targeting siRNA molecules and the cancer drug 
doxorubicin to cells by hybrid MSNs, further highlighting the extensive drug-loading 
capacity of MSNs. The inherently fluorescent doxorubicin was shown to evade the 
polyamidoamine (PAMAM) –functionalized MSNs and also somewhat from the 
endosomal compartment, but the MSN-delivered doxorubicin resided at the perinuclear 
region and for an unknown reason did not accumulate to the nucleus like the free 
doxorubicin did. The endosomal escape of MSN cargo inside the cells is likely to stem 
from the proton ‘sponge property’ of particle coating when dendritic structures, like PEI or 
PAMAM that promote endosome rupture at lowering pH, are used for surface 
functionalization (Demeneix et al. 2004, Rosenholm et al. 2010). Indeed, we observed that 
within 4h the particles colocalize with an acidotropic probe, LysoTracker, suggesting that 
the intracellular compartment where the particles resign becomes acidified (V, Figure 7B). 
Interestingly, we can see that the MSNs remain compartmentalized inside the cell up to 
72h (V, Figure 7A). The intracellular localization of non-functionalized MSNs was 
reported to depend on particle size, as only MSNs ≤420 nm localized in the lysosomal 
compartment (He et al. 2009). PEI may also function as a ‘gate-keeper’ and contribute to 
the fact that the loaded DiI is not released to a neutral pH-buffered solution during 24h 
incubation (data not shown). Further studies will address how other release mechanisms, 
such as pH, redox, light, heat or magnet-controlled release systems, could be introduced to 
the developed drug carrier system (reviewed by Slowing et al. 2008). For example, 
azobenzene derivative -functionalized MSNs have been designed to release the loaded 
molecules in response to specific light wavelength, while modification of light intensity 
and excitation time allows graded drug release (Lu et al. 2008).  
 
3.3 FA-conjugated MSNs are non-toxic, but cellular uptake of methotrexate-
conjugated MSNs induces apoptosis specifically in folate receptor expressing cancer 
cells (III,IV,V) 
 
Nanoparticle toxicity to living organisms is a critical issue that researchers must carefully 
manage in order to develop truly biocompatible drug carrier systems (reviewed by Nel et 
al. 2009). Materials such as silica have the advantage of being biodegradable as well as 
being synthesized by methods that permit careful control over the particle size, 
morphology, porosity and surface properties, all of which are factors that determine how 
the particle will interact in a biological system and whether the particle is going to be 
cytotoxic. It has been demonstrated that mesoporous silica is less cytotoxic than non-
porous (amorphous) silica (Lin & Haynes 2010), and thiol- or amino-functionalization, that 
creates a positive charge on the particle surface, further reduces cytotoxic effects of MSNs 
in vitro (Di Pasqua et al. 2008, Tao et al. 2009). Importantly, the surface functionalized 
MSNs have not induced acute toxicity in animal models indicating that the drug carrier 
system is likely to have clinically relevant implications (reviewed by Rosenholm et al. 
2010).  
 
According to our results, the PEI- and FA-functionalized hybrid MSN carrier is non-toxic 
in vitro, but only within certain concentrations and time limits. A microscopic and flow 
cytometric analysis of HeLa cells after 24h incubation with 10µg/ml FITC/PEI/FA 
particles suggested a normal nuclear morphology (III, Figure 6). However, quantification 
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of the nuclear integrity after long-term incubation (72h) with 10 µg/ml MSNs shows a 
detectable increase in apoptotic cell death of HeLa cells (V, Supplementary Figure 2A). 
The reason for toxicity was found to not be the particle per se, but DMSO that is used as a 
solvent, because particles suspended in HEPES were not toxic in same circumstances. 
However, DMSO provides better stability of the synthesized particles. To avoid these 
undesired effects of DMSO dissolved particles, we chose to use a ten times lower particle 
concentration (1 µg/ml), which was harmless to cells, when long term incubations were 
required (V, Figure 6). Our results support the previous reports showing that functionalized 
MSNs are non-toxic when used at low concentrations (Radu et al. 2004, Di Pasqua et al. 
2008, Tao et al. 2009). The information concerning the potentially cytotoxic effects of 
mesoporous silica or PEI is limited, and the only reported data suggest that very high doses 
(>200µg/ml) of non-functionalized mesoporous silica may induce puncture of cell 
membranes, generation of reactive oxygen species, mitochondrial dysfunction and caspase 
activation (Di Pasqua et al. 2008, Heikkilä et al. 2010), whereas high molecular weight 
PEI promotes mitochondrial depolarization (Xia et al. 2009). However, the doses of silica 
and PEI used in our experiments, however, are considerably lower. 
 
Our next aim was to investigate if the targeted MSN system could be used for selective 
induction of apoptosis in FR-expressing cancer cells. To this end, we took advantage of the 
folate analog, MTX, which is a commonly used cytostatic anticancer drug that inhibits the 
biosynthesis of nucleotides and proteins (reviewed by Schmiegelow 2009). Currently, the 
dose-related toxic side effects and occurrence of drug resistance limit the clinical 
application of MTX in cancer therapy. Linking MTX to macromolecular carrier systems, 
such as albumin or PAMAM dendrimers, has previously been shown to reduce the side 
effects, increase the plasma half-life as well as promote the antitumor efficacy of MTX in 
vivo (Wosikowski et al. 2003, Kukowska-Latallo et al. 2005). Because of the structural 
similarity between FA and MTX, both are internalized by common cellular uptake 
mechanisms, which is why we were able to use MTX as an FR-targeting ligand for MSNs 
in addition to its function as an active drug molecule. In folate free culture conditions, we 
observed that the cellular endocytosis of MSNs with covalently conjugated MTX is 
slightly more efficient than the uptake of FA-conjugated MSNs, but still a clear difference 
in particle endocytosis can be seen between FR-expressing HeLa cells and 293 cells that 
have low FR expression (V, Figure 4). The total amount of endocytosed MTX-conjugated 
MSNs was calculated to be ten times higher in HeLa cells than in 293 cells, a difference 
large enough to affect the delivered drug concentration. Therefore, the developed drug 
carrier with MTX functioning both as a targeting ligand and as a cytotoxic agent may be 
used to selectively induce apoptosis of FR-expressing cells.  
 
Our results show that non-cancerous 293 cells and HeLa cancer cells have very similar 
sensitivity to free MTX, with concentrations of 200ng/ml and upwards clearly inducing 
apoptotic cell death within 72h in both cell types (V, Figure 2). To demonstrate that 
utilizing the MTX-conjugated MSNs instead of free MTX increases selectivity of MTX-
induced cell death, we incubated 293 and HeLa cells with FA-conjugated control particles 
or MTX-conjugated particles in a concentration corresponding to 20ng/ml of free MTX. In 
the free drug form this concentration was found to induce approximately 10–15% of 
nuclear fragmentation in the treated samples (V, Figure 2), while the corresponding values 
for particle-attached MTX were 33% in HeLa cells and 7% in 293 cells, the latter being 
close to level of apoptosis in response to free MTX (V, Figure 6). These data suggest that 
MTX-conjugation is able to promote selective MSN uptake to FR-expressing cells and 
subsequently compromise cell survival in the targeted cell population. Administration of 
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MTX-conjugated MSNs to a co-culture of both cell types would further test the targeting 
capability of the developed carrier system. It is likely that the free MTX and the particle-
conjugated MTX are transported via different endocytic pathways, which may lead to 
reduced drug-efflux and higher intracellular accumulation of MTX when it is in the 
particle-attached form. Such mechanisms could mediate the enhanced MTX cytotoxicity 
that was observed in HeLa cells upon treatment with MTX-functionalized hybrid MSNs. 
Liong et al. (2008) reported cell growth inhibition by FA-functionalized MSNs containing 
the cancer drug camptothecin adsorbed inside the particle pores. In their study, about 40% 
of FR-expressing human pancreatic carcinoma cells were viable after 24h incubation, 
while 70% of the human foreskin fibroblasts, which do not express FR, were viable at the 
same time point  (Liong et al. 2008). Also Zhu et al. (2009) reported a fairly high 
cytotoxicity in the non-targeted cells as compared to aptamer-targeted cancer cells (60% 
vs. 40% viability, respectively) when the cells were treated with doxorubicin loaded 
MSNs. Both studies show that the cytotoxic action is selectively increased in the FR 
expressing cell type when the targeting ligand is attached to the MSN carrier system. 
However, as no comparison to efficacy of the free anticancer agent was included in the 
studies, it is difficult to judge the therapeutic benefit of the new administration approach. 
 
Interestingly, the covalently attached MTX exerted cytotoxic activity in the cytoplasm, 
implying that the amide bond between MSN and MTX is broken in the cell interior and 
that MTX seems to preserve the original structure of the active drug molecule upon 
detachment. Recently, reduction of the disulfide bond released covalently linked cysteine 
from thiol-functionalized MSNs when the particles entered the intracellular environment 
where higher redox-potential prevails (Mortera et al. 2009). It is currently unknown, how 
MTX is released from the endosomal compartment where the fluorescent particles remain 
up to 72h (V, Figure 7A), but the enzymatic activity of lysosomal proteases may be 
responsible for the bond cleavage. We were surprised to find that MTX demonstrated 
potent cytotoxicity in HeLa cells even when it was covalently conjugated to pore walls 
prior to PEI-functionalization of the MSN surface, implying that efficient release of MTX 
must take place inside the cells (V, Supplementary Figure 3). In addition to providing a 
carrier for passive tumor targeting, conjugation of MTX to the hybrid MSNs would allow 
simultaneous delivery of other cancer drugs loaded inside the mesoporous matrix. This 
approach could reduce the dose of MTX-conjugated MSNs that is needed for effective 
apoptosis induction, and subsequently decrease the off-target toxicity in cells that do not 
overexpress FR.  
 
The in vivo biodistribution and elimination of functionalized MSNs is only starting to be 
understood, and the relevance of active targeting in the in vivo application of MSNs is 
currently being evaluated. Lu et al. (2010) recently demonstrated that MSN-based drug 
delivery systems are biocompatible and eliminated from the body without causing any 
adverse effects. However, they did not observe any difference in antitumor efficacy of non-
targeted and FA-conjugated MSNs loaded with camptothecin, suggesting that passive 
targeting mechanisms play a major role in the characterized MSN drug delivery system (Lu 
et al. 2010). The physicochemical properties of silica nanoparticles, such as size (Cho et al. 
2009) and surface modifications (He et al. 2008, Park et al. 2009b, Souris et al. 2010) have 
a clear impact on the biodistribution and degradation kinetics of the particles in vivo. 
Mamaeva et al. have recently tested the in vivo tumor targeting capacity of the hybrid 
MSN system that was characterized in vitro during the course of this thesis work. Rapid 
clearance of the particles by renal excretion was observed and no toxic adverse effects 
were detected, but more importantly, prolonged tumor accumulation and significantly 
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enhanced inhibition of tumor growth were seen, when the FA targeting ligand was 
conjugated to the PEI-functionalized hybrid MSNs loaded with an anticancer agent 
(Mamaeva et al.).  
 
Alternative ligands will be needed for targeted delivery of drugs into tumors that do not 
overexpress FR. For example, prostate cancer may require other approaches for MSN 
delivery and androgen receptors could serve as potential receptors for targeting. In addition 
to binding nuclear ARs, the lipofilic androgen has been shown to bind factors on the 
plasma membrane (Kampa et al. 2002). The membrane ARs are selectively overexpressed 
in aggressive prostate tumors in comparison to healthy prostate tissue, and engagement of 
these receptors by albumin-conjugated androgen in LNCaP prostate cancer cells induces 
endocytosis of the complex as well as cellular apoptosis (reviewed by Papadopoulou et al. 
2009). Liposomes with androgen as a targeting ligand have previously been used for 
cancer drug delivery into AR expressing tissues in vivo (Mishra et al. 2009). As membrane 
AR activation has also been shown to enhance the anticancer effects of paclitaxel in 
prostate cancer cells (Papadopoulou et al. 2009), loading of membrane AR targeted hybrid 
MSNs with various cytotoxic agents, including paclitaxel, would allow efficient drug 
delivery for targeted elimination of prostate cancer cells. 
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CONCLUDING REMARKS 
 
Cancer-specific cell surface receptors may serve as signposts for drug delivery vehicles, 
mediating selective uptake of nanometer scale particles that contain therapeutic agents. 
Other types of receptors, called death receptors, have the ability to induce intracellular 
signaling cascades leading to apoptotic cell death in a cancer cell-specific manner. In this 
thesis project, I set out to investigate methods of targeted cancer cell elimination with 
minimal toxicity to non-cancerous cells. 
 
Active targeting of cancer drugs to tumor cells is currently explored as means to reduce the 
adverse effects of chemotherapy, to increase the therapeutic efficacy of drugs and to enable 
the use of cancer drugs that previously have been too toxic or too insoluble for systemic 
administration. This thesis work aimed at evaluating the cancer cell targeting capacity of a 
novel drug carrier system consisting of mesoporous silica nanoparticles with 
hyperbranched poly(ethylene imine) coating. The tested MSNs were functionalized with 
folic acid to enable their targeted internalization by folate receptor overexpressing cancer 
cells. The results presented in this thesis demonstrate that the developed carrier system can 
be employed in vitro for cancer cell-specific delivery of adsorbed or covalently conjugated 
molecules and furthermore, for selective induction of apoptotic cell death in folate receptor 
expressing cancer cells. Due to the high drug-loading capacity of the hybrid MSNs, several 
anticancer agents may be incorporated to this system in the future, as combinatorial 
chemotherapy is likely to be required for successful cancer treatment. The biocompatibility 
and in vivo tumor targeting ability of the folic acid -functionalized hybrid MSNs have 
recently been studied with promising results, and therefore, this drug carrier system has 
good potential for clinical application in cancer therapy. The challenges of nanotechnology 
remain especially in finding new and more specific cancer-targeting ligands and designing 
nanocarriers that optimally deliver their cargo and become then completely eliminated 
from the body. Also reaching the targeted cell populations that may resign in poorly 
inaccessible locations, such as the brain or weakly vascularized tumors, needs to be 
addressed in future studies. 
 
During this thesis work, I have also investigated the anticancer effects that lignans have 
been reported to induce. Earlier studies have examined the influence of lignans on cell 
signaling, and shown that lignans can downregulate the activity of various signaling 
pathways. These studies, however, have been non-systematic in the sense that they only 
investigated a few lignan compounds at a time. The survival mechanisms of cancer cells, 
often involving deregulated receptor tyrosine kinase activity, are critical for the malignant 
cell behavior, whereas inhibition of these signaling pathways provides new opportunities 
for cancer cell elimination. The findings of this thesis present a novel mechanism of action 
for lignans, namely sensitization to death receptor-mediated apoptosis, and provide further 
support for lignans as potent inhibitors of cell survival signaling. Furthermore, increased 
cross talk between death receptor-mediated signaling and mitochondrial apoptosis pathway 
was observed upon lignan pretreatment, while lignans alone were non-toxic. Our structure-
activity relationship analysis of lignans demonstrated that only dibenzylbutyrolactone 
lignans are capable of increasing susceptibility of prostate cancer-cells to induction of 
apoptosis by the tumor-targeting death ligand TRAIL.  
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Of the tested lignans, NTG was identified as the most efficient inhibitor of Akt survival 
signaling as well as sensitizer to TRAIL-induced apoptosis. This interesting molecule is 
not found in human diet, but can be extracted from knots of coniferous trees. Dietary 
lignans or lignans used as chemotherapeutic agents could be employed for priming cancer 
cells to therapeutic TRAIL receptor agonists, which provides interesting possibilities for 
cancer treatment. The observations of efficient and rapidly reversible TRAIL-sensitizing 
activity in androgen-dependent prostate cancer cells, but not in non-malignant prostate 
cells, encourage to employ NTG in in vivo studies together with TRAIL treatment in a 
mouse model for TRAIL-resistant prostate cancer. Furthermore, potential cancer 
preventive effects should be examined closer as dibenzylbutyrolactone lignans may 
increase efficacy of the endogenous TRAIL-mediated immunosurveillance against cancer 
types that rely on deregulated growth factor signaling for their survival. In fact, it is 
possible that the combined anticancer effects of plant-derived factors, including lignans 
and other polyphenols, in human diet can have a significant impact on the life-time risk of 
cancer.  
 
Taken together, the results of this thesis describe two novel approaches for targeted cancer 
cell elimination, the first taking advantage of the receptor-mediated endocytosis of 
multifunctional nanocarriers and the second employing lignans for sensitization to death 
receptor-mediated apoptosis. Due to acquisition of therapeutic resistance towards single-
agent cancer treatments, development of effective and safe treatment protocols for multi-
drug cancer therapy is at the focus of cancer research. Recurrence of cancer is currently 
thought to originate from the multi-drug resistant tumor stem cell population that has 
capacity for self-renewal and tumor regeneration. Application of the approaches presented 
in this thesis to targeted elimination of cancer stem cells can provide new and interesting 
lines of research.  
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